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 Abstract 




Cellular adhesion is crucial in the pathogenesis of many bacterial species, where receptor-
ligand interactions mediate host colonisation and/or invasion leading to host pathologies. 
Fusobacterium nucleatum (Fn) is a bacterial species gaining greater interest due to recent 
links with a variety of diseases, such as colorectal cancer. Fn is known to harbour a vast array 
of adhesive proteins (adhesins), however only a few have been studied in depth, such as FadA. 
This study aims to characterise a new previously unstudied subset of trimeric autotransporter 
adhesins (TAAs) found within Fn, responsible for binding the human receptor CEACAM1. 
These proteins were given the name CEACAM-binding proteins of Fusobacterium (CbpF). 
To examine the distribution of these receptors among Fusobacterium spp., we screened and 
sequenced a library of clinical isolates. From sequencing these strains, we identified two novel 
species of Fusobacterium (F. oralis sp. nov. and F. ovarium sp. nov.), both of which harboured 
CbpF. While performing the taxonomic analyses on the new strains we addressed the 
conflicting nomenclature and phylogenetic boundaries with respect to the genus. By utilising 
computational methods, we could confidently delineate species and show how the genus 
should be organised to better reflect the genomic differences and similarities between strains. 
Through screening two different types of CbpF from different species we confirmed the ability 
of both classes to bind CEACAM1 through proteomic- and cellular adhesion-based assays as 
well as showing that both classes of protein were capable of binding to CEA (CEACAM5), but 
not to other CEACAM variants examined. This highlighted the highly specific nature of these 
proteins, which was explored further by examining point mutants of CEACAM1, of which few 
showed any significant adhesion. As well as examining CbpF, we briefly looked at two other 
TAAs from Fn: FN0471 and FN0735; the former of which could bind indiscriminately to HeLa 
cells, thus indicating another important adhesin yet to be fully characterised. 
Structural analysis of CbpFs highlighted a gap in the literature with respect to TAA motifs and 
topologies, where no known structures showed significant homology to large portions of the 
proteins particularly in a region predicted to be occupied with a coiled-coil motif. X-ray 
crystallography, SAXS and CD were used to infer structural features of CbpF, however an 
atomic resolution structure could not be accurately produced from a protein crystal X-ray 
diffraction dataset. 
The work conducted here lays the foundation for additional studies into TAAs from 
Fusobacterium highlighting the requirement for increased detail on how these proteins 
contribute to pathogenesis and whether these proteins could be used as potential future 
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Chapter 1: Introduction 
Cellular adhesion plays an important role in pathogenesis for many bacterial pathogens, 
where receptor-ligand interactions facilitate a broad range of functions, for example, in 
mediating host colonisation and/or invasion potentially leading to disease. Fusobacterium 
nucleatum (Fn) represents a bacterial species gaining greater interest due to recent links 
with a variety of pathologies, such as colorectal cancer (1-3). Fn is known to harbour a vast 
array of adhesive proteins (adhesins) (4, 5), however very little is known regarding their 
roles in pathogenesis with only a few being studied in depth, such as FadA (6). This study 
aims to characterise a new previously unstudied subset of adhesins found within Fn. 
1.1 The Fusobacterium genus 
1.1.1 Biophysical and Biochemical Characteristics 
Fusobacterium comprises a heterogeneous bacterial genus, however each species shares 
some fundamental traits. Fusobacterium species are obligate anaerobic, Gram negative, 
nonsporulating, nonmotile bacteria that adopt a pleomorphic filamentous shape; hence the 
name originates from the Latin fusus meaning spindle (7, 8). The lengths of these bacteria 
can range from 1 to 10 μm making them some of the longest bacteria (FIGURE 1.1). 
 
Figure 1.1 | Gram-stained Fusobacterium nucleatum micrograph. 
Image obtained from Partners’ Infectious Disease Images eMicrobes Digital Library 
(https://www.idimages.org/images/detail/?imageid=943). 




Fusobacterium spp. ferment carbohydrates yielding butyric acid as the primary product and 
will only grow in atmospheres containing typically less than 5 % O2 though they can tolerate 
up to 6 % (9). In addition to using glucose and peptones as metabolites, Fusobacterium will 
also use amino acids such as lysine, glutamate, aspartate and histidine, which is contrary 
to most other rod-shaped Gram-negative bacteria, though it has been shown that 
Fusobacterium will bias the use of peptides over free amino acids (10-12). A further unusual 
property was discovered where it was found glucose is not the primary metabolite for energy 
production and is, however, used for the synthesis of other small molecules within the cell 
(13-16). It has also been demonstrated that glutamate alone can be used as the primary 
energy source for Fn (17).  
1.1.2 Taxonomy 
The Fusobacterium genus exists within the Fusobacteriaceae family and form the 
predominant group of bacteria that have been characterised, where they are subdivided 
into several distinct species. Of these species, arguably the most studied is F. nucleatum 
(Fn). This species is very diverse and as such, was historically split into several distinct 
subspecies. The currently acknowledged subspecies are: nucleatum (Fnn), vincentii (Fnv), 
animalis (Fna), polymorphum (Fnp) and W1481 (Fnw). These classifications are a 
conglomeration of multiple previous literature (18-21). As will be explored later and which 
has been discussed in recent studies (22, 23), these boundaries may not be definitive where 
the reorganisation of the genus may be required. For example, for a brief period, another 
subspecies called fusiforme (19) existed, though it has since been disregarded due to its 
overwhelming likeness to Fnv when comparing whole-genome data (20). 
F. necrophorum (Fnec) accounts for the majority of other research within the genus. Like 
Fn, Fnec has been categorised into subspecies: Fnec subsp. funduliforme (Fnecf) and Fnec 
subsp. necrophorum (Fnecn), where the names originate from previously misclassified 
bacteria (24). With respect to health and disease, this species has the most far-reaching 
documented consequences, affecting both animals and humans (24).  
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In addition to these, there are also other minor and uncategorised species with 
comparatively little information. On the same major evolutionary lineage as Fn, is F. 
periodonticum (Fperio) and the newly discovered F. hwasookii (Fh), though fewer studies 
have been undertaken and both have so far only been associated with periodontal disease 
(25, 26). The current list of other minor strains with whole-genome sequencing (WGS) data, 
at the time of writing, are as follows: F. equinum, F. gonidiaformans, F. massiliense, F. 
mortiferum, F. naviforme, F. perfoetens, F. russii, F. ulcerans and F. varium. These strains 
have been associated with a diverse set of diseases, but a lack prevalence in humans is 
the likely cause for there to be less information on them. Other strains such as F. 
necrogenes, F. simiae and F. canifelinum have been identified using 16S rRNA sequencing, 
but their genomes have yet to be sequenced and therefore will not be included herein. The 
evolutionary relationship, as determined by 16S rRNA comparisons, within the 
Fusobacterium genus is displayed in FIGURE 1.2. 
 
Figure 1.2 | The Fusobacterium genus organisation. 
This dendrogram shows the evolutionary history between representative strains from Fusobacterium 
as determined by their 16S rRNA sequence.  
F. nucleatum subsp. nucleatum ATCC 25586
F. nucleatum W1481
F. nucleatum subsp. animalis ATCC 51191
F. nucleatum subsp. vincentii ATCC 49256
F. hwasookii ChDC F174
F. nucleatum subsp. polymorphum NCTC10562
F. periodonticum 2 1 31
F. periodonticum ATCC 33693
F. massiliense Marseille-P2749
F. russii ATCC 25533
F. ulcerans ATCC 49185
F. varium ATCC 27725
F. mortiferum ATCC 9817
F. gonidiaformans 3-1-5R
F. equinum CMW8396




















1.1.3 Health and Disease 
1.1.3.1 Periodontal Disease 
F. nucleatum primarily resides in the oral cavity, where it is often located within dental 
plaque. Fn is particularly promiscuous and can act as a ‘biological cement’ via 
coaggregation with many other organisms forming biofilms. It relies on this nature to 
colonise teeth, as it cannot bind enamel directly and so binds to the existing primary 
colonisers (27, 28). With poor oral hygiene, over time, more pathogenic organisms that 
cannot bind to primary colonisers or tooth enamel directly, such as Porphyromonas 
gingivalis and Aggregatibacter actinomycetemcomitans, have a chance to establish 
themselves utilising Fn as a scaffold (FIGURE 1.3). 
 
Figure 1.3 | Dental plaque formation over time. 
Primary colonisers such as S. oralis and S. sanguinis can bind directly to the tooth surface and hence 
will colonise the area quickly. The majority of bacteria are unable to colonise directly, including Fn, 
where they colonise using interactions with the primary colonisers. Once Fn has colonised, this then 
allows for the establishment of a wide array of other organisms via interactions with Fn. Some of 
these late colonisers can be more pathogenic, such as P. gingivalis, and lead to more severe 
diseases. 
These later colonisers, with Fn, can then go on to invade the subgingival crevice causing 
periodontitis. Fn thrives here as this environment is much lower in oxygen (27, 29, 30). 
FIGURE 1.4 shows how periodontitis compares to a healthy state. 
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An inability of the immune system to clear the infection, or the lack of appropriate treatment, 
consequently leads to chronic infection, where the production of acidic by-products from the 
invading organisms can slowly dissolve the tooth and the release of inflammatory cytokines 
by the immune system can trigger immune-mediated damage to the surrounding tissues. If 
left untreated, as well as localised damage, further complications can arise due to gingival 
bleeding when tooth brushing, allowing for bacteria to enter the bloodstream leading to a 
state of transient bacteraemia, which can go on to cause other diseases such as bacterial 
endocarditis (31).  
 
Figure 1.4 | Periodontal health compared with periodontitis. 
The left shows the state of periodontal health where only resident commensals microbes are present. 
The right shows advanced periodontitis where Fn and late colonisers invade the subgingival crevice 
causing severe inflammation and tissue degradation. Adapted from Hajishengallis et al. Nat Rev 
Immunol. 2015 (32). 
Bacterial invasion of the subgingival 
crevice by pathogenic microbes 
Resorbed 
bone  











1.1.3.2 Colorectal cancer 
In recent years, Fusobacterium has been linked with colorectal cancer (CRC) progression, 
where numerous studies have shown significantly increased levels of the bacteria in 
colorectal adenomas and carcinomas (33-40). As such, it can be determined that there is a 
definite association, however, there remains debate over what the consequences and 
importance of this are. One study in mice showed direct evidence for the presence of 
Fusobacterium leading to more rapid tumourigenesis and poorer prognoses (41), however 
this study does not provide evidence for why this occurs and may not give an accurate 
model for the human case, especially when other environmental factors come into play. 
Other studies have provided evidence for the role of Fusobacterium only being of 
importance in the later stages (stage III to IV) of CRC progression and not in the initial 
stages (42, 43). 
Various models have been proposed for the activity of certain virulence factors within 
Fusobacterium. Two outer-membrane proteins (OMPs) have been indicated as potential 
aetiological agents in CRC: FadA (6, 44) and Fap2 (45). FadA is responsible for binding to 
vascular endothelial cadherin (VE-cadherin) which can the mediate β-catenin signalling in 
the cell and could lead to the generation of a proinflammatory microenvironment (44, 46). 
Fap2 instead may aid in creating an immunosuppressive microenvironment via binding and 
signalling through the TIGIT (T cell immunoreceptor with Ig and ITIM domains) receptor on 
Natural Killer (NK) cells (45). It remains unclear what these two proteins may be doing in 
vivo, however they have both been shown they have potential to be involved in disease. 
Other studies have examined the origin of the Fusobacterium species that have been 
isolated from CRC and there is evidence to suggest that the bacteria associated with CRC 
adenomas are haematogenous and have not traversed from the colon lumen. Moreover, it 
is unclear if the bacteria travel with metastases or if they reconvene after establishment at 
a secondary site (47, 48). 
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Some research has suggested that the association could be entirely circumstantial where 
the increased expression of CRC biomarkers leads to increased adhesion of these bacteria, 
nevertheless, further research is required in this field to determine the true impact of the 
bacteria on this disease. Bashir et al and Han provide more in-depth reviews on the topic 
(49, 50). In addition to colorectal cancer, Fusobacterium species have been linked with 
pancreatic and oral cancers, which have yet to be as thoroughly explored as CRC (51, 52).  
1.1.3.3 Preterm births 
In periodontal disease, Fn itself has a chance enter the bloodstream from gingival bleeding, 
giving rise to a state of transient bacteraemia. This is of particular issue in pregnant women; 
it is known that poor oral hygiene during pregnancy is a risk factor for adverse foetal 
development and even miscarriage (53-55). The mechanisms of this are not yet fully 
characterised, though Fn species are the most commonly isolated bacteria from significant 
tissues such as the placenta from preterm births. Interestingly, the only two subspecies that 
have been isolated from intrauterine infections are Fna and Fnp (56-58).  
The FadA protein has been indicated, again, in the model for infection upon colonisation of 
the placenta. It was demonstrated that a fadA knockout mutant was unable to bind the 
murine placenta where the re-complemented mutant restored binding (59, 60). It is 
proposed that the redistribution of VE-cadherin upon binding by FadA increases 
permeability of the tissue disrupting tight junctions, therefore allowing for bacteria to 
traverse the barrier (44). 
1.1.3.4 Lemierre’s Syndrome 
Currently, the only human disease attributed almost exclusively to Fusobacterium spp. is 
Lemierre’s Syndrome. This disease is most commonly characterised by thrombophlebitis of 
the internal jugular vein when peri-tonsillar abscesses containing Fusobacterium rupture 
and leak into the vein (61). It is often fatal if left undiagnosed and largely affects young 
healthy individuals (61). Other sites have been shown to be affected such as the hepatic 
portal vein (62). Emboli can break off the initial site of infection and travel through the 




bloodstream leading to coronary or pulmonary embolisms for example, therefore patient 
fitness becomes largely irrelevant at this point, thus the indiscriminate relationship to age.  
Fnec species, specifically Fnec subsp. funduliforme, cause approximately 80 % of all 
diagnosed cases and a further 10 % caused by other Fusobacterium species (61, 63). 
Unfortunately, from a patient’s and a researcher’s perspective, this disease is both rare (~1 
per million incidence) and commonly misdiagnosed (61, 64). This makes identifying risk 
factors and bacterial relationships with this disease hard to study. A typical case can present 
with a sore throat and general malaise, so combined with its rarity and the reduction in 
prescribing antibiotics for sore throats, it is no surprise this disease is being mistreated and 
incidence may even be increasing as a result (65).  
1.1.3.5 Footrot 
Footrot is a disease restricted to hooved animals such as sheep and cattle that inflicts a 
particularly heavy burden on sheep farmers. F. necrophorum is one of two causative agents 
of infection, the other being Dichelobacter nodosus, where coinfection of the two is required 
for disease (66, 67). The disease is highly contagious between animals, though it is thought 
not to transmit between species, such as sheep and cattle (67). Due to the high transmission 
rate between animals, whole herds can become infected if the diseased animal is not 
quarantined quickly. As a result, this disease has large financial implications, for example, 
the estimated cost of ovine footrot to UK farmers alone was £24.4 million in 2005 (68). 
The disease is characterised by the degradation of the interdigital tissue between the toes 
of the animal caused by keratinases and proteases produced by D. nodosus (67). This can 
lead to lameness of the affected animal as it becomes painful to stand due to the infection. 
Treatment with antibiotics should clear the infection and limit further damage, though there 
have been cases reported with infection that develops much faster and cannot be dealt with 
using normal treatment, often leading to euthanising the animal. Some vaccines have been 
marketed, though the effectiveness has been doubted and they only offer a limited immune 
duration (69).  
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1.1.3.6 Other Diseases 
In addition to the listed pathologies, Fusobacterium spp. have been shown to be implicated 
in several other diseases. These cases are generally less numerous and not as well 
characterised but interesting nevertheless. Many of these other associated diseases are 
thought to be onset from a prior case of periodontitis. For instance, Fn were detected within 
the synovial fluid of an arthritic joint where the exact same bacterial clone was also identified 
in a case of periodontitis within the same patient (70). Other diseases Fusobacterium spp. 
has been associated with include (but are not limited to): inflammatory bowel disease (71, 
72), atherosclerosis (73), appendicitis (74) and it has even been indirectly implicated in 
Alzheimer’s disease (75). 
1.1.3.7 Treatment 
The primary method for treating Fusobacterium-related infections rely upon physical 
removal of the biofilms (in dental applications) and using broad-spectrum antibiotics, such 
as penicillin or cephalosporin derivatives, or tetracycline (76). These are usually 
accompanied by an additional anaerobic bacterium-targeting drug such as metronidazole, 
as beta lactamases have since been identified within some strains of Fusobacterium. 
However, metronidazole can cause some severe side-effects so is not always used (77). 
More recently, the anaerobe-targeting drug Amixicile could be a possible alternative 
treatment as it selectively targets anaerobic organisms via the pyruvate:ferredoxin 
oxidoreductase enzyme (78). This drug would also solve the problem of potential onset of 
C. difficile colitis that treatment which metronidazole or clindamycin could cause (79). 
1.1.4 Virulence Factors 
A number of proteins and cellular components have been implicated as aetiological agents 
in Fusobacterium-related diseases.  
Extracellular vesicles derived from Fusobacterium cells have been shown to co-aggregate 
with P. gingivalis and have been shown to possess proteolytic activity, which could be 
important in various pathological pathways, such as tissue invasion and immune 




sequestering (80, 81). A serine protease found on the surface of these vesicles, named 
fusolisin, was found to degrade extracellular-matrix (ECM) proteins fibronectin, fibrinogen, 
and collagen I and IV. This protease also showed the ability to degrade IgA alpha-chains. 
The ability to degrade ECM components highlights a role for this protein in tissue invasion 
(81, 82).  
Secreted haemolysin is also considered to be a major virulence factor in Fusobacterial 
pathogenesis whereby lysis or erythrocytes yields iron and can lead to a hypoxic 
environment at the site of infection, which is favourable for the obligate anaerobic nature of 
Fusobacterium spp. (83, 84).  
1.1.4.1 Adhesive Proteins 
Crucial to Fusobacterium pathogenesis are its vast array of adhesins. FadA is likely the 
most studied of the adhesins that some Fusobacterium strains possess (6). This protein is 
relatively small at around 150 residues long and exists within the outer membrane in Fnn, 
Fnv, Fna and Fnp. As previously stated, it is responsible for binding to cadherins on human 
cells, specifically VE-cadherin (44). In addition to this receptor, other adhesins have been 
identified as key factors in colonisation and disease.  
The major outer-membrane protein, FomA plays a key role in biofilm formation as well as 
serving other functions for Fusobacterium. It was identified as a voltage-dependant porin 
that was capable of binding to FC (Fragment crystallizable region) domain of human IgG 
which aids evasion of the immune system by sequestering potentially immune-activating 
antibodies (85-87). This protein also has the property of binding other bacteria such as P. 
gingivalis and S. sanguinis, therefore facilitating a bridge between commensal and 
pathogenic organisms (80).  
In addition to adhesion to TIGIT, as previously mentioned, the Fap2 protein is also involved 
in other interspecies interactions, specifically to P. gingivalis (88). Likewise, the OMP RadD, 
a Type Va secretion system, has been shown to be involved in enabling interactions with 
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P. gingivalis as well as various less pathogenic Gram-positive bacteria such as A. 
naeslundii, S. gordonii, S. mutans and S. oralis similarly to FomA playing a role in bacterial 
coaggregation (89, 90). Recently, another coaggregation-promoting OMP was identified in 
Fnn called CmpA, which was shown to allow dual-species biofilm formation with S. gordonii 
(91). 
In addition to these proteins, in Fnn three genes encoding putative Type Vc Secretion 
Systems have been identified. The gene loci for these are FN0471, FN0735 and FN1499 
(Fnn ATCC 25586). Hitherto, none of these genes have been examined and are likely 
facilitating adhesion to unidentified targets. It is products from these genes, and related 
proteins, that this study aims to characterise. 
1.2 Trimeric Autotransporter Adhesins 
Trimeric autotransporter adhesins (TAAs), also known as Type Vc Secretion Systems, 
encompass a large variety of bacterial outer-membrane proteins. These proteins are used 
mainly for facilitating adhesion between a bacterium and substratum, such as human or 
other bacterial cells (92). They are close relatives of the classical Type V Secretion System 
(T5SS) where several key differences exist, which will be explained. 
1.2.1 Structure and Assembly 
The structures of TAAs varies widely, however all contain a few common features. The first 
is a signal peptide that, after initial folding in bacterial cytoplasm, will traffic the proteins to 
the inner-membrane where they cross into the periplasm via the Sec pathway. Here the 
signal sequence will be cleaved, and three protein monomers will form a trimer before 
inserting into the outer membrane (92-94). This is very similar to how the classical Type V 
secretion pathway works; however, the protein does not undergo cleavage when inserted 
into the membrane and instead retains the extracellular domain, also known as the 
passenger domain, unlike the classical T5SS which normally secretes the passenger 
domain (95). 




The most conserved region of TAAs is the membrane anchor – this serves to hold the 
protein in the outer membrane of the bacterium, as well as serving to export the rest of the 
protein to the extracellular space on construction (92, 93). The membrane anchor is found 
at the C-terminus of the protein and can sometimes have extra amino acid residues further 
downstream that reside in the intermembrane space. At the core of this domain is a 
homotrimeric 12-stranded β-barrel fold containing a coiled-coil that traverses the length of 
the β-barrel and links to the extracellular domain. The fold is highly conserved among TAAs 
with little to no variation found. FIGURE 1.5 displays the membrane-spanning structure of Hia, 
a TAA from Haemophilus influenzae. 
 
Figure 1.5 | Membrane anchor structure for a trimeric autotransporter adhesin.  
The structure of Hia [H. influenzae] residues 992-1098 is shown (PDB ID: 2GR7) (96) and its state 
post outer-membrane insertion. The membrane anchor is comprised of a 12-stranded β-barrel 
composed of three identical monomers (3 x 4 β-sheets). The length of the coiled-coil extruding from 
the membrane anchor varies in length depending on the protein. 
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1.2.2 Specialised folds 
The structure of the region flanked by the membrane anchor and the signal peptide can 
contain a wide variety of different folds that can be split into three classes: heads, 
connectors and stalks (93, 97). 
Head domains contain predominantly β-sheet motifs. The head class can be split into two 
subclasses: transverse and interleaved heads, where transverse heads have their β-
strands perpendicular to the longitudinal axis and interleaved are parallel. Transverse head 
domains are likely to contain repeating sequential runs of a particular motif varying in length, 
whereas interleaved do not repeat and have a set size (97, 98). One common fold in the 
transverse head class is represented by the architype TAA, YadA, from the bacteria 
Yersinia enterocolitica. This structure, known as the YadA-like head domain has a 
characteristic β-solenoid motif which can repeat any number of times giving rise to multitude 
of head lengths (97, 98). This structure is probably the most common head domain type 
found within TAAs. This structure provides an extracellular trimerization region where the 
head regions are held tightly to each other through a hydrophobic core (FIGURE 1.6) (99, 
100). 
The number of residues per turn of YadA-like heads varies between individual proteins but 
is usually 14 or 15 residues for TAAs. Kajava & Steven (101) provide a detailed look at other 
β-solenoid motifs from Type V Secretion Systems and how the equivalent domains differ 
between the classical T5SS and TAAs (T5cSS). 
 





Figure 1.6 | YadA-like Head Motif.  
The structure of the YadA-like head domains from the partial structures of A) UspA1 (PDB ID: 3PR7) 
(102) and B) YadA (PDB ID: 1P9H) (103). This fold adopts an O-shaped beta roll, also known as the 
β-solenoid motif, with 15 and 14 residues per turn for UspA1 and YadA respectively. The number of 
residues per turn can vary between alternate TAAs. The core of the head domain is stabilised by 
hydrophobic residues and prevents the head domain monomers from dispersing. 
 
An example of an interleaved head domain is the Tryptophan-Ring which is made up of a 
β-meander motif. It is the most common variant of interleaved heads and others identified 
all use this as a backbone structure. An example of this fold is shown in FIGURE 1.7. This 
structure can be found in the protein BadA from B. henselae. The head domain of this 
protein was shown to be essential for host cell adhesion and interactions (104). 
Stalks form the next common feature of TAAs. The stalk domains of TAAs are usually made 
up of trimeric coiled-coils, which can adopt either a right-handed or left-handed shape and 
may also contain various inserts. FIGURE 1.8 shows a typical arrangement of a coiled-coil. 
TAA stalks can adopt several amino acid motifs for residues 𝑎𝑎 − 𝑔𝑔, an example heptameric 
peptide that some stalks with a polar core use is: LXXTNXN (where X is undefined), though 
more commonly small hydrophobic residues are found in the 𝑑𝑑 register (98). 
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Figure 1.7 | The Tryptophan Ring Motif.  
This is the structure of the Trp-Ring β-meander fold of BadA (residues 385-431) from Bartonella 
henselae. This is an example of an interleaved head motif. The Trp-Ring head is characterised by 
the interactions between three tryptophan residues, one from each chain spaced approximately 4 Å 
apart. Each chain of the trimer is coloured for clarity. 
 
Some TAAs can incorporate both a left-handed and right-handed CC into their structure 
such as the IgG-binding protein EibD from E. coli (105). Interestingly, in this case, it utilises 
the right-handed CC to bind human IgA and the left-handed CC to bind human IgG. 
Connecting the two opposite-handed coiled-coils is a domain known as the Eib saddle, 
which is composed of a short loop. 
The final common TAA domain are the necks which are responsible for connecting head 
and stalk domains. These can vary in length from 19 to 22 residues long but show higher 
variation between different TAAs (98). A detailed list of known TAA domains is given in 
TABLE 1.1. 





Figure 1.8 | Trimeric Coiled-coil Structure.  
A) The atomic structure of the UspA1 stalk fragment (amino acids 527-665), rD-7. Seven amino acids 
from each chain have been shown as lines to demonstrate one repeating unit. B) Amino acid residue 
positions within coiled-coils. Letters 𝑎𝑎 − 𝑔𝑔 represent a heptameric peptide repeat as part of an alpha 
helix. Residues at positions 𝑎𝑎 and 𝑑𝑑 face inwards towards the core and contribute most to structure 
formation through interactions 𝑎𝑎 − 𝑎𝑎 − 𝑎𝑎 and 𝑑𝑑 − 𝑑𝑑 − 𝑑𝑑. Residues at 𝑒𝑒 and 𝑔𝑔 can further stabilise the 
coiled-coil using polar interactions.    
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Table 1.1 | Known common domains and motifs of TAAs.  
A brief description of each domain is given, stating its class, structure and function (if applicable). In 
addition, example structures of each domain are given if known or relevant. 1 position 𝑑𝑑 refers to the 
position of an amino acid residue on a coiled-coil structure, see FIGURE 1.8-B. 2 Hia [H. influenzae]. 
3 YadA [Y. entercolitica]. 4 BpaA [B. psudomallei]. 5 UspA1 [M. catarrhalis]. 6 SadA [S. enterica]. 7 
BadA [B. henselae]. 8 EibD [E. coli]. Table adapted from tables in (97, 98). 
Domain Description Example PDB ID Reference(s) 
Membrane 




Responsible for trafficking pre-protein to 
periplasm, cleaved after this - (106) 
Ylhead Transverse head, β-solenoid motif 1P9H3 (103) 
HIM1, 2 & 






GIN Transverse head, β-prism motif, found only after interleaved heads 3D9X
7 (109) 
TrpRing Interleaved head, β-meander motif, most common of its type 3D9X (109) 
FxG Interleaved head, variant of TrpRing -  
GANG Interleaved head, deletion variant of TrpRing -  
Stalks α-helices in trimeric left or right handed coiled-coil (CC) 1P9H (103) 
N@𝑑𝑑1 Asn residue in position 𝑑𝑑 of CC, most common polar amino acid in the ‘core’ of TAA CCs.  - (110) 
FGG 3-stranded β-meander insertion into CC 2YO26 (108) 
Eib saddle Unique to Eib proteins, insertion of non-helical structure into CC 2XQH
8 (105) 
Neck Connector, links β-sheet motifs to α-helices 1P9H (103) 
Short neck Connector, neck variant containing 19 amino acids 3D9X (109) 
Long neck Connector, neck variant containing 22 amino acids 3LAA (107) 
KG Connector, neck variant missing initial β-strand 3EMI2 (111) 
DALL 
Connector, links α-helices to β-sheets, 
exclusively found before neck domains, three 
known conserved variants (DALL1-3) 
2YO36 (108) 
HANS Connector, links β-sheet motifs to α-helices, always followed by a Ylhead 2YO3 (108) 




1.2.3 Receptor binding 
TAAs are used by bacteria to bind to many different structures, such as human surface 
receptor proteins or ECM proteins. It has been found that the presence of these adhesins 
can dramatically increase virulence in some pathogens, such as BpaB in Burkholderia 
mallei (112), indicating their adhesive roles are sometimes necessary to cause disease.  
The protein BadA from B. henselae is a TAA that uses its different domains to selectively 
bind certain ECM components. It utilises both its head and stalk domains to bind to collagen 
in a redundant fashion whereas binding to fibronectin is exclusively mediated by the stalk 
domain (113).  
The ubiquitous surface proteins (Usp) A1 and A2 proteins from Moraxella catarrhalis bind 
to several different receptors, each having different roles in pathogenesis. UspA1 can 
adhere to the human receptor carcinoembryonic antigen cell-adhesion molecule 1 
(CEACAM1) on epithelial cells in the respiratory tract, aiding establishment of the bacteria 
in the host (114). In addition, these proteins interact with extracellular matrix proteins, such 
as laminin, fibronectin and vitronectin (115-117). UspA2 binding to vitronectin has been 
demonstrated to be important in immune escape by interfering with complement-mediated 
killing (117). 
The CEACAM1 binding region in UspA1 has been determined to be the coiled-coil stalk 
domain. This region has been isolated and expressed as the recombinant peptide rD-7 
(118), which was shown to bind CEACAM1 specifically. This is another occurrence of a TAA 
using its stalk domain to bind an Ig-like protein, in addition to EibD (105). 
Through an unpublished study, it was found that the FN1499 protein from Fn coprecipitated 
with CEACAM1. This was identified through sequencing of the N-terminal domain using 
Edman degradation. Similarly to UspA1, this is another identified TAA protein responsible 
for cellular adhesion using the CEACAM1 receptor. These proteins have been labelled 
CbpF for CEACAM-binding proteins of Fusobacterium. 
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The carcinoembryonic antigen (CEA) family of proteins are members of the immunoglobulin 
superfamily that contains several cell surface proteins that are expressed variably on 
different tissues throughout the body (119). The family is split into two branches: CEA cell 
adhesion molecules (CEACAMs) and pregnancy specific glycoproteins (PSGs) (120). 
CEACAMs are thought to be evolutionarily recent, mainly appearing in mammals, though 
orthologues in other species have been identified (120-122). They can interact with each 
other in either a homo- or heterotypic fashion and are involved in cell-cell adhesion, but also 
have many other functions (123-126).  
CEACAMs come in many different types, each having a different structure with varying 
features (TABLE 1.2). The genes encoding CEACAMs can also produce altering products 
due to exonic splice events, for example, the gene for CEACAM1 (also known as CD66a 
and BGP1) has 12 known protein products (120). Some of the resulting splice variants from 
CEACAMs may result in a truncated extracellular domain or produce soluble protein with 
no membrane anchor which can then be secreted by the cell. 
1.3.1 Functions 
Some of the features CEACAMs can contain, relate to their functions, for example, 
CEACAM1 and 3 have immunoreceptor tyrosine-based inhibitory and activating motifs 
(ITIM and ITAM) respectively on their intracellular domains. These have contrasting roles 
in immunomodulation, whereby, the ITIM can supress the local immune response of a cell 
and ITAM can activate it (127). CEACAM3 is found exclusively on neutrophils and upon 
receptor binding, the ITAM can induce phagocytosis (128). This would normally be 
disadvantageous to any pathogen that could activate this receptor.  
In addition to CEACAMs, PSGs form the sister branch in the CEA family. All these proteins 
lack a membrane anchor and are expressed in soluble form from trophoblasts. As the name 
suggests, these proteins are expressed in pregnancy, though very little is known regarding 




their specific functions within the host, however are essential for successful pregnancy 
(129). 
Of the many proteins within the CEA family only four have been identified as pathogen 
receptors (CEACAM1, 3, 5 and 6) and each of these uses their N-terminal domain as the 
pathogen-binding domain. The N-terminal domain is structurally very similar across the 
whole family of CEACAMs, therefore, the pathogens utilising these receptors as adhesion 
sites have evolved to do so in a very specific way. In addition, analogous CEACAMs from 
other species, such as murine do not appear to allow binding of the human pathogen 
receptors – this would allow pathogens to target humans in a very specific manner. The 
difference in the head domains between species is more diverse than the intrinsic difference 
across the CEACAMs from an individual species. 
Compared to membrane bound CEACAMs, little is known regrading secretory CEACAM 
splice variants; however, secretory CEACAM1 has been indicated in tissue 
immunomodulation and angiogenesis (130, 131). Additionally, secreted CEACAMs could 
be a diversion tactic as a defence against pathogens, preventing cellular adhesion.  
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Table 1.2 | The CEA family of receptors.  
Shown are the members of the known human CEA family with the number of splice variants for each 
and whether they have been observed as a pathogen receptor. ITAM – immunoreceptor tyrosine 
kinase activating motif. ITIM – immunoreceptor tyrosine kinase inhibitory motif. GPI – 
Glycosylphosphatidylinositol. 1 By number of mRNA transcript variants on NCBI. 2 As identified by 
current literature. 
CEA family member Splice variants1 
Pathogen 
receptor2 Additional features  
CEACAM1 12 + Intracellular ITIM 
CEACAM3 3 + Intracellular ITAM-like 
CEACAM4 1 - Intracellular ITAM-like 
CEA (CEACAM5) 3 + GPI anchor 
CEACAM6 1 + GPI anchor 
CEACAM7 2 - GPI anchor 
CEACAM8 1 - GPI anchor 
CEACAM16 1 - No membrane anchor; two IgV-like domains 
CEACAM18 1 -  
CEACAM19 74 - Intracellular ITAM 
CEACAM20 4 - Truncated N-domain; intracellular ITAM 
CEACAM21 4 -  
PSG1 5 - No membrane anchor 
PSG2 1 - No membrane anchor 
PSG3 1 - No membrane anchor 
PSG4 4 - No membrane anchor 
PSG5 1 - No membrane anchor 
PSG6 (PSG10) 2 - No membrane anchor 
PSG7 1 - No membrane anchor 
PSG8 1 - No membrane anchor 
PSG9 3 - No membrane anchor 
PSG11 1 - No membrane anchor 




1.3.2 Structural Properties 
With the exception of CEACAM20, all CEA family members begin with one IgV-like domain 
followed either directly by a membrane anchor or an arbitrary number of IgC-like domains. 
The IgV-like domain (immunoglobulin ‘variable’ fold) is slightly larger than the IgC 
(immunoglobulin ‘constant’ fold) domains containing usually 9 β-sheet motifs compared to 
7 in IgC. These β-sheets are labelled for easy identification: A, B, C, C’, C’’, D, E, F and G, 
where C’ and C’’ are only found in IgV domains (132). The positions of the β-strands and 
the structure of the CEACAM1 IgV-like domain is shown in FIGURE 1.9.  
 
Figure 1.9 | Structure of the CEACAM1 IgV-like domain. 
The crystal structure of the N-terminal IgV-like domain of CEACAM1 (PDB ID: 4WHD) contains 9 β-
sheets each labelled as shown from A to G. The IgC fold lacks the C’ and C’’ sheets. 
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The two cases of CEA-family members that do not conform to the extracellular domain 
topology are CEACAM20 and CEACAM16. CEACAM20 harbours a severely truncated IgV-
like domain and CEACAM16 contains two IgV-like domains flanking two IgC-like domains 
at the N and C termini. Moreover, CEACAM16 is the only member of the CEACAM branch 
not to contain a membrane-anchored splice variant, although all members of PSG branch 
do not either. 
The length of the IgC-like repeating domains varies greatly between CEA family members 
as well as intrinsic splice variants, with CEACAM3, 4 and 19 lacking any IgC-like domains 
and CEA containing 6 IgC-like regions (FIGURE 1.10). The splice variant nomenclature states 
the total number of Ig-like domains (both IgV and IgC), as well as any other features which 
may be present/absent such as the membrane anchor or internal signalling domains, for 
example CEACAM-4L stands for CEACAM1 with 4 Ig-like domains and is the long variant 
form which contains the intracellular ITIM domain. 
The major splice variant of CEACAM1 (CEACAM-4L) consists of one IgV- and 3 IgC-like 
domains in the extracellular unit. These domains are labelled as follows: N, A1, B and A2 
from N- to C-terminus. Each domain is glycosylated via N-linked glycosylation similarly to 
other Ig-like proteins. This feature is important as it often overlooked in the crystal structures 
of recombinant CEACAMs expressed within E. coli, though it is not thought have much 
impact on pathogen-binding (133). It also contains the membrane spanning region and the 
intracellular ITIM domain. 
  





Figure 1.10 | CEACAM topological domain diagram. 
The domain topology of the major splice variants of CEACAM1, CEACAM3, CEA, CEACAM6, 
CEACAM7 and CEACAM8 are displayed. GPI – glycophosphatidylinositol; ITIM – immunoreceptor 
tyrosine-based inhibition motif; ITAM – immunoreceptor tyrosine-based activation motif. 
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The predicted binding face of the N-terminal domain of CEACAM1 maps very closely to 
other CEACAMs, such as 3, 5 and 6, therefore, proteins such as UspA1 can bind to these 
proteins as well (118, 134). The pathogen binding surface utilises the C, C’, C’’, F and G β-
sheet regions on the IgV-like fold and is given the name CFG face for brevity. Through 
computational and mutagenesis studies (133), key residues on the CFG face of CEACAM1 
were identified that played a role in adhesion to UspA1: Y34, G47 and I91 found on the C, 
C’ and F strands respectively. Other mutants were studied but were found to have a lesser 
to no impact on binding affinity (residue and domain location): S32 (C), V39 (loop between 
C and C’), Q44 (C’) and V96 (loop between F and G) – though only alanine substitutions 
were examined for these residues. T56 (C’’) and Q89 (F) were studied using more 
substitutions, but T56A, D and L showed little effect whereas Q89N appeared to increase 
binding affinity to UspA1 (133). 
The Y34 residue is completely conserved across the entire CEA family and is likely involved 
in maintaining structural integrity – though it may increase affinity for binding proteins using 
hydrophobic interactions. CEACAM20 is an exception to this where it has a severely 
truncated N-terminal domain and lacks this residue entirely. However, CEACAM4, 
interestingly has a histidine at the equivalent position, making it the only member of the 
CEA-family to have this position and not have a tyrosine here. 
In addition to the extracellular region, most members of the CEACAM branch have at least 
one splice variant that either possesses an alpha helical membrane-spanning region or a 
glycosylphosphatidylinositol (GPI) anchor. However, CEACAM16 and all PSGs do not 
possess any membrane anchor. As previously mentioned, some CEACAMs, such as 1 and 
3, contain an intracellular signalling domain, but so does CEACAM4, CEACAM19 and 
CEACAM20. CEACAM1 is the only family member to possess an ITIM domain, where 
CEACAM3 and 4 contain an ITAM-like endocytic domain and CEACAM19 and 20 have a 
classical ITAM. 




1.3.3 Pathogen Interplay and Disease 
Since CEACAM1 has the potential to confer an immune inhibitory response when activated, 
it could therefore be advantageous for a pathogen to bind this receptor. Conversely, it would 
be to a pathogen’s disadvantage to bind CEACAM3. Many bacteria do in fact bind to 
CEACAM1; Neisseria meningitidis, Neisseria gonorrhoeae, Moraxella catarrhalis and 
Haemophilus influenzae all harbour adhesins that specifically target human CEACAM1. The 
specificity for human CEACAM1 by these particular bacteria may explain why some of these 
pathogens cause disease exclusively in humans. The TAA UspA1 from Moraxella 
catarrhalis is known to bind to CEACAM1 facilitating bacterial adhesion. This protein is 
unique among known CEACAM-binding proteins as it utilises a coiled-coil stalk to adhere 
to CEACAM1 (114, 135, 136). 
A separate study examined bacterial-induced signalling in the TIGIT receptor and its effect 
on the prevention of Natural Killer (NK) cells killing tumour cell lines (45). Like CEACAM1, 
this receptor contains an ITIM domain. In this case it was found that bacteria binding this 
receptor could activate the local immunosuppression response through ITIM in the tumour 
cells, preventing killing by NK cells. 
As briefly mentioned, CEACAMs are primarily involved with cell-cell adhesion by interacting 
in a homo- or heterotypic fashion, for example, CEACAM1 will for homodimers though 
binding of the N-terminal domain and CEACAM6 and CEACAM8 can form heterodimers. 
CEACAM dimers also exist within the same membrane where the two distal N-domains can 
form dimers on the same cell and CEACAM1, for example, predominantly exits in homo-
dimeric form (137). All known pathogen adhesins that bind CEACAMs utilise this same 
dimerization interface (CFG face), for example HopQ [H. pylori], Opa [N. meningitidis], 
UspA1 [M. catarrhalis] and Dr adhesins [E. coli] (114, 133, 138, 139).  
The adhesion of pathogens to these receptors can have many different consequences, from 
passive adhesion to direct involvement in pathogenesis, for example, when the HopQ 
protein from H. pylori binds CEACAM1, this allows for the subsequent translocation of the 
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CagA oncoprotein into the target cell, which can lead to an increased risk of tumourigenesis 
(140). Other consequences can be immune evasion, as previously mentioned, via signalling 
using the ITIM domain on CEACAM1, such as with the Opa proteins from N. meningitidis.  
There also exist certain genetic diseases with mutations in the CEACAM genes. A mutant 
variant of the CEACAM16 gene can lead to hearing disorders in later life as this protein is 
specifically expressed in the auditory system (141-144). 
The GPI anchor of CEA (CEACAM5) is thought to have a role in cancer progression – it can 
inactivate the intrinsic cell-death pathway hence inhibiting anoikis (145) and CEA is a known 
biomarker for progression of colorectal cancer (146). However, the specific role of CEA in 
cancer remains vague. 
1.4 Fusobacterium Vaccine Antigen Targets 
Recently, TAAs have been used as successful vaccine antigens, such as the case for NadA 
[N. meningitidis] in a serogroup B meningococcal vaccine (147). This vaccine candidate 
was first proposed over 10 years prior to successful development of the full multicomponent 
vaccine. It was ideal as it was widely distributed and overexpressed in more virulent strains 
making it an ideal target (148).  
Like NadA, the ubiquitous spread of TAAs throughout Fusobacterium represent potential 
future vaccine candidates. As the selection and sequences of TAAs is heavily based on the 
species, there would be little cross-reactivity between the harmful and more benign species, 
for example F. necrophorum compared to F. periodonticum. As mentioned in SECTION 1.1.3.5, 
there has been a number of attempts at cultivating a successful vaccine to prevent footrot, 
however the efficacy of these vaccines has been limited and the transition to equivalent 
human alternatives is doubtful. Therefore, a new approach at specifically targeting bacterial 
surface antigens may provide a promising avenue of research. 





The primary aims of this study are to characterise the interactions between Fusobacterium 
and CEACAMs through the use of genomic, functional and structural analyses. The three 
aspects will combine to give an overall picture of the importance of these interactions and 
how it may vary from species to species. 
Using whole-genome sequencing data, we will firstly clarify the species definition of 
Fusobacterium, which has been a topic of discussion recently (22, 23). The clarification of 
the species should provide an insight into the large disease variance seen between 
separate strains throughout the genus. In addition, we will sequence various 
uncharacterised clinical strains that were isolated from a range of diseases and examine 
their CEACAM-binding profiles and how this relates to Fusobacterium species. 
In addition, we will characterise the proteins involved in CEACAM binding, labelled CbpFs, 
both from a functional and structural perspective using recombinant constructs. We will 
determine specificity to CEACAMs through binding assays and mutagenesis studies. This 
should help to identify features that may be important in disease progression and potentially 
provide useful information with respect to future vaccine design. 
Chapter 2: Materials and Methods 
2.1 Bacterial strains and growth conditions 
Unless otherwise stated, E. coli strains were grown in Luria-Bertani (LB) broth at 37 °C with 
shaking at 200 RPM, or on LB agar plates supplemented with relevant antibiotics and 
compounds at the following concentrations: 100 μg∙ml-1 ampicillin (Amp); 50 μg∙ml-1 
kanamycin (Kan); 34 μg∙ml-1 chloramphenicol (Cm); 100 μg∙ml-1 Zeocin™ (Zeo); 1 mM 
isopropyl β-D-1-thiogalactopyranoside (IPTG); 20 μg∙ml-1 5-bromo-4-chloro-3-indolyl-β-D-
galactopyranoside (X-Gal). Fusobacterium spp. were grown in Fastidious Anaerobe broth 
(FAB) or on Fastidious Anaerobe agar (FAA) at 37 °C under anaerobic conditions: 90 % N2, 
5 % CO2 and 5 % H2 obtained in an anaerobic jar with a 2.5 L Oxoid™ AnaeroGen™ Sachet 
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(Thermo). Both static and shaking conditions were used for liquid cultures. Bacterial strains 
used in this work are listed in TABLE 2.1. Bacterial stocks were maintained at -80 °C in growth 
medium (LB broth or FAB) containing 25 % (v/v) glycerol. 
Table 2.1 | Stock bacterial strain list. 
The clinical strains stated use the source reference identifier as the strain name. 1 Made chemically 
competent. 2 Anaerobe Reference Unit (ARU), Public Health Wales Microbiology Cardiff, University 
Hospital of Wales, Cardiff CF14 4XW. 3 School of Oral and Dental Sciences, University of Bristol, 
Bristol BS1 2LY. 
Strain Name Source 
Stellar™ E. coli Clontech 
BL21 (DE3) E. coli 1 Sigma 
BL21 (DE3) pLysS E. coli Promega 
Rosetta™ 2 (DE3) pLacI E. coli Novogen 
XL10-Gold® E. coli Agilent 
F. nucleatum ATCC 25586T ATCC 
F. nucleatum ATCC 49256T ATCC 
F. nucleatum ATCC 10953T ATCC 
F. nucleatum R32310 ARU 2 
F. nucleatum R31249 ARU 
F. nucleatum R30927 ARU 
F. nucleatum R30464 ARU 
F. nucleatum R32935 ARU 
F. nucleatum R29976 ARU 
F. nucleatum R26872 ARU 
F. nucleatum R24394 ARU 
F. nucleatum R18932 ARU 
F. nucleatum R33458 ARU 
F. nucleatum R30604 ARU 
F. nucleatum R28385 ARU 




F. nucleatum R28211 ARU 
F. nucleatum R33533 ARU 
F. nucleatum R18528 ARU 
F. nucleatum R16531 ARU 
F. nucleatum R5001 ARU 
F. nucleatum R28427 ARU 
F. nucleatum R28400 ARU 
F. nucleatum R15792 ARU 
F. nucleatum 2B3 SODS 3 
F. nucleatum 2B2 SODS 
F. nucleatum 2B16 SODS 
F. nucleatum 2B17 SODS 
F. nucleatum 2B4 SODS 
 
2.2 Eukaryotic strains and growth conditions 
HeLa cell lines used were grown in Roswell Park Memorial Institute medium 1640 (RPMI-
1640; Sigma) containing the following antibiotics and supplements: 100 μg∙ml-1 penicillin 
(Pen); 100 μg∙ml-1 streptomycin (Strep); 300 μg∙ml-1 L-glutamine; and 10 % (v/v) foetal 
bovine serum (FBS). COS-1 cells were grown in Dulbecco’s Modified Eagle Medium 
(DMEM; 1 g∙l-1 glucose; Sigma) containing identical quantities of antibiotics and 
supplements as with RPMI. FBS is replaced with Gibco® Insulin-Transferrin-Selenium (ITS-
G; Thermo) media supplement for low-serum (< 5 % [v/v] FBS) and serum-free 
requirements. CHO cells were grown in Ham′s Nutrient Mixture F12 (Sigma) with the 
addition of the same supplements though lacking serum. All cells were grown at 37 °C with 
5 % CO2 and were passaged before cells became confluent using a tryptic digestion.  
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Table 2.2 | Eukaryotic cell lines used. 
Strain Growth Media  
HeLaNeo RPMI 1640  
HeLaCEACAM1 RPMI 1640  
HeLaCEACAM3 RPMI 1640  
HeLaCEA RPMI 1640  
HeLaCEACAM8 RPMI 1640  
COS-1 DMEM  
CHO Ham’s F12  
 
2.3 Gene Cloning 
2.3.1 Creating a Plasmid for Producing Soluble Recombinant Protein 
Two expression modes were used in assessing CbpF-CEACAM binding – soluble 
extracellular protein and surface expressed protein. 
To produce recombinant soluble CbpF proteins, the genes encoding residues for 
extracellular protein, minus signal peptide, were cloned into pOPINE using ligation-
independent cloning (LIC; In-Fusion® kit; Clontech). The pPOPINE plasmid encodes a 
hexa-histidine tag at the translated protein C-terminus (pOPINE was a gift from Ray Owens 
(149); Addgene plasmid 26043; FIGURE S 1). The plasmid was linearized with the restriction 
enzymes NcoI-HF® (New England Biolabs [NEB]) and PmeI (NEB) at 37 °C for 1 hr and 
the linearized plasmid DNA was purified with a QIAquick® PCR Purification Kit (Qiagen) 
according to the manufacturer’s instructions to exchange buffers and remove the restriction 
enzymes.  
The CbpF region of interest was amplified using the polymerase chain reaction (PCR) with 
primers listed in TABLE 2.4 that had 5’ DNA regions which were homologous with the ends 
of the linear plasmid for use in LIC. PCR was performed using CloneAmp™ high fidelity 
PCR premix (containing deoxynucleoside triphosphates (dNTPs), enzyme and additives; 




Clontech), 0.5 μM primers and 1 ng∙μl-1 genomic DNA. The conditions used in PCR were 
as follows: initial 95 °C 10 min, 95 °C 10 sec, 60 °C 10 sec (some primers required for 
higher/lower temperatures to anneal), 72 °C 5 sec∙kbase-1 DNA, repeat from step 2 30 
times, lastly 72 °C 10 min for the final extension. 
The linearized plasmid and PCR were incubated at 50 °C for 15 min with 1X In-Fusion® 
master mix at a 2:1 molar ratio of PCR to plasmid. The In-Fusion® reaction was then 
incubated with chemically competent Stellar® E. coli cells (Clontech) for 30 min on ice. The 
cells were subsequently heat-shocked by incubating them at 42 °C for 40 secs followed by 
5 min on ice, before the addition of preheated (37 °C) SOC medium (Super Optimal broth 
with Catabolite repression) at a ratio of 1:10 cell suspension to SOC. The cells were then 
incubated with shaking at 37 °C at 200 RPM for 1 hr before plating onto LB agar plates 
(containing Amp, IPTG and X-Gal) and incubated overnight (O/N) at 37 °C. 
Individual white colonies were picked and grown in 10 ml LB broth (containing Amp) O/N at 
37 °C with shaking at 200 RPM before extracting the plasmid DNA using a QIAprep® Spin 
kit (Qiagen). The plasmid was adjusted to a concentration of 100 ng∙μl-1 (as measured using 
a DeNovix® DS-11 FX UV-Vis spectrophotometer) and was sequenced using Sanger 
sequencing (Source BioScience, Nottingham) using the T7F and T7R standard primers. 
Sequences were aligned with the expected sequence and plasmids shown to have the 
correct gene of interest (GOI) were then transformed into expression cells: E. coli BL21 
(DE3), E. coli BL21 (DE3) pLysS (Promega) and Rosetta™ 2 (DE3) pLacI (Novagen) using 
the heat shock method as previously described. The plasmids produced using pOPINE 
were labelled pCFR1 and pCBR1 for CbpFa and CbpFb respectively (TABLE 2.3). 
In addition to using pOPINE in protein production, the pMAL-c5X plasmid (NEB; FIGURE S 3) 
was also used for producing fragments of CbpFa. This plasmid encodes maltose-binding 
protein (MBP) as well as a ploy-asparagine linker directly upstream of the GOI start codon. 
This plasmid was linearized using XmnI and BamHI-HF® (NEB) and purified with identical 
conditions to pOPINE. Constructs using this vector as a backbone are detailed in TABLE 2.3. 
 Chapter 2: Materials and Methods 
   
33 
 
The genes inserted into this vector were amplified using the primers listed in TABLE 2.4 which 
were designed for LIC using In-Fusion®. A hexa-histidine tag was also encoded within the 
3’ reverse primer, therefore providing an additional method of purification in downstream 
applications. 
2.3.2 Creating a Plasmid for Surface Expression of Protein 
The same cloning method was used as described in the previous section, however the 
plasmid pOAF was used. This plasmid encodes the E. coli OmpA signal peptide directly 
upstream of the pOPINF 5’ addon sequence, which contains a hexa-histidine tag and a 
linker sequence prior to the GOI start codon. This plasmid was linearized using KpnI-HF® 
and HindIII-HF® (NEB) for 1 hr at 37 °C and subsequently purified using the QIAquick® 
PCR purification kit as previously explained. 
The regions encoding CbpFa and CbpFb lacking the signal peptide were then amplified by 
PCR (using method described in SECTION 2.3.1) and cloned into pOAF using In-Fusion® LIC. 
Other TAAs from Fusobacterium were cloned into this vector as well as truncation mutants 
of CbpFa. All the plasmids created using pOAF and the primers used in PCR are listed in 
TABLE 2.3 and TABLE 2.4 respectively. After successful sequencing, pOAF-based plasmids 
were cloned into E. coli BL21 (DE3) pLysS (Promega) using the heat-shock method ready 
for expression. 
2.3.3 Site-directed Mutagenesis 
To create mutants of the CEACAM1 N-terminal IgV-like domain, a variant of site-directed 
mutagenesis was performed utilising the LIC with the InFusion® kit. Parent plasmid was 
transformed into XL10-Gold® E. coli competent cells (Agilent), prior to extraction and 
purification using a QIAprep® Spin kit. These cells were used instead of Stellar™ cells as 
they methylate their DNA. Primers were designed where the forward primer contained to 
desired mutation as well as 15 bp of complementary DNA (on the 5’ end) to the 5’ end of 
the reverse primer. The reverse primer was directly upstream of the forward primer, such 
that the whole plasmid would be amplified. After plasmid amplification using PCR and 




verification on an agarose gel, the reaction was purified using a QIAquick® PCR purification 
kit followed by parent plasmid digestion using DpnI (NEB) according to the manufacturer’s 
protocol. This reaction was purified using the PCR purification kit again and 1 μl 5X 
InFusion® master mix was added to 1 μl of digested PCR and 3 μl of water. The reaction 
was incubated for 15 min at 50 °C before transforming into Stellar™ cells using the heat 
shock method. Colonies were selected the following day and 10 ml liquid cultures were set 
up O/N at 37 °C and the plasmids purified using a miniprep kit (Qiagen). Purified plasmids 
were then sent for sequencing to confirm the presence of the desired mutations. Primers 
for these constructs are detailed in TABLE 2.4.  
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2.3.4 Plasmids and Primers 
Table 2.3 | Plasmids List. 
A list of all plasmids used and created in this study. Plasmid maps are detailed in APPENDIX C. hCC1 
– human CEACAM1. 1 pINFUSE-hIgG1-FC2 is the full name. 2 The start residue is 22 and the end 
residue number is 330. 3 APPENDIX B clarifies the CEACAM1 numbering convention. 
Vector Name Backbone CDS Product Resistance Source 
Stock Plasmids 
pOPINE pTriEx-2  AmpR (149) 
pOAF pOPINF OmpA signal peptide AmpR Inhouse 
pcDNA3.1-CC1 pcDNA3.1(+) hCC1 NA1BA2-FC AmpR, NeoR Inhouse 
pMAL-c5X  MBP AmpR NEB 
pINFUSE21  IL2 signal peptide ZeoR Invivogen 
Soluble Protein Expression Plasmids 
pCFR1 pOPINE CbpFa 22-330 AmpR This study 
pCBR1 pOPINE CbpFb 25-374 AmpR This study 
pCFR2 pOPINE CbpFa 22-128 AmpR This study 
pCFR3 pOPINE CbpFa 128-180 AmpR This study 
pCFR4 pOPINE CbpFa 180-235 AmpR This study 
pCFR5 pOPINE CbpFa 214-330 AmpR This study 
pCFR6 pOPINE CbpFa Δ148-1792 AmpR This study 
pCFR7 pOPINE CbpFa 22-283 AmpR This study 
pCFM1 pMAL-c5X MBP-CbpFa 40-331 AmpR This study 
pCFM2 pMAL-c5X MBP-CbpFa 40-190 AmpR This study 
pCFM3 pMAL-c5X MBP-CbpFa 120-240 AmpR This study 
pCFM4 pMAL-c5X MBP-CbpFa 180-331 AmpR This study 
Surface Expression Plasmids 
pCFS1 pOAF CbpFa 22-479 AmpR This study 
pCBS1 pOAF CbpFb 25-519 AmpR This study 
pTAAS1 pOAF FN0471 17-240 AmpR This study 
pTAAS2 pOAF FN0735 25-602 AmpR This study 




pTAAS3 pOAF FNP1391 25-644 AmpR This study 
pCFS2 pOAF CbpFa 111-479 AmpR This study 
pCFS3 pOAF CbpFa 180-479 AmpR This study 
pCFS4 pOAF CbpFa 214-479 AmpR This study 
pCFS5 pOAF CbpFa 293-479 AmpR This study 
pCFS6 pOAF CbpFa 329-479 AmpR This study 
Mammalian Protein Expression Shuttle Vectors 
pCCR3 pINFUSE2 hCC1 NA1B-FC ZeoR This study 
pCN29G pCCR3 hCC1 NA1B F29G-FC3 ZeoR This study 
pCN29I pCCR3 hCC1 NA1B F29I-FC ZeoR This study 
pCN29R pCCR3 hCC1 NA1B F29R-FC ZeoR This study 
pCN29Y pCCR3 hCC1 NA1B F29Y-FC ZeoR This study 
pCN44E pCCR3 hCC1 NA1B Q44E-FC ZeoR This study 
pCN44L pCCR3 hCC1 NA1B Q44L-FC ZeoR This study 
pCN44R pCCR3 hCC1 NA1B Q44L-FC ZeoR This study 
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Table 2.4 | Primers used to create plasmids. 
Both forward and reverse primers are listed for all the constructs made in this study. Regions of 
homology required for LIC are underlined and primer mismatches encoding specific mutations are 
highlighted in bold. 1 gDNA – genomic DNA extracted and purified from parent strain. 2 Two primer 
pairs are listed for this construct as it requires two PCRs, digestion and a ligation to create the insert 
for the final plasmid. The XhoI restriction site is shown in italics. 3 Reverse primers for the pMAL-c5X 
constructs also encode a hexa-histidine tag. 
















































pCBS1 2B3 gDNA 
ATGGTCTAGAAAGCTTTATTTATTTTTTAAATTCATATTTAAT 
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2.4 Bacterial Protein Expression and Purification 
Expression and purification methods were optimised on a case-by-case basis, which will be 
explained where necessary. The most common and reliable methods used are explained 
here in detail and primarily pertain to the expression of the full-length constructs of CbpFa 
and CbpFb. 
2.4.1 Small-scale Expression and Native Purification 
Transformed E. coli BL21 (DE3) pLysS cells were grown in LB (< 1 l) containing Amp and 
Cm until mid-log phase, 𝑂𝑂𝑂𝑂600𝑛𝑛𝑛𝑛 = 0.4, where they were induced with 1 mM IPTG and 
grown for a further 3 hours at 37°C. Cells were harvested by centrifugation at 6000 x g for 
10 min and were resuspended in Lysis Buffer (Native Buffer A [TABLE S 1] with 1X protease 
inhibitor cocktail [TABLE S 1], 1 U∙ml-1 DNAse I [Thermo], 2 mM MgCl2 and 100 μg∙ml-1 
lysozyme [Sigma]). The volume (ml) of lysis buffer used was 5 times the mass (g) of the cell 
pellet. The suspension was incubated on ice for 30 min before sonicating. Lysates were 
spun at >10000 x g for 1 hr and the supernatant was retained.  
His-tagged protein was purified using Ni-NTA agarose (Qiagen). The cell lysate supernatant 
was incubated with Ni-NTA agarose (1:50 ratio agarose to lysate) for 1 hr at 4 °C with gentle 
mixing. The agarose was pelleted by centrifuging the tube for 5 min at 200 x g. The 
supernatant was carefully decanted and retained for downstream analysis. The remaining 
slurry was loaded onto a 5 ml polypropylene gravity flow column. 20 column volumes (CV) 
of Native Buffer A (TABLE S 1) were flowed through the column under gravity. 10 CV of the 
same buffer containing 150 mM imidazole was then run down the column to wash off non-
specifically bound proteins. 5 x 1 CV size elution fractions were collected using Native Buffer 
B (TABLE S 1). 




Fractions were run on an 4-20% acrylamide gel and stained with Coomassie Quick Stain 
(Generon) and assessed for purity. Pure protein fractions were then exhaustively dialysed 
(> 100:1 dialysate to fraction; 3 buffer changes with > 4 hours between each, and one O/N 
at 4°C) against the dialysate of choice, e.g. 20 mM Trizma®-HCl pH 7.5, 100 mM NaCl, 1 
% (v/v) glycerol or phosphate buffered saline (PBS; TABLE S 1). Protein was then 
concentrated to a sufficient concentration using Vivaspin® 20 spin columns (Sartorius; 
protein concentrations were measured using a DeNovix® DS-11 FX UV-Vis 
spectrophotometer with predicted Mr and Ext. coefficient).  
2.4.2 Large-scale Expression and Native Purification 
Rosetta™ 2 (DE3) pLacI cells containing pOPINE with the GOI were inoculated into 10 ml 
LB broth containing Amp and Cm and grown O/N at 37 °C with shaking at 200 RPM. This 
starter culture was then added to total of 8 l autoinduction terrific broth (Formedium), 
containing Amp and Cm, before incubating for 24 hrs at 37 °C with shaking 200 RPM. Cells 
were pelleted and resuspended in Lysis Buffer and sonicated as described previously. The 
cell lysate was applied to a 5 ml HisTrap FF (GE Healthcare) column charged with NiCl as 
according to the manufacture’s procedures and equilibrated with Native Buffer A (TABLE S 
1). The flow through was retained and the column was then connected to an ÄKTA and 
washed with Native Buffer A with a flow rate of 1 ml∙min-1 until a stable UV280 nm absorbance 
was attained. A gradient was then setup with a target of 100 % Native Buffer B (TABLE S 1) 
over a time course of 1 hour. 
Fractions where a clear UV280 nm absorbance peak was observed were retained and 
analysed on a 4-20% SDS-PAGE gel. Fractions with protein bands at the correct size were 
pooled, concentrated and dialysed against SEC Buffer A (TABLE S 1) in preparation for size-
exclusion chromatography (SEC). A gel filtration column (ProteoSEC 3-70 kDa 16x600 mm; 
Generon) was equilibrated with SEC Buffer A before loading the pooled sample and running 
with a flow rate of 0.5 ml∙min-1. Fractions with a strong UV280 nm absorbance peak were 
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analysed on a 4-20% SDS-PAGE gel, pooled and adjusted to the desired concentration for 
use in downstream applications. 
2.4.3 Large-scale Expression and Denaturing Purification 
For purifying protein under denaturing conditions, the protocol remained largely the same 
as under native conditions, however, the cell resuspension and lysis is achieved using 
Denaturing Buffer A (TABLE S 1) which contains 8 M urea with an incubation at room 
temperature (RT) for 1 hr with gentle agitation. The lysed and denatured solution was then 
spun at 10000 x g for 1 hr and the supernatant retained. The supernatant was passed 
through a HisTrap FF column charged with Ni2+ and protein purified as previously described, 
though replacing Native Buffer B with of Denaturing Buffer B (TABLE S 1). Protein containing 
fractions were pooled and concentrated. During concentration using a spin column, the urea 
concentration was reduced in a stepwise manner using concentrations of 6, 4, 2 and 1 M 
urea and the resulting solution was centrifuged at >10000 x g for 20 min and the supernatant 
was exhaustively dialysed against SEC Buffer A (TABLE S 1). The solution was spun for a 
further 5 min at 10000 x g to remove precipitants prior to loading onto the gel filtration 
column where the procedure is identical to native conditions. 
2.4.4 Surface Expression 
To produce surface expressed proteins, cells harbouring the pOAF-based plasmids were 
grown overnight at 37 °C before being diluted in fresh LB broth and grown at 37 °C O/N in 
the presence of 1 mM IPTG, after reaching 𝑂𝑂𝑂𝑂600 𝑛𝑛𝑛𝑛 = 0.4, prior to use in binding assay 
experiments. 
2.5 Fusobacterium Lysate Preparation 
Fusobacterium strains were grown for 2 days under anaerobic conditions as described in 
SECTION 2.1, before being resuspended in PBS (TABLE S 1) containing protease inhibitors 
(TABLE S 1) and adjusting to an 𝑂𝑂𝑂𝑂280 𝑛𝑛𝑛𝑛 = 2. The cell suspensions were then freeze-thawed 




three times to lyse the cells and SDS-PAGE loading buffer (TABLE S 1) was added to a final 
concentration of 1X. Lysates were stored at -20 °C. 
2.6 Human CEACAM IgG1-FC fusion protein production 
2.6.1 DNA Preparation 
For small-scale transfections, plasmid DNA was purified from E. coli XL10-Gold® cells using 
a miniprep kit (Qiagen) to yield >20 μg DNA from a 10 ml O/N culture. For large-scale 
transfections, 1 l cultures of E. coli were setup and grown to O/N before preparing the 
plasmid DNA using an EndoFree® Plasmid Maxi kit (Qiagen) to yield up to 10 mg DNA.  
2.6.2 Large Scale Transient Transfection 
COS-1 cells were grown in T175 tissue culture flasks to 70-90% confluency. The cells were 
washed with copious amounts of Dulbecco’s phosphate buffered saline (DPBS) to remove 
excess serum. The cells were then transfected using Lipofectamine® 2000 (Thermo) 
according to the manufacture’s protocols using serum-free media throughout. Supernatants 
were taken at days 3 and 7 post transfection and analysed by dot-blotting using anti-human 
FC to detect the presence of the recombinant peptide. The resulting positive supernatants 
were pooled, filtered through a 0.2 μm syringe filter (Sartorius) and concentrated to 10 ml 
using centrifugal concentrators (14 ml capacity; 5000 kDa MWCO; Sartorius). 
Concentrated supernatants were diluted 1:1 with Protein A Loading Buffer (TABLE S 1) and 
loaded onto a column containing 1 ml Protein A-Sepharose® resin (Sigma; pre-equilibrated 
with loading buffer) and allowed to run through under gravity. The column was washed with 
20 ml loading buffer to thoroughly remove excess unbound proteins. Protein was eluted into 
1 ml fractions using Protein A Elution Buffer (TABLE S 1; 200 mM Na2HPO4, 100 mM citric 
acid, pH 3.0). The fractions were immediately neutralised with Protein A Neutralisation 
Buffer (TABLE S 1 ; 1 ml 1 M Trizma®-HCl pH 7.5) and samples were collected and analysed 
using a Western blot using a CEACAM-specific primary antibody, AO115. Positive fractions 
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were then pooled and concentrated to a suitable volume and resulting protein concentration 
was quantified using a BCA assay (Thermo) according to the manufacture’s procedures. 
2.6.3 Small-scale Transfections and Purification 
COS-1 cells were grown to 70-90 % confluency in 6-well tissue culture plates. DNA-lipid 
complexes were created using Lipofectamine 3000 (Thermo) and cells were transfected 
according to the manufacture’s protocols. Supernatants were analysed for protein by 
immunodot blotting and positive wells were harvested at day 5, prior to purification.  
Supernatants were diluted in a 1:1 ratio with Protein A Loading Buffer (TABLE S 1) and filtered 
through a 0.2 μm syringe filter. 100 μl Protein A Sepharose® was added per 5 ml diluted 
sample and incubated at RT for 1 hr. Samples were subsequently centrifuged for 5 min at 
200 x g. The supernatant was removed (but retained for further analysis) leaving 
approximately 1 ml liquid to resuspend the resin pellet in. This was then loaded onto 
Pierce™ spin cups (Thermo; paper filters) and spun at 1000 x g for 1 min. All column flow-
throughs were retained for analysis post-purification. 10 CV of Protein A Loading Buffer was 
passed through the columns by iterative centrifugation at 1000 x g for 1 min. 5 fractions with 
1 CV Protein A Elution Buffer (TABLE S 1) was then passed through and immediately 
neutralised with 1:9 ratio of Protein A Neutralisation Buffer (TABLE S 1) to fraction volume. 
All fractions and flow-throughs were analysed for protein using immunodot blotting with an 
anti-human IgG1 FC-AP antibody. Positive fractions were pooled and concentrated to < 100 
μl. 
As the protein yield from this method was very low (not measurable with BCA or NanoDrop) 
quantitative ELISA was used to determine the relative protein abundance as described in 
SECTION 2.7.1, often in the order of fM. 
2.7 Western blots, Immunodot blots and ELISAs 
Proteins were transferred to a nitrocellulose membrane either by direct pipetting and 
vacuum drying (immunodot blots), or by electrophoretic transfer from an acrylamide gel at 




0.3 A for 1 hour (Western blots). For ELISAs, proteins are diluted in carbonate buffer (50 
mM Na2CO3, 50 mM NaHCO3 pH 9.6) to a suitable concentration (0.1 – 1 μg∙ml-1) prior to 
incubation on an ELISA plate for 1 hour at RT or O/N at 4°C. The non-specific binding sites 
on the membrane/plate were then blocked with 3% (w/v) bovine serum albumin (BSA; 
diluted in PBS-T: PBS containing 0.05% [v/v] TWEEN®-20 [Sigma]). Primary antibodies are 
diluted from stock solutions (0.1-1 μg∙ml-1) in 1% (w/v) BSA in PBS-T with 0.05% (w/v) NaN3 
and added to the membrane/wells at RT for 1 hour. The membrane/wells were then washed 
3 times with PBS-T with the final wash incubated for 5 min before decanting. The secondary 
antibody formulation, addition and wash steps are identical.  
The blots were developed using NBT/BCIP in AP buffer. NBT (4-nitro blue tetrazolium 
chloride) stock: 50 mg∙ml-1 in 100% DMF (dimethylformamide); BCIP (5-bromo-4-chloro-3-
indolyl-phosphate) stock: 50 mg∙ml-1 in 70% DMF; AP (Alkaline phosphatase) Buffer (TABLE 
S 1). Developing buffer uses 66 μl NBT and 33 μl BCIP per 5 ml of AP buffer. The 
development was stopped by washing thoroughly with distilled water and the blots were 
then allowed to dry.  
ELISAs were developed using SIGMAFAST™ p-Nitrophenyl phosphate tablets (Sigma) 
dissolved in distilled water and incubated at 37°C for sufficient time to see development 
(0.5-5 hours). The absorbance for each well was measured using a 96-well plate reader 
using a wavelength set to 405 nm. 
2.7.1 Quantitative ELISA 
To measure very low relative protein concentrations, quantitative ELISA (qELISA) was 
used. A protein of known concentration and equivalent immunogenicity (identical protein or 
close mutant) was added in range of concentrations from 100 fM to 100 nM (diluted in 
carbonate buffer). Unknown samples were diluted in a range of 1:10, 1:100 and 1:1000 
sample to carbonate buffer. 100 μl for all conditions and the standards were added to wells 
in an ELISA plate in triplicate. The samples were then incubated O/N at 4 °C before 
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continuing the ELISA as previously described, using an identical specific primary antibody 
for the unknowns and standards. 
After measuring absorbance at 405 nm, a standard curve was produced that adhered to a 
logarithmic curve, which formula was calculated using logarithmic regression. This was then 
used to calculate the unknown concentrations that were within the range of the standard 
curve. 
2.8 Adhesion assays 
2.8.1 Eukaryotic cell preparation 
HeLa cells transfected with DNA conferring neomycin resistance and with the human 
CEACAM genes were grown to confluence at 37 ° in a T75 flask. The cells were trypsinised, 
collected, counted and diluted to attain a 20% confluence in a 96-well plate (approximately 
2x104 cells). 100 μl of cell suspension was added to each well and grown for 48 hours until 
confluent. The media was replaced with antibiotic free pre-warmed (37 °C) Medium 199 
(Sigma) and washed a further 2 times to remove traces of antibiotics from the wells.  
2.8.2 Inhibitor preparation 
The recombinant peptides rD-7 and MsfA (kindly provided by Darryl Hill and Clio Andreae 
respectively) were diluted to a concentration of 10 μg∙ml-1 in Medium 199 (at 37 °C) and 
100 μl was added to the relevant wells. The plates were incubated for 30 minutes at 37 °C. 
The media was then removed prior to bacterial incubation. 
2.8.3 Bacterial preparation 
The bacteria to be tested were grown and induced as described earlier. The overnight 
cultures were diluted to 𝑂𝑂𝑂𝑂600𝑛𝑛𝑛𝑛 = 1 in Medium 199 (at 37 °C) to reach an estimated 
multiplicity of infection (MOI) of 500 bacterial cells per 1 eukaryotic cell. All medium was 
removed from the wells and 100 μl of the bacterial suspension was then added. The plates 
were incubated for 3 hours at 37 °C. 




2.8.4 Cell fixation 
After incubation with bacteria, each well was washed thoroughly with pre-warmed Medium 
199 four times to remove any unbound bacteria. The wells were then washed twice with 
warm DPBS. All liquid was removed from each well and 50 μl of 4% (w/v) paraformaldehyde 
(PFA; dissolved in PBS) was added. The plates were incubated at 4 °C O/N to fix. The PFA 
was removed and the wells washed twice with DPBS-Azide (DPBS containing 0.05% [w/v] 
Sodium Azide [NaN3]) to remove any residual PFA to prevent interference with antibody 
staining.  
2.8.5 Cell staining 
The wells were blocked to prevent non-specific antibody binding to the well surface by 
adding 100 μl of 3% (w/v) BSA and incubating at RT for one hour with gentle agitation. The 
BSA was removed and 100 μl of rabbit anti-E. coli LPS (Biogenesis) diluted to 1 μg∙ml-1 in 
1% (w/v) BSA in PBS-T, containing 0.05% NaN3, was added to each well and incubated for 
one hour at RT with gentle agitation. The primary antibody was aspirated off and the wells 
were washed thoroughly three times with PBS-T with the final wash step incubating in PBS-
T for 5 minutes at RT with gentle agitation to remove residual antibody. 100 μl of the 
secondary antibody (Goat anti-Rabbit Alexa Fluor® polyclonal antibody conjugated to 
Fluorescein isothiocyanate [FITC; Thermo Scientific]) diluted to 1 μg∙ml-1 in 1% (w/v) BSA 
in PBS-T with 0.05% NaN3 was added to each well and incubated at RT with gentle agitation 
for one hour. The secondary antibody was removed, and the wells washed as before three 
times with PBS-T. 100 μl of 0.1% (v/v) Triton™ X-100 (diluted in distilled water) was added 
to each well and incubated at RT for 10 min to permeabilize the HeLa cells. The liquid was 
aspirated off and 100 μl of 4',6-diamidino-2-phenylindole (DAPI; Sigma) diluted to 1 μg∙ml-1 
in 1% (w/v) BSA in PBS-T with 0.05% NaN3 was added and the plates incubated for 15 min 
at RT with gentle agitation. The wells were washed as before to remove any excess DAPI 
with PBS-T three times prior to the addition of 50 μl of PBS-Azide to each well.  
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2.8.6 Cell imaging 
A photograph of representative cells within each well was taken using a fluorescent 
microscope (Olympus IX70) using wavelengths set at 360 nm and 500 nm to detect DAPI 
and FITC respectively. Bacteria fluoresced green and HeLa cell nuclei blue. Images were 
captured using a Hamamatsu C4247-95 ORCA 100 series camera and analysed using 
HCImage (release 4.3.1; Hamamatsu Corporation). Post analysis of images only examined 
the green channel and calculated total fluorescence. 
2.9 Crystallography 
Purified protein was concentrated to a concentration between 1-10 mg∙ml-1, where the 
highest possible concentration was favoured prior to precipitation. Concentration was 
determined using a NanoDrop using predicted extinction coefficient and molecular weight, 
calculated using ExPasy ProtParam tool (150). Protein solutions were screened against a 
variety of high throughput crystallography screens with drop volume, ratio and protein 
concentration being varied as well. High throughput screens and proteins were dispensed, 
using a Crystal Phoenix robot (Art Robbins Instruments), onto 96-well sitting drop MRC 2 
Lens Crystallisation UVXPO Microplates (SWISSCI), with a typical reservoir volume of 50 
μl and a combined drop volume ranging between 0.4-1 μl (with varying ratios of protein to 
precipitant). 
Post dispensing, plates were incubated and imaged in a ROCK IMAGER® (Formulatrix) 
either at 20 or 4 °C. Images were collected using visible, UV and cross polarised light and 
plates were monitored for crystal growth for up to one year. Any hits identified were either 
directly looped and frozen in liquid nitrogen (see SECTION 2.9.1) or an optimisation screen 
was setup around the hit conditions, altering factors such as pH, precipitant, protein 
concentration, drop ratio etc.  




2.9.1 Crystal Looping and Data Collection 
Promising crystals that we wanted to collect X-ray scattering data for were looped using a 
LithoLoop™ (Molecular Dimensions) with cognate dimensions to the crystal. The looped 
crystal was briefly incubated (< 2 min) in a cryoprotectant solution containing 30 % (v/v) 
glycerol, if there was not already a cryoprotectant at sufficient concentration in the drop 
solution. The cryoprotectant was a close condition match (identical buffer, pH, salts and 
precipitants) to the original drop, however containing the glycerol. After incubating the 
crystal for approximately 1 min in cryoprotectant, the crystal was transferred directly into 
liquid nitrogen and kept there until data was collected. 
Data were collected on a synchrotron X-ray beamline (I04-1, Diamond Light Source) with 
360° of rotation with 6 data frames collected per degree. Data reduction and analysis was 
performed using the iMOSFLM (151), CCP4 (152) and Phenix (153) program suites where 
the specific procedures are described in the relevant sections. 
2.10 Small-angle X-ray Scattering 
Protein samples were prepared and concentrated to 5-10 mg∙ml-1 in a minimal buffer, 
typically 50 mM Tris-HCl pH 7.5, 200 mM NaCl. 45 μl of sample was loaded onto either a 
Superdex 200 Increase 3.2 (2.4 ml) or Shodex kW-403 (4.6 ml) column connected to an 
HPLC where the frames were captured on the eluate at a rate of 3 f∙s-1. Data were collected 
on a high energy X-ray beamline at a synchrotron (B21, Diamond Light Source). The 
collected data was subsequently processed using ScÅtter (version 3.0). Frames 
corresponding to peaks on the A280 nm trace were merged and averaged about regions where 
the estimated Rg was consistent. Buffer subtraction was performed using averaged frames 
directly prior to the first peak. Further SAXS analysis, including Guinier analysis, 𝑃𝑃(𝑟𝑟) 
distribution fitting and dummy atom modelling are described in detail in the appropriate 
section. 
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2.11 Molecular Dynamics 
Spatiotemporal molecular dynamics (MD) was performed using GROMACS (Groningen 
Machine for Chemical Simulations; version 5.0) (154, 155). Simulations were conducted 
using either the GROMOS 54a7 (156) or the OPLS-AA/L (157) forcefields. The system was 
solvated using the SPC/E water model (extended simple point charge model) (158) prior to 
adding 0.1 M Na+ and Cl- ions (by replacing water molecules) and neutralised to a net 
charge sum of 0 with additional Na+ or Cl- ions as necessary. 
The system underwent energy minimisation prior to temperature and pressure equilibration. 
Full details of the default molecular dynamics parameters (MDP) are given in the digital 
information appendix (APPENDIX I). The system was temperature and pressure equilibrated 
for 100 ps each before running 1-100 ns production MD. For longer time courses, MD was 
performed on the BlueCrystal high performance computing (HPC) machine utilising MPI to 
run across 100s of computer cores or in GPU-accelerated mode. 
The resulting trajectory was re-centred on the protein while removing the periodic boundary 
conditions (PBC) that were set on initialisation. The root-mean-square deviation (RMSD) 
was then calculated over the MD time course on the protein backbone. Further details will 
be provided in the necessary sections. 
2.12 Whole Genome Sequencing 
Isolates chosen to be sequenced had their genomic DNA prepared using a DNeasy® Blood 
& Tissue kit (Qiagen) according to the manufacturer’s instructions. Genomic DNA integrity 
was verified on a 0.8 % (w/v) Agarose Tris-Borate-EDTA (TBE) gel – any lanes containing 
a smear, indicating DNA degradation, were re-purified. Purified genomic DNA was sent to 
MicrobesNG™ (Birmingham, UK) who carried out sequencing, assembly and initial 
annotations. Genomes were sequenced with a minimum 30X coverage using the Illumina 
MiSeq platform with 250 bp paired-end reads. 





2.13.1 Genome and Proteome Mining 
All up-to-date (as of March 2018) genomes and proteomes tagged as Fusobacterium were 
downloaded from the GenBank and RefSeq FTP repositories (159, 160) using a search and 
retrieval script. Both databases were used as some files are only found in one and not the 
other. GCA (GenBank) and GCF (RefSeq) assembly accession numbers were filtered to 
use the GenBank over the RefSeq accession where available. Human-readable names 
were then assigned using the species and strain information found within the assembly 
report file. 
2.13.2 Average Nucleotide Identity 
Average nucleotide identity (ANI) scores were calculated using a program called orthoANI 
(161) which utilises USEARCH (162) to implement fast genome searches and comparisons. 
ANI scores, denoted 𝐴𝐴𝑎𝑎𝑎𝑎𝑎𝑎, range from 25 % (all noise; meaningless result) to 100 % 
(complete identity). For use in some post-analyses, 𝐴𝐴𝑎𝑎𝑎𝑎𝑎𝑎 was converted to relative distance 
(𝐴𝐴𝑟𝑟𝑟𝑟𝑟𝑟) using EQUATION 2.1.  





When 𝐴𝐴𝑟𝑟𝑟𝑟𝑟𝑟 equals 0, the two strains are identical and a score of 100 is the most distant 
comparison in the full set. Because the relationship is increasing with distance, phylogenetic 
trees can easily be created using this value. 
2.13.3 Maximal Unique Matches and MUMi 
The MUMmer package was used to generate unique matches between two genomes. 
Genome sequences containing multiple scaffolds or contigs were concatenated prior to 
running MUMmer, such that the output result could be processed by downstream scripts 
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provided with the package. The input for MUMmer consisted of each genome with a minimal 
match length (𝑙𝑙) equal to 19 to produce the following terminal command:  
“mummer -𝑚𝑚𝑚𝑚𝑚𝑚 -𝑏𝑏 -𝑐𝑐 -𝑙𝑙 19 genome1 genome2 > mummer_out”.  
The MUMmer output file was then parsed to a Perl script (163) with the two genome lengths, 
which outputted a value between 0 and 1 for genomic distance: 0 being identical and 1 
being extremely distant – this is called a Maximal Unique Match index (MUMi; 𝑀𝑀𝑖𝑖).  
A script was written in Python to compare all downloaded genomes to one another utilising 
multiple processes. To increase speed and efficiency of the included MUMi script, it was 
translated into an optimised Python script that could directly process the MUMmer output. 
The scripts used are posted on GitHub (164). 
To produce a 𝑀𝑀𝑖𝑖 that correlated with 𝐴𝐴𝑎𝑎𝑎𝑎𝑎𝑎 and 𝐴𝐴𝑟𝑟𝑟𝑟𝑟𝑟 in a linear fashion, a transformation was 
applied to 𝑀𝑀𝑖𝑖 in post analysis, with the result denoted 𝑀𝑀𝑟𝑟 in EQUATION 2.2. 





Identical strains remain at 0, however, more distant strains will separate further, with no 
upper bound. For the strains tested, 𝑀𝑀𝑟𝑟 positively correlates with 𝐴𝐴𝑟𝑟𝑟𝑟𝑟𝑟 with an approximate 
linear relationship. Like 𝐴𝐴𝑟𝑟𝑟𝑟𝑟𝑟 this score can also be used to create phylogenetic trees. 
2.13.4 Pan-Locus Sequence Analysis 
Conserved protein sequences were isolated from the whole proteome set of Fusobacterium 
using successive BLAST (165) queries and filtering out hits with % similarity < 65 % and 
coverage < 60 % to produce refined proteomes with ordered analogous protein sequences. 
From these, random gene samples (n = 10) were taken from each, concatenated and 
aligned using MUSCLE (166), with the maximum number of iterations set to 2 to limit the 
time spent aligning. Pairwise distances were calculated from the alignments using the 




Poisson correction model in MEGA7 (167). The random sampling, alignment and distance 
calculation steps were repeated 1000 times.  
The distances between strains for all trees were collated and averaged for each strain pair, 
denoted 𝑁𝑁𝑎𝑎 (average number of amino acid substitutions per site). 𝑁𝑁𝑎𝑎 = 0 is an exact match 
and 𝑁𝑁𝑎𝑎 approaching 1 is very dissimilar – and impossible in the analysis, as dissimilar 
proteins were filtered out in the pre-processing stage. The scripts for this analysis can be 
found at GitHub (168). No post-processing was applied to this score as it already has the 
desired properties. 
2.13.5 Phylogenetic Trees 
Pairwise distances from 𝑁𝑁𝑎𝑎, 𝑀𝑀𝑟𝑟 and 𝐴𝐴𝑟𝑟𝑟𝑟𝑟𝑟 were arranged into the MEGA or Nexus file formats, 
from which, phylogenetic trees were created using MEGA7 (167) or SplitsTree4 (169) 
respectively. These trees were then converted to either unrooted phylogenetic trees or 
rooted phylograms using the BioNJ (Biological Neighbour Joining) method (170, 171) or the 
UPGMA (Unweighted Pair Group Method with Arithmetic Mean) method as stated when 
performed. 
Protein sequences were aligned using Clustal Omega (172) before creating phylogenetic 
trees in MEGA7 using the BioNJ method with 1000 bootstrap replications to measure 
branch confidence. 
Group clustering analysis was performed using a simple agglomerative algorithm that 
grouped strains based on genomic distances in accordance to the similarity threshold that 
was set prior. The corresponding outgroups were then scored against each other using the 
mean distance between each individual pair within the two groups. From these scores, 
condensed phylogenetic trees could be created using the same method as described 
previously. 
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2.13.6 Hive Plots 
For direct visualisation between two or more lengths of DNA, hive plots were used to show 
the regions of homology graphically. To do this, a Python script was written to perform 
homology searches between regions of DNA using BLASTN (version 2.7.0). In essence, 
the first length of DNA was split into sequential, overlapping, shorter chunks with equal 
lengths. The lengths of the chunks and the region of overlap varied according to the desired 
resolution, for example, a whole genome of about 2 Mbp would be split into 1000 bp regions 
with 500 nucleotide overlaps. A BLAST database was created for the second genome using 
the BLAST+ suite (165), before carrying out searches for each length of DNA. Up to four of 
the highest scoring hits were retained and evaluated based on sequence identity. A cut-off 
for identity was set, by the user, and any hit below this threshold was excluded from the 
graphical representation as well as regions that had no hits. Hits were then matched 
between two linear representations of the lengths of DNA and a connecting line was 
coloured according to the percent identity. The script for this application was posted on 
GitHub (173). 
2.14 Statistics 
Unless otherwise stated, all experiments conducted consisted of at least three biological 
repeats, including three technical replicates where practical. The relevant statistical tests 
are stated in the text, with p values lower than 0.05 considered significant. The R software 
package (174) was utilised to perform tests such as ANOVA (Analysis of Variance) or 
PPMCC (Pearson’s Product Moment Correlation Coefficient). Phylogenetic statistics, 
unless otherwise stated, were generated in the MEGA7 application (167).  




Chapter 3: A comprehensive phylogenetic analysis of the 
Fusobacterium genus 
3.1 Introduction 
Recently, conflicting classification of some Fusobacterium species has been reported in the 
literature (22, 23, 175) and it is now raising questions regarding phylogenetic boundaries in 
general. The current accepted definition of species, from a genomics perspective, is ≥ 70 
% DNA-DNA Hybridisation (DDH) and/or ≥ 98.6 % 16S identity, though other more stringent 
values have been suggested (176).  
The importance of describing a species is vital in many fields ranging from medicine to 
biosecurity, though none of these rely solely upon genomic similarity for the importance of 
classifications, rather use their shared phenotypic traits. However, it is likely that organisms 
that have closer genetic similarity will possess a similar phenotype, though this is excluding 
mobile genetic elements. In the case of Fusobacterium spp., mobile genetic elements are 
less concerning when examining genetic composition as they are not naturally 
transformable due to their diverse array of restriction endonuclease systems, though some 
strains have been found to possess plasmids (177-179). Therefore, by only examining the 
genome, this would provide enough information to determine the most likely phenotype of 
any given strain.  
Modern computational approaches can reverse engineer DDH values, such as Average 
Nucleotide Identity (ANI), Genome-Genome Distance Calculator (GGDC) and Maximal 
Unique Matches index (MUMi). It has been shown that these methods correlate well with 
empirically derived DDH values, with a 95 % ANI score representing approximately 70 % 
DDH (180). Computational and empirical DDH values both exhibit pitfalls that over- and 
underestimate species difference, for example, neither method considers mobile genetic 
elements that may be passed around between a subset of organisms, though this is less of 
a concern for Fusobacterium spp., for reasons previously explained. Other intra-genome 
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rearrangements would decrease DDH considerably; however, this limitation is largely 
overcome by most computational methods that do not bias neighbouring genes as strongly. 
However, incomplete genomes from whole-genome sequencing (WGS) studies will reduce 
the accuracy of computational methods and the genus of Fusobacterium has many 
incomplete (contig/super-contig/scaffold levels) genomes. Further complications exist 
inherently within all Fusobacterium strains where the GC % content is extremely low, 
ranging between 25 and 35 % typically across the genus, which has the effect of biasing 
certain sequences, hence leading to overrepresentation of short runs of nucleotides.  
It has been proposed that the Fusobacterium nucleatum (Fn) species be dismantled and 
the current acknowledged subspecies of animalis, nucleatum, polymorphum, vincentii and 
W1481 be reclassified as separate species (22). These proposals were justified using 
reverse engineered DDH values produced by ANI and GGDC methods. Some of the results, 
however, conflicted with 16S rDNA comparisons where the predicted DDH value was < 70 
% and 16S rDNA was > 98.6 %. One such result came when comparing Fn subsp. 
polymorphum CTI-6 strain to the F. hwasookii KCOM 1249T type strain, which exhibited a 
99.7 % 16S identity and 49.3 % predicted DDH. As later discussed, the scope of this study 
could have been extended further into the realms of the whole genus, with the omission of 
the F. periodonticum species and no representation of the other clinically important strain, 
F. necrophorum, which both would have impacted the conclusions drawn. 
This study explores different computational methods for classifying the entirety of 
successfully sequenced genomes (at the time of writing) from the Fusobacterium genus 
and what implications this may have on the taxonomy for the genus. Furthermore, some 
new, previously uncharacterised clinical strains will be sequenced and brought into the 
analyses. Three principle approaches were used for computational analysis, one proteomic 
method and two established genomic analyses respectively: Pan-Locus Sequence Analysis 
(PLSA), MUMmer (Maximal Unique Matches) and Average Nucleotide Identity (ANI). 




In addition to the analyses conducted in this study, the results can be compared with a much 
larger recent global study regarding the reclassification of all bacterial species (23). 
3.2 Whole-Genome Sequencing of Clinical Strains 
For work carried out in later chapters of this study, we examined various clinical 
Fusobacterium isolates for their CEACAM1-bining propensities, and the proteins related to 
this. By comparing our strains to the current database, we aimed to use these additional 
data to validate the genetic comparison approaches used in this chapter. 
From our lab collection of clinical strains, obtained from the Anaerobe Reference Unit 
(Cardiff, UK; TABLE 2.1) and School of Oral and Dental Sciences (Bristol, UK; TABLE 2.1), 25 
isolates were chosen for whole-genome sequencing. The strains to sequence were 
primarily chosen for whether they could bind CEACAM1, as well as a few that did not to for 
comparison. The CEACAM1 screening is described further in CHAPTER 4. Additionally, we 
aimed to keep the associated pathologies from which the strains were cultured as varied as 
possible. Four strains were isolated from blood culture, five from the oral cavity, two from 
cerebrospinal fluid and the remaining from various abscesses and pus. 
The whole-genome sequencing method is described in detail in the Methods (SECTION 2.12). 
In short, the bacteria were grown under anaerobic conditions and had their genomic content 
extracted and purified. This was then sent off for sequencing, where library preparation, 
sequencing and initial analyses were conducted. Draft genome assemblies were returned 
together with gene annotations and data quality. All the strains had a genome coverage that 
exceeded 30X giving sufficient depth for further analyses.  
From the results, 22 of the strains examined returned whole genomes at the contig 
assembly level. Each possessed genomic traits expected of Fusobacterium, such as 
approximately 2 million base pairs (Mbp) of DNA and a GC % content between 25 and 35 
%. Three of the tested strains exceeded these expected parameters. The R33458 strain 
was found to be a mixed culture of Fusobacterium (likely vincentii) and Bacillus sp. 
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(unidentified species). The 2B17 strain had an abnormally large genome (3.7 Mbp), though 
none of the genomic content appeared abnormal with respect to Fusobacterium. This could 
have been due to poor assembly or issues with library preparation; however, the genome 
could still be used in some downstream analyses. The 2B3 strain also could not be resolved 
to a single species and finished with a large heterogeneous genome of 8.2 Mbp, and thus 
could not be used accurately within ANI and MUMi analyses as there is a bias introduced 
with any contaminating genomic content. However, for all 25 strains examined, PLSA could 
still be carried out, as any anomalous genes from contaminating organisms were discarded 
at the filtering stage (see PLSA method; SECTION 2.13.4). 
Strains were assigned to a specific species/subspecies using MUMi against the reference 
type strains that have been identified. For 5 strains, excluding the aforementioned 
anomalous strains, a subspecies/species could not be matched. For the remaining strains, 
they each fell into either the nucleatum, vincentii or animalis subspecies, with no 
representation of polymorphum, W1481, hwasookii or periodonticum. TABLE 3.1 lists the 
results of the WGS together with the initial classifications made. 
The reference strains used were: Fnn ATCC 25586T (nucleatum), Fnv ATCC 49256T 
(vincentii), Fna 7_1 (animalis), Fnp ATCC 10953T (polymorphum), Fnw (W1481), Fperio 
ATCC 33693 (periodonticum), Fh ChDC F128 (hwasookii), Fmal Marseille-P2749 
(massiliense), and Fr ATCC 25533 593A (russii). A MUMi score (𝑀𝑀𝑖𝑖(19)) less than 0.4 
considered the same species (the reason for this value is explained in SECTION 3.4). As all 
strains examined had initially been typed as F. nucleatum originally, only strains within the 
major clade surrounding nucleatum were initially used for testing, with the most distant 
strain used being F. russii. 
  




Table 3.1 | Whole-Genome Sequencing Results. 
1 Species prediction compared the MUMi result to a representative of each species. Species names 
listed conform to the new nomenclature explained later. 2 No matched type-strain, so assigned as 
novel species. 3 Inconclusive sequencing. 4 Low coverage. 2B- strains from SODS. R- strains from 
ARU. 





2B16 27 218887 65.5 2248027 nov.2 
2B173 967 52747 34.1 3808046 vincentii 
2B2 106 44814 36.2 2279829 nov. 
2B33 891 33561 59.8 8247164 multiple 
2B4 18 282219 235.8 2261255 nov. 
R15792 135 49336 136.0 2640740 animalis 
R16531 109 44665 43.2 2122526 nov. 
R18528 80 71186 117.5 2457181 nucleatum 
R18932 91 52467 48.3 2291618 animalis 
R24394 223 18552 33.2 2268759 nucleatum 
R26872 18 369250 118.6 2251292 vincentii 
R28211 76 71725 56.4 2343767 vincentii 
R28385 107 36920 32.6 2136526 nucleatum 
R28400 68 60923 56.0 2221750 nucleatum 
R28427 45 69838 111.3 2152299 nov. 
R29976 64 66844 30.7 2191054 vincentii 
R30464 21 503369 270.2 2098906 vincentii 
R30604 33 173259 106.8 2197183 vincentii 
R30927 166 41066 84.3 2784735 animalis 
R31249 23 259872 111.3 2095525 vincentii 
R32310 27 216428 52.5 2237187 vincentii 
R32935 56 99708 48.1 2178570 nucleatum 
R334583 903 30252 27.34 8140144 multiple 
R33533 48 96764 41.4 2140227 vincentii 
R5001 229 19824 35.8 2574309 animalis 
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3.3 Method Comparison 
3.3.1 Pre-screening for Non-Fusobacterium Strains 
Prior to continuing with other analyses, certain strains were found to most likely not be 
Fusobacterium, though their classification suggested otherwise. These include F. sp. 
CAG:815, F. sp. CAG:439 and F. naviforme ATCC 25832. These strains were likely 
classified according to 16S rRNA identity, which is not a good metric when comparing 
Fusobacterium species as it can be often misidentified for Clostridium 16S rRNA and, as 
previously mentioned, distinct species within Fusobacterium have 16S % identities higher 
than what is needed for species definition. These discrepancies were found in preliminary 
testing with MUMi against representative strains from each species. These three strains all 
had a score distinctly above any other pairwise comparison, with F. naviforme ATCC 25832 
being the most dissimilar to everything else. It is overwhelming likely they are not 
Fusobacterium strains – the fact they lack the mre genes (rod-shape determining proteins; 
highly conserved among all Fusobacterium) immediately gave cause for concern. The mre 
genes by themselves are a good indication for classifying a bacterium within the 
Fusobacterium genus, however comparative resolution is lost when examining 
species/subspecies relationships, which is a similar drawback when using 16S rRNA-based 
classification.  
We also included the newly sequenced strains in all analyses conducted, partly to confirm 
the initial classifications made, but also whether comparing them to all strains in the 
database, we could identify the unclassified strains or even classify them as novel species. 
Three clinical strains, R33458, 2B17 and 2B3, were excluded from analysis with MUMi and 
ANI due to likely contaminating genomic content; however, they were still included in PLSA 
as this should not be greatly affected. 
3.3.2 Average Nucleotide Identity 
The first approach used for whole-genome analysis was Average Nucleotide Identity (ANI), 
which is the current gold standard for computational genomic distance calculation (180). 




This yields an overall percent identity between two organisms. A pair scoring above 95 % 
are generally considered matching species, based on a reversed engineered DDH value of 
approximately 70 % (180). For each strain in Fusobacterium, a pairwise ANI score (𝐴𝐴𝑎𝑎𝑎𝑎𝑎𝑎) 
was given to each using the orthoANI software package (161). This leverages the 
USEARCH program (162) for performing genomic searches and uses the results to infer 
overall identity. This provides a severe limitation in computation speed and can take days 
or even weeks of computation time for only a few thousand pairwise comparisons. This 
program had to be compiled and run on the inhouse supercomputer BlueCrystal (University 
of Bristol) in order to achieve results more quickly. Aside from the computational difficulties, 
ANI provided the most human-readable result in clear genomic percentages, where other 
methods were somewhat more abstract. In addition, the species threshold for this technique 
has been previously established (180). 
3.3.3 MUMmer and MUMi 
The second genomic analytical method used the MUMmer (Maximal Unique Matches) 
application with the related MUMi (MUM index) package (163, 181). This method uses 
MUMmer to identify unique matches with a minimum length between genomes and then 
lists the regions, which is then fed to a script (MUMi) that produces a score. The pairwise 
scores (𝑀𝑀𝑖𝑖) produced are distilled to a value between 0 and 1, with 0 being identical and 1 
being very distant (see Methods for details; SECTION 2.13.3). Throughout the remainder of 
this study, the minimum match length for MUMmer, 𝑙𝑙, was set to 19. This was determined 
to be a suitable value for whole-genome comparisons between Fusobacterium strains and 
was used in a previous study comparing Fusobacterium species/subspecies (175). Higher 
values would increase resolution for similar strain comparisons while decreasing the 
resolution for more distant pairs.  
To improve the execution speed and compatibility of this program, the MUMi-generating 
script as described in (163) was converted into a Python script that could directly process 
the MUMmer output in a more efficient manner. All the scripts were then packaged into one 
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main script, which again allowed for the leveraging of multiple processors to improve speed 
and scalability. The scripts used are posted on GitHub (164).  
One limitation of MUMi is that comparable resolution is lost when examining two more 
distant genomes. This is primarily an issue for data visualisation as it is harder to interpret 
the scale with increased resolution for more similar organisms. To overcome this issue, the 
MUMi value was transformed (EQUATION 2.2) such that a linear correlation to ANI was 
produced (the transformed value is described as 𝑀𝑀𝑟𝑟; see Methods), thus increasing 
resolution at the distant ends. FIGURE 3.1 shows all genome comparisons using 𝑀𝑀𝑖𝑖 and 𝑀𝑀𝑟𝑟 
values and how they differ graphically and their correlations with respect to ANI and PLSA. 
Formulae representing MUMi will represented in the following form herein: 𝑀𝑀𝑥𝑥(𝑙𝑙) where 𝑙𝑙 
equals the minimum match length and 𝑥𝑥 equals either 𝑖𝑖 (raw) or 𝑙𝑙 (transformed) depending 
on the scenario. 
3.3.4 Development of Pan-Locus Sequence Analysis 
In the past, MLSA (Multi-locus Sequence Analysis) based studies used a very limited subset 
of genes (typically fewer than 10) known to be found within all target species to classify 
different strains based on more subtle changes in sequence. In this method, all similar 
genes were identified within all species of Fusobacterium using a proteomic-based search 
with a cut-off value of > 65 % similarity and > 60 % coverage. This was achieved using an 
iterative local BLASTP (BLAST+ version 2.7.1) search with filtering and refinement at each 
stage, the Python script used (168) was optimised for multicore execution running multiple 
BLAST searches split across all cores before refining and running new restrained searches. 
This method vastly increased execution time versus optimising the individual searches 
themselves across many cores, as this did not fully utilise the performance available. 
In total, 215 conserved protein sequences were found, out of approximately 2000 total 
predicted protein-coding regions per organism. The number would almost certainly be 
higher if more of the deposited sequences in GenBank (182) and other genome archives 




were complete, therefore reducing the number of partial genes that would be discarded at 
the filtering stage due to a lack of coverage. This is an inherent problem with Illumina-based 
sequencing platforms where read lengths are shorter and so the resulting assembly has 
more short gaps where repeat sequences for example could exist. As confirmed with MUMi 
in the preliminary stage, two labelled Fusobacterium strains, F. sp. CAG:439 and F. sp. 
CAG:815, were so different from everything else that the conserved gene pool produced 
was very limited at fewer than 50 and so were omitted from the analysis.  
From the refined list of conserved proteins, a 10-protein random sample was taken, 
concatenated and aligned using MUSCLE (version 3.8.31). The sample size was set at 10 
to ensure enough internal diversity, but also not too many such that execution time was 
greatly increased. Pairwise distances were calculated from the alignment using the Poisson 
correction model (183) in MEGA7, which produced a result pertaining to the average 
number of substitutions per site. This process was repeated 1000 times and the distances 
between each strain pair were averaged. As before each individual alignment was assigned 
to a single thread where multiple alignments and scoring was performed across as many 
cores as available, as opposed to running MUSCLE in multithreaded mode. 
A script was written in Python to combine all the stages of the process of the analysis and 
completely automate execution for many strains (168). 
3.3.5 Score Comparison 
Overall, all three methods yielded data that strongly correlated with one another. When a 
Pearson’s Product Moment Correlation Coefficient (PPMCC) is applied the following 
statistics were obtained:  𝜌𝜌 ≥ 0.98 or 𝜌𝜌 ≤ −0.98 and  𝑝𝑝 < 0.01 for all comparisons of ANI, 
LMUMi and PLSA (FIGURE 3.1). FIGURE 3.2 shows the comparison MUMi and PLSA against 
ANI at the highly similar end of the scale demonstrating where the cut-off for species 
definition is for each method. From looking at these data, it is very clear where the cut-off 
for ANI lies as there is a distinct separation at the 94 % mark; however, the same cannot 
be attributed to PLSA or MUMi, though the species cut-off for MUMi groups the same strains 
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as ANI does. This is mostly the case for PLSA, though, there are a number of conflicting 
results, but these are restricted to F. periodonticum comparisons which will be discussed 
later. 
 
Figure 3.1 | Distance method overall correlations. 
The above set of graphs show the correlations between the three methods used with r (ρ) and p 
values according to Pearson’s Product-Moment Correlation test. Included are two transformations 
applied to ANI and MUMi (EQUATION 2.1 and EQUATION 2.2 respectively) that were used in some 
analyses. All methods correlate strongly, though variance increases at the low-resolution 
comparisons. MUMi – Maximal Unique Matches index; ANI – Average Nucleotide Identity; PLSA – 
Pan-Locus Sequence Analysis; LMUMi; Linear-transform of MUMi; RANI – Relative-inverted ANI. 
  
PLSA 





Figure 3.2 | Comparison between the three methods used at the intra- and interspecies 
interface. 
This species interface can be clearly identified from examining the ANI score, where there is a distinct 
gap in the data. This gap is not so evident when only looking at the MUMi or PLSA results; however, 
MUMi does have the same gap as ANI, though it is much slighter. PLSA on the other hand does not 
share this gap and there are a group of conflicting results. ANI v MUMi – blue; ANI v PLSA – orange.  
 
Each method has their own advantages and disadvantages for speciation and it is not 
entirely certain if only performing one analysis is sufficient. Nonetheless, each of these 
methods has a distinct improvement over 16S rRNA sequence identity or single gene 
comparisons, by taking direct observations spanning entire genomes.  
3.4 Defining the Taxonomic Boundary 
For the majority of strain comparisons, a clear definition is seen between intraspecies and 
interspecies in agreement with Kook et al (22). The highest score between two distinct 
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species came from F. hwasookii ChDC F206 and Fn subsp. polymorphum KCOM 1275 at 
𝐴𝐴𝑎𝑎𝑎𝑎𝑎𝑎 = 93.37 %. This result compares with findings by Kook et al (22) and shows F. 
hwasookii is a separate species. From this point, strain comparisons with 𝐴𝐴𝑎𝑎𝑎𝑎𝑎𝑎 < 94 % can 
be considered different species.  
For MUMi, the cut-off value can be set at 𝑀𝑀𝑖𝑖(19) = 0.456. The intraspecies scores close to 
this value are the same that go below the 95 % ANI score. MUMi has previously been used 
to determine that the W1481 strain belongs to the F. nucleatum species (21). This was 
determined under the assumption that all subspecies under Fn belong to the nucleatum 
species, however, it is evident that this is not the case. To contain W1481 within Fn (all 
strains within the old species) a threshold of 𝑀𝑀𝑖𝑖(19) = 0.693 (𝐴𝐴𝑎𝑎𝑎𝑎𝑎𝑎 ≈ 89 %) is required – this 
would mean that F. hwasookii species would also belong to Fn, moreover it causes F. 
varium and F. ulcerans to be within a single species. As this is not the case, where these 
species are distinct, in agreement with Kook et al (22), the previous subspecies of Fnp, Fna, 
Fnn, Fnv, and Fnw should be classified as their own individual species.  
For PLSA, the corresponding species threshold lies at 0.0232 average number of 
substitutions per site across the 215 conserved proteins. This boundary is adhered to by 
the large majority of intraspecies comparisons, with the only exception being for F. 
periodonticum ATCC 33656 and the rest of F. periodonticum which will be discussed later. 
PLSA becomes less well correlated with MUMi and ANI at the more distant ends of the 
comparisons, as seen in FIGURE 3.1, where the clusters are much larger. There are also 
visible clusters throughout the complete range, where ANI or MUMi rate the differences 
either more or less stringently than PLSA. This could be attributed to silent mutations and 
differences in the non-proteomic content, as the genomic content represented by the 215 
conserved genes is approximately a tenth of the total content. Nevertheless, PLSA may be 
advantageous, as MUMi and ANI do not consider silent mutations or mobile genetic 
elements that can be lost or gained, affecting overall identity. When PLSA was restricted to 




a single species, more proteomic content could be retained, therefore increasing the 
accuracy of the analysis. 
There are a number of genome pairs that fall close to the species boundary and below the 
previous threshold of 95 % average nucleotide identity. These pairs all originate from the F. 
periodonticum and F. polymorphum species, for example F. periodonticum 1_1_41 and F. 
periodonticum D10 have an ANI score of 94.43 %, though comparisons with other 
periodonticum strains are higher than the cut-off point, thus representing a diverse species 
with a broad spectrum of strains. See TABLE 3.2 for the fringe cases and the point at which 
interspecies comparisons are made. 
Table 3.2 | Fusobacterium comparison fringe cases. 
This shows the interchange between species and non-species comparisons, from periodonticum-
periodonticum comparisons and other closely related species that fall outside the classification 
window, for example polymorphum-hwasookii. The table is sorted by ANI score and the three metrics 
used are given, as well as the accessions (where applicable) and the predicted species. Key: perio 
– F. periodonticum; poly – F. polymorphum; hwas – F. hwasookii; anim – F. animalis; vinc – F. 
vincentii; nov. – unidentified species. 
Accession 1 Accession 2 ANI MUMi PLSA Species 
GCA_000163935.1 GCA_000297655.1 94.43 0.434 0.0165 perio perio 
GCA_000163935.1 GCA_002763695.1 94.40 0.434 0.0163 perio perio 
GCA_000163935.1 GCA_002763925.1 94.37 0.425 0.0169 perio perio 
GCA_000163935.1 GCA_002761935.1 94.32 0.427 0.0164 perio perio 
GCA_000163935.1 GCA_002763915.1 94.22 0.434 0.0163 perio perio 
GCA_002211625.1 GCA_000455905.1 93.37 0.475 0.0301 poly hwas 
GCA_000479225.1 R16531 93.33 0.521 0.0353 anim nov. 
GCA_001455085.1 GCA_002211625.1 93.33 0.479 0.0301 hwas poly 
R16531 R30927 93.32 0.548 0.0350 nov. anim 
GCA_002749995.1 R16531 93.31 0.496 0.0366 vinc nov. 
R15792 R16531 93.30 0.530 0.0351 anim nov. 
GCA_002202115.1 GCA_000455925.1 93.30 0.481 0.0302 poly hwas 
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The genus also appears to be very polarised with distinct major clades spread far apart with 
clusters of closely matched pairs extremely distant from other clusters. The F. necrophorum 
clade is furthest from the main cluster of the F. nucleatum with few organisms bridging the 
gap. Other non-typed strains can be seen to fall into groups, such as Fusobacterium CM21 
belonging to F. vincentii. Numerous other loosely typed strains could be identified as 
specific species/subspecies (see TABLE S 2 for details of classifications). 
As there is no well-defined genus boundary at the time of writing, all scores below the 
species cut-off threshold bear little significance for the meantime, though there are definite 
clusters of scores around certain values. Approximately 30 % of comparisons have ANI 
scores > 80 and < 94 %, which allows the data to be split into three groups with intraspecies, 
similar species and very different species. The bounding thresholds for these groups can 
be set as follows: 𝐴𝐴𝑎𝑎𝑎𝑎𝑎𝑎 > 94, 80 < 𝐴𝐴𝑎𝑎𝑎𝑎𝑎𝑎 < 94 and 𝐴𝐴𝑎𝑎𝑎𝑎𝑎𝑎 < 75 % respectively. 
3.5 Reclassification of Multiple Species 
By defining a more rigorous set of parameters for classifying species, multiple 
reclassifications were made across the whole Fusobacterium genus. The full list of 
classifications if provided in APPENDIX E. 
3.5.1 Identification and Classification of F. oralis sp. nov. 
Using the defined taxonomic boundaries and novel data gathered through whole-genome 
sequencing, a new species emerges. This species lies on the periodonticum-containing 
branch at the split between the previous Fn and Fperio species (FIGURE 3.3). At least four of 
the clinical strains (2B2, 2B4, 2B16 and R28427) belong to this group with a fifth (2B3) likely 
but undetermined due to inconclusive sequencing results. One unclassified strain (F. sp. 
oral taxon 370 strain F0437) also belongs to this group. We suggest the name F. oralis sp. 
nov. for this species as every strain isolated originated from the oral cavity. This species 
has a genome length between 2.1 and 2.3 Mbp with a GC % content of 27.4 – 27.6 %. 




This species currently is only associated with periodontal disease and related diseases – 
none of these species have been identified in other pathologies, such as colorectal cancer, 
preterm births or Lemierre’s syndrome for example. That puts these bacteria very close to 
F. periodonticum in that respect, limited to oral infections. However, as there are currently 
very few strains that fall into this clade, it does not necessarily mean that this species is not 
associated with any other diseases.  
3.5.2 Identification and Classification of F. ovarium sp. nov. 
One of the clinical strains, R16531, did not fall into any species and lied almost equally 
between Fn, Fv and Fa (FIGURE 3.3). This strain was isolated from an ovarian mass; 
therefore, the name ovarium is suggested, from the Latin ovarium inferum. Very little is 
known about this strain as it the first of its type to be identified and may even represent a 
bridging strain that has not succumbed to the usual evolutionary trait of convergent 
evolution, whereby species tend to belong to a larger containing group.  
As this is a singleton, little can be said about this species, other than what can be inferred 
directly from the data there is. It has a GC % content of 26.9 % and its genome is 
approximately 2.1 Mbp. Moreover, because it is a completely isolated case, disease 
relationship cannot be confirmed, though it has been shown that it existed within an ovarian 
mass. 
3.5.3 Reclassification of various minor species 
In accordance with Kook et al (22), the previously named Fn W1481 strain is actually further 
removed from the majority of other previous Fn species than, for example, F. hwasookii is 
from polymorphum. Its MUMi, ANI and PLSA scores are all far beyond the species threshold 
to its nearest neighbour – F. animalis (assembly accession: GCA_000220825.1; 𝐴𝐴𝑎𝑎𝑎𝑎𝑎𝑎 =
90.21; 𝑀𝑀𝑖𝑖(19) = 0.639; 𝑁𝑁𝑎𝑎 = 0.0553). Once more, as this is an isolated case, no further 
conclusions can be made about this strain, but like with F. ovarium sp. nov., it may represent 
another strain that has diverged from the most commonly isolated lineages.  
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There are several other species, away from the old Fn and Fperio clade that have been 
incorrectly classified or have not been attributed to any species at all. One strain, assembly 
accession GCA_900015295.1, falls on a distant branch, shared with F. mortiferum. It is 
however, far removed even from this strain (also a singleton) and belongs to its own 
species. As it was originally classified as a clostridium species, evident on the name given 
to the specific strain, it will now be referred to as F. closii sp. nov.  
The strain F. equinum (Fe) was previously identified and classified by Dorsch et al (184) 
and has remained uncharacterised ever since. This is contrary to the observations made in 
this study, where it is closely related to F. gonidiaformans (Fg), so much so, that is more 
closely related to Fg 3_1_5R than Fg ATCC 25563 is to the other Fg strain, with ANI and 
MUMi equal to 98.8 % and 0.190 for Fe v Fg 3_1_5R compared to 98.6 % and 0.215 for Fg 
3_1_5R v Fg ATCC 25563. As there are two F. gonidiaformans strains and one equinum, it 
is therefore simpler to reclassify the one strain than the two, hence, F. equinum CMW8396 
becomes F. gonidiaformans CMW8396. 
Recently, a new F. varium strain was identified (185), however, the results of the work 
conducted in this study do not align with this classification. One key point is that it has a 
genome length of > 3 Mbp, which is far removed from what is expected across the entire 
genus, which suggests there is either a contaminating strain or it is not Fusobacterium. It is 
more likely the prior as its nearest neighbour, using MUMi and ANI, remains F. varium, 
though it is not that much further removed from F. ulcerans (Fu). PLSA, which should 
remove, at least non-Fusobacterium, contaminating genes still classifies it outside the 
boundary of F. varium and is likely its own species. The closest neighbour comparisons are 
as follows: 𝐴𝐴𝑎𝑎𝑎𝑎𝑎𝑎 = 88.8 %; 𝑀𝑀𝑖𝑖 = 0.695; 𝑁𝑁𝑎𝑎 = 0.0316 (compared against Fu ATCC 49185). 
Further work will be needed to confirm the true identity of this strain. 





Figure 3.3 | Phylogenetic tree for clustered species. 
All strains were clustered using an agglomerative algorithm to the species level based on the linear 
MUMi, 𝑀𝑀𝑟𝑟, metric. The bounding threshold for the clusters was set at 𝑀𝑀𝑟𝑟(19) < 0.6 which is equivalent 
to 𝑀𝑀𝑖𝑖(19) = 0.451. From this the evolutionary history was inferred using the UPGMA method in the 
MEGA7 application (167). The number of strains within the cluster, mean and maximum score are 
shown in parentheses after the species name for non-singleton species. The mean score gives a 
good representation of the spread for each species where a higher mean indicates a more diverse 
species. 
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3.5.4 The F. periodonticum paradox 
For F. periodonticum, the type strain for this species is F. periodonticum ATCC 33656. This, 
interestingly, has one major problem in that under ANI and MUMi, this strain falls outside 
the definition of a species with ANI and MUMi scores equal to 93.0 % and 0.502 respectively 
to its closest neighbour (Fperio KCOM 1282). Examining the PLSA data, it falls within the 
species boundary definition, though existing on the fringes with a range of 0.0235 to 0.0267 
for the whole of F. periodonticum. This compares to the largest intraspecies comparison of 
0.0270 seen between Fn R18528 and Fn R28400. 
As PLSA uses an algorithm that discards non-conserved or non-complete genes from the 
whole genus, any subtle differences in locally conserved genes within a single species by 
itself, could be missed. By performing PLSA for an individual species, fewer genes are 
discarded in the filtering stage, leading to a wider, more diverse gene set, which should 
increase the comparable resolution of sequence diversity. Running PLSA on the species of 
periodonticum (including ATCC 33656) and oralis, 1357 protein sequences are retained in 
the analysis. When comparing the ATCC 33656 strain to all other periodonticum strains, the 
minimum and maximum diversities become 0.0546 and 0.0580 respectively. The minimum 
value is 0.013 higher than the maximum intra-periodonticum comparison and is closer to a 
comparison to oralis at 0.0632. These scores cannot be compared directly to the original 
PLSA analysis as there are many more genes that are less highly conserved than the 
original 215 used. 
Nevertheless, the fact that the genomic pairwise comparisons put this strain further from 
the main cluster of Fperio than F. polymorphum is to F. hwasookii for instance, raises the 
question whether this species even belongs to Fperio. As all other Fperio strains fall within 
the accepted species definition of one another, then it is more sensible to remove this single 
strain from the species, rather than reclassifying the remaining strains. The name F. 
pseudoperiodonticum sp. nov. (meaning false periodonticum) will be applied to this 




particular strain for the remainder of this study. Of the 188 total strains compared (including 
the two non-Fusobacterium strains), this was the only anomaly of this kind. 
3.6 Genomic Visualisation of WGS Strains 
In addition to giving specific metrics to pairwise comparisons, to give a more tangible 
description of genomic similarity, genomic hive plots were created. Genomic hive plots are 
maps that connect two axes, representing two genomes, with a line representing a region 
of homology where a corresponding percent identity colour applied to each connection. 
Using these plots, it is easier to visualise whole genomes compared to each other, where 
features such as inversions, gaps and regions of low homology can be quickly identified.  
To create these maps, a Python script was used that leveraged the BLAST+ program suite 
and the SVG writing library. See Methods for complete details (SECTION 2.13.6). In short, 
genomes had their contigs re-indexed against a reference genome, usually a complete 
genome from their parent species. The reordered contigs were split into short 2000 bp sub-
sequences and these were mapped against the target strain using BLAST+. Hit lengths 
shorter than 1500 bp with less than 90 % identity were filtered out before connecting the 
axes. The stringent filtering increased execution speed and clarity of the resulting map. 
Other more specialised specifications can be set.  
Genomic hive plots were created for 23 of the WGS strains using the following reference 
genomes for contig indexing: Fn ATCC 25586 (for nucleatum), Fn 3_1_36A2 (for vincentii), 
Fn 7_1 (for animalis and ovarium) and 2B16 indexed against Fn ATCC 25586 (for oralis). 
An example of unindexed contigs versus post-indexed contigs is displayed below in FIGURE 
3.4.  
These maps complement the raw genome-genome distance calculations providing a 
tangible representation of what each method is calculating. FIGURE 3.5 gives another 
example of the comparisons that can be made. In this instance, it is displaying the 23 newly 
sequenced strains compared in a pairwise fashion to Fn ATCC 25586. The resulting maps 
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show the differences when comparing more distant strains to one another where the oralis 
comparisons produce a much thinner graph, whereas the nucleatum strains produce highly 
similar, densely packed maps with far fewer large-scale rearrangements. 
FIGURE 3.6 shows four hive plots clustered for the sequenced strains ordered by species. 
Here, the species identities relative to themselves can be clearly observed, though F. 
ovarium sp. nov. R16531 had to be grouped with the F. animalis species as it is the only 
species of its type. 
 
 
Figure 3.4 | Unindexed contig hive plot versus indexed. 
A) Unindexed genomes of WGS strains R32935, R15792 and R30604. There are many regions 
mapping seemingly arbitrarily as a consequence of the contigs ordered by size within the genome. 
B) Contigs were indexed against Fn ATCC 25586 before comparing against each other, hence 









Figure 3.5 | Pairwise genome maps for newly sequenced strains against F. nucleatum ATCC 
25586. 
Contigs from all WGS strains (not including 2B3 and R33458) were ordered against their position in 
the reference strain Fn ATCC 25586. Positions of close identity were then connected with a line from 
the reference strain (left) to the target strain (right) and low scoring (hit length and % identity) regions 
were filtered for clarity. The maps were then grouped based on their predicted species. 
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Figure 3.6 | Hive plots for all sequenced strains grouped by species. 
The four genomic hive plots shown represent 23 genomes of the newly sequenced strains. They are 
correspondingly arranged by species group, with the singleton F. ovarium sp. nov. R16531 grouped 
with F. animalis. Strains for F. oralis sp. nov. do not have a completed reference genome so contigs 































3.7 Extension of Analyses to the Family 
In addition to examining the Fusobacterium genus, a brief study into the Fusobacteriaceae 
family was conducted, which looked at whole-genome comparisons using MUMi. In addition 
to the strains used previously, 7 other taxa from Fusobacteriaceae were used: Ilyobacter 
polytropus (186), Psychrilyobacter atlanticus (187), Fusobacteriaceae bacterium UBA2433 
(188), Cetobacterium somerae (189), Cetobacterium ceti (190), Cetobacterium sp. 
ZOR0034 and Cetobacterium sp. ZWU0022. 
Pairwise MUMi scores were calculated for all strain pairs with the additional non-
Fusobacterium species. The scores were transformed to the LMUMi metric (see Methods) 
and clades were collapsed to the species level using an agglomerative algorithm with a 
threshold set at 𝑀𝑀𝑟𝑟(19) < 0.6. The evolutionary hierarchy was inferred from the mean clade 
differences using the UPGMA method. The resulting phylogenetic tree is shown in FIGURE 
3.7. From this, it is evident that F. necrophorum is as far removed from the F. nucleatum 
branch as other non-Fusobacterium strains such as C. ceti. In addition to the pairwise 
genomic distance scores, the taxa were arranged in a way such that the GC % content was 
increasing going down the tree, which for the most part is the case, except for F. perfoetens, 
which has a GC % content of 26.0 %, which is not comparable to its nearest neighbours of 
F. mortiferum (29.0 %) and F. closii sp. nov. (28.9 %). 
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Figure 3.7 | Phylogenetic tree of the Fusobacteriaceae family. 
The above phylogenetic tree was constructed using UPGMA evolutionary inference of grouped taxa 
(𝑀𝑀𝑟𝑟(19) < 0.6) in the same way as FIGURE 3.3. Additionally, subtrees were arranged such that strains 
with lower GC % content were placed above, which for the majority of strains could be achieved to 
fit the general pattern with the exception of F. perfoetens (GC % = 26.0). The GC % bounds are 25.2 
(Fa ATCC 51191) to 35.3 (Fnec LS 1195). The GC % content of I. polytropus is very similar to Fnec 
at 34.4 %. The horizontal scale represents evolutionary distance based on the average 𝑀𝑀𝑟𝑟(19) scores 




 F. animalis (29 0.326 0.549)
 F. vincentii (22 0.229 0.373)
 F. ovarium sp. nov.
 F. nucleatum (14 0.281 0.535)
 F. polymorphum (23 0.413 0.623)
 F. hwasookii (8 0.211 0.304)
 F. W1481
 F. pseudoperiodonticum sp. nov.
 F. periodonticum (14 0.419 0.570)
 F. oralis sp. nov. (5 0.218 0.234)
 F. massiliense
 F. russii
 F. pseudovarium sp. nov.
 F. varium (2 0.180 0.180)
 F. ulcerans (2 0.231 0.231)
 F. perfoetens




 C. ZWU0022 (2 0.170 0.170)
 UBA2433
 P. atlanticus
 F. gonidiaformans (3 0.209 0.242)
 F. necrophorum (34 0.232 0.461)
 I. polytropus
0.000.501.001.502.00





Using these methods of analysis, it is apparent that the current accepted taxonomic 
boundaries for Fusobacterium spp. must be redefined to better appropriate species 
definition. The proposed removal of Fn subsp. fusiforme has existed since its inception 
where it was incorrectly placed outside of the vincentii subspecies where it clearly belongs 
(19, 20, 191, 192); this was the first of many cases of misnomers within the genus. There 
is an inherent data bias for the Fusobacterium genus that adds to the struggles; there are 
more data for Fn (prior to redefinition) alone than all the remaining strains in Fusobacterium. 
This is likely because most of the strains isolated and sequenced predominantly come from 
Fn and Fnec, as these two are the most common human pathogens.  
It has previously been stated that F. naviforme ATCC 25832 strain had a GC % content 
higher than other members of the species at 49 % (52.8 % calculated directly from genome 
assembly), whereas typically it should be 25-35 % for Fusobacterium. However, this strain 
is the only one of the species to have been sequenced, therefore no definitive remarks can 
be made concerning the remaining strains within the species. 
Using the classifications derived in this study, the whole genus of Fusobacterium, for which 
full genomes are available, can be split into at least 20 distinct species (as seen in FIGURE 
3.3): animalis, closii sp. nov., gonidiaformans, hwasookii, massiliense, mortiferum, 
necrophorum, nucleatum, oralis sp. nov., ovarium sp. nov., perfoetens, periodonticum, 
polymorphum, pseudoperiodonticum sp. nov., pseudovarium sp. nov., russii, ulcerans, 
varium, vincentii, and W1481. Henceforth, Fna, Fnn, Fnp, Fnv and Fnw will be referred to 
as F. animalis (Fa), F. nucleatum (Fn), F. polymorphum (Fpoly), F. vincentii (Fv) and F. 
W1481 (Fw) respectively. The most notable findings were the identification of two novel 
species within our strain collection, F. oralis sp. nov. and F. ovarium sp. nov., the former of 
which only had one comparative unclassified genome in the database prior to this study 
and the latter having no sequenced homologous strains at all. Additionally, various 
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misnomers were addressed to conform to the newly set species boundaries, such as the 
removal of the F. equinum species, which was internalised by F. gonidiaformans.  
The reclassifications made in this research closely mirror other studies that have looked at 
Fusobacterium and all bacterial classifications (22, 23). The combination of new data and 
the examination of the genus as a whole, provide a much more in-depth picture with respect 
to Fusobacterium compared to the other studies, which focussed on just F. nucleatum or 
every bacterial species. An example of this can be seen when examining a phylogenetic 
tree representing every strain (at the time of writing) that cluster around the previous F. 
nucleatum species (FIGURE 3.8). Here, we can see the wide diversity within a group of 
bacteria once considered its own species (excluding Fh and Fperio). 
 
 
Figure 3.8 | F. nucleatum sub-genera-related species phylogenetic tree. 
This cropped tree displays the species spread about the Fusobacterium that cluster around F. 
nucleatum. Each node is coloured uniquely to the related species. The branch lengths correspond 
to the relative distance as calculated with the MUMi linear transform metric (𝑀𝑀𝑟𝑟). The unrooted tree 
was calculated and drawn using the Neighbour-Joining method in SplitsTree4. 


















3.8.1 The Duality of F. polymorphum 
When examining the organisation of F. polymorphum species in FIGURE 3.8, there is a clear 
split with two dominant clades emerging from this. Interestingly, there are a few 
comparisons from the far edges of these two groups where the pairwise score crosses the 
species threshold. This discrepancy is not as severe as it would be as there are 24 strains 
within the species – this increases power when judging classifications and means that it can 
remain a single species if an adequate type strain to compare against is used. As there are 
multiple candidate strains that do not leave the species definition when compared against 
any of the existing strains, such a type strain can exist, therefore keeping the species intact. 
This emergent duality, however, should not go unnoticed as it suggests an evolutionary split 
that caused the bacteria to diversify into one of two types. With more data and careful 
curation, the difference in the two linages could be identified, such as a change in 
pathogenicity or adaptations to different environments.  
3.8.2 A New F. nucleatum Subgroup 
In FIGURE 3.8 there is a small subgroup that can be seen within F. nucleatum, which is 
juxtaposed to the main cluster of strains. Previously, this group only consisted of one strain, 
however, with the new sequencing data, is joined by two other strains. Similarly to F. 
polymorphum, this highlights a divergent evolutionary step that occurred, giving rise to this 
distinct subgroup. There is no correlation between isolation site and any three of these 
strains, with one coming from periodontitis, one from a liver abscess and the last from an 
arthritic hip. As there are few strains within this group, not much can be concluded regarding 
disease association. 
3.8.3 Reorganisation of the Fusobacteriaceae family 
The overall organisation of the Fusobacterium genus shows that each species belongs to 
a higher order group within the genus. This higher order clustering could contribute partly 
to the reason why the nucleatum species originally contained several subspecies, as the 
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strains clustered on a cladogram with a distinct separation from necrophorum. Though on 
reflection, this was incorrect; the entire clade of necrophorum was spread over a smaller 
distance than the subspecies of animalis for example. The three higher order groups that 
emerge within the genus are: necrophorum and gonidiaformans; animalis, nucleatum, 
polymorphum, vincentii, hwasookii, W1481, periodonticum, oralis sp. nov. and ovarium sp. 
nov.; ulcerans, varium and mortiferum. F. perfoetens, F. massiliense, F. russii do not belong 
to any of these groups and are alone in their respective clades and more data is needed to 
confirm their positions within the genus.  
Analysis comparing Cetobacterium, another genus within the Fusobacteriaceae family, 
demonstrated equivalencies to the most distant strains used in the original analysis. For 
example, C. sp. ZOR0034 and F. ulcerans ATCC 49185 𝐴𝐴𝑎𝑎𝑎𝑎𝑎𝑎 = 72.25 %, which is about 2.4 
% higher than the lowest score seen in the Fusobacterium data (F. ulcerans 12-1B and F. 
necrophorum subsp. funduliforme F1309 𝐴𝐴𝑎𝑎𝑎𝑎𝑎𝑎 = 69.83 %) and is higher than 191 other intra-
genus comparisons. This discontinuity is also evident in FIGURE 3.7 where F. necrophorum 
clusters outside of the previous genus boundary, existing in a higher order above that of 
Cetobacterium. 
Based on the findings presented in this study as well as the observations made in the global 
bacterial taxonomic study (23), Fnec, Fg, Fvar, Fpv, Fu, Fmort, Fperf, and Fc, should all be 
removed from the Fusobacterium genus and reclassified into at least two separate distinct 
genera. This would lead to three genera within the Fusobacteriaceae family previously all 
grouped under one. Based on the clustering observed in FIGURE 3.7, these new genera 
would contain the following species: (1) Fn, Fa, Fv, Fpoly, Fw, Fov, For, Fh, Fperio, Fpperio, 
Fmal, and Fr; (2) Fu, Fvar, Fpv, Fmort, Fperf, and Fc; (3) Fnec and Fg.   




Chapter 4: Fusobacterium TAAs and Adhesion to 
CEACAMs 
4.1 Introduction 
As previously explained in SECTION 1.3, CEACAM1 (Carcinoembryonic Antigen Cell 
Adhesion Molecule 1) can make an ideal pathogen-binding receptor with the potential to 
confer local immune suppression. From prior unpublished studies conducted by this 
research group, it was found certain Fusobacterium strains could bind this receptor; these 
interactions were limited to F. nucleatum and F. vincentii strains as well as some previously 
uncharacterised clinical isolates. In Fn ATCC 25586, a protein, encoded from the gene 
locus FN1499, was found to be responsible for mediating the interaction with CEACAM1. 
This protein was identified by coprecipitation of bacterial lysates with CEACAM1, followed 
by N-terminal sequencing using Edman degradation and mass spectroscopy of the 
corresponding protein bands on an SDS-PAGE gel. 
The protein product of FN1499 was predicted to belong to the Trimeric Autotransporter 
Adhesin (TAA; also known as Type Vc Secretion System) family of proteins as described in 
SECTION 1.2. This prediction was made by identifying a classical T5SS 12-stranded β-barrel 
in the C-terminus of the predicted coding sequence. This is further backed up by the 
presence of YadA-like head domains and the presence of a neck domain, however, the 
stalk region of this protein remains undefined and there are no close homologues for it in 
other non-Fusobacterium strains when examining BLAST results.  
TAAs can be found within all members of the Fusobacterium genus, though their roles have 
yet to be characterised. Fn ATCC 25586 contains three gene loci that encode putative 
TAAs, FN0471, FN0735 and FN1499, the latter of which has been shown to bind human 
CEACAM1. While TAAs are ubiquitous among the genus, homology to these three protein 
sequences is varied. For example, a homologue to FN0735 can be found in Fn, Fv, Fa, and 
Fpoly, previously all classified under the umbrella of F. nucleatum. FN0471 homologues 
 Chapter 4: Fusobacterium TAAs and Adhesion to CEACAMs 
   
83 
 
appear to much less prevalent, with only Fn and Fv strains showing possession. In addition 
to the close homologues originating from Fn for example, more distant species such as F. 
necrophorum also possess genes encoding putative TAAs, which are far-removed from 
proteins encoded in Fn for example. As explored in SECTION 1.2.3, TAAs have been shown 
to be important in bacterial adhesion to many human cellular components, such as cell-
surface receptors or extracellular matrix components, and often play an important role in 
pathogenesis. Successful characterisation of these proteins may indicate whether they are 
suitable and targetable as vaccination candidates. 
Functional homologues to FN1499 were identified in F. vincentii and in several of the clinical 
isolates, such as strain 2B3, since classified as F. oralis sp. nov., that were also able to bind 
CEACAM1. The 2B3 strain exhibited a slightly longer protein of 519 amino acids compared 
to 479 residues in FN1499 with molecular weights of mature (lacking signal peptide) protein 
monomers at 51.2 and 48.1 kDa respectively. This contrasts to the homologues found in Fv 
strains which bared a much closer resemblance to FN1499 from Fn. These proteins will 
henceforth be denoted by the term CbpF for CEACAM-binding proteins of Fusobacterium 
– FN1499-like proteins as CbpFa and 2B3-like as CbpFb. 
The overall predicted topology of CbpFs, as well as other TAAs within Fusobacterium spp. 
is relatively simple when compared to TAAs from other species such as S. enterica or M. 
catarrhalis where the respective proteins SadA and UspA1 are large complex multidomain 
proteins (102, 108). The predicted architecture, which is investigate in depth in SECTION 5.2, 
contains only the core elements required for a TAA: a membrane anchor, a single stalk 
followed by a neck and then a series of head domains. In the case of FN0735 and its 
homologues, there is additional stalk and neck domain. All of the head domains adopt the 
YadA-like motif and no other more exotic features, listed in TABLE 1.1, were identified; 
however, it is possible that Fusobacterium-derived TAAs have novel structures yet to be 
characterised. A schematic topology of CbpFs is displayed in FIGURE 4.1, showing the 




domain organisation as predicted using sequence analysis described in detail in SECTION 
5.2. 
 
Figure 4.1 | CbpF domain topology. 
CbpFs are trimeric proteins that contain four core domains identified in sequence analysis: a 
membrane anchor consisting of a 12-strand β-barrel, a stalk region (likely a coiled coil), a neck, and 
series of head domains all adopting a YadA-like head motif. These domains are the minimal 
requirements for any TAA and in this case, show one of the simplest architectures. 
Interestingly, CbpFb has no direct homologues within the Fn or Fv species – in fact the 
closest match in the current database (excluding newly characterised strains within this 
study) belongs to that of an F. animalis species (Fa CAG:649). This agrees with our previous 
findings in CHAPTER 3 that the 2B3 strain belongs to a distinct species within Fusobacterium 
– F. oralis sp. nov. – which is genetically further from Fn and Fv by approximately the same 
distance as F. periodonticum. In contrast, a CbpFa homologue appears in all Fn and Fv 
species, with the exception of where the gene lies on the end of an incomplete contig, such 
as in the case of Fn CTI-2, where a partial hit is found spanning two contigs. It is likely that 
this gene is present within all other non-sequenced Fn and Fv strains. This could therefore 
have implications in disease, as it appears to be completely conserved among these 
species and could have a role in host specificity or even be directly involved in 
pathogenesis, both of which will be discussed later. 
In addition to CEACAM1 binding, there is little data on whether these CbpF proteins can 
adhere to other members of the CEA family, which could include other CEACAMs, such as 
3, 5 or 6, which are known to bind to other pathogens, such as M. catarrhalis (118, 134). 
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Alternatively, there could be interactions with pregnancy-specific glycoproteins (PSGs), 
which form a large understudied branch of the CEA family of receptors. Any interactions 
with these additional receptors could have strong implications with pathogenesis and 
disease specificities. 
In this chapter, we aim to characterise the binding profiles of CbpFa and CbpFb with 
different CEACAMs. In addition, we will explore the CbpF-CEACAM1 binding interface at 
cellular and molecular levels using a variety of methods which will be described in turn. 
4.2 CbpF-CEACAM Interactions 
4.2.1 CEACAM1 Screening in Fusobacterium Clinical Strains 
To confirm CEACAM1-binding of strains that possess a predicted CbpF homologue within 
their genome, a combination of data from previous unpublished studies and data gathered 
in this study were used to cross-validate results. Data were collected by detecting adhesion 
between a soluble CEACAM1 conjugate protein with bacterial cell lysates using Western 
blots. The 25 clinical strains that were used for WGS and some type-strains of other 
Fusobacterium species were used in these experiments. The control type strains used 
were: Fn ATCC 25586, Fv ATCC 49256, Fa ATCC 51191, Fpoly ATCC 10953 and F. 
pseudoperiodonticum sp. nov. ATCC 33693. From which, only the Fn and Fv type-strains 
displayed CEACAM1 adhesion. 
The protocol used for lysate preparation and blotting are described thoroughly in the 
Methods. Fusobacterium lysates were prepared and were then run on a 4-20% SDS-PAGE 
gel before either staining with Coomassie or transferring to a nitrocellulose membrane. 
Western blots were then carried out, however the primary antibody used was, instead, the 
CEACAM1-4C1-hIgG1 FC conjugate (CC1-FC) which was detected with an anti-human IgG-
AP secondary antibody. In addition to this, a CC1-FC mutant lacking the N-terminal IgV 
domain of CEACAM1 (CC1 ΔN-FC) was used as a negative control, as the IgV-like domain 
of CEACAM1 is very likely responsible for adhesion. An example of the blots is shown in 




FIGURE 4.2 comparing CbpFa and CbpFb-harbouring strains. TABLE 4.1 shows the full 
consensus of results from this study as well as previous work conducted by Hill et al 
(unpublished), from the clinical isolates and their CEACAM1-binding capability. 
 
Figure 4.2 | F. oralis sp. nov. CEACAM1-binding profile compared to F. nucleatum. 
Displayed are Western blots of Fusobacterium lysates from 5 F. oralis and 4 F. nucleatum clinical 
strains overlaid with CC1-FC (A) or CC1 ΔN-FC (B) and anti-human IgG-AP. Included as controls 
were F. nucleatum ATCC 25586 (* – CDS product of FN1499, predicted 144.3 kDa) and F. 
polymorphum ATCC 10953 (harbours no predicted binding protein). As can be seen, the F. oralis 
CEACAM1-binding proteins are slightly larger than the F. nucleatum proteins, which is to be expected 
as a CbpFa trimer is approximately 10 kDa smaller than a CbpFb trimer (144 and 154 kDa 
respectively). F. oralis: 2B3, 2B4, 2B16 and R28427. F. nucleatum: R28385, R28400, R18528 and 
R32935. CC1-FC – CEACAM1-4C1-hIgG1 FC; CC1 ΔN-FC – CEACAM1 A1BA2-hIgG1 FC; AP – 
Alkaline phosphatase. A total of three blots were carried out in this study – shown is an example of 
one. 
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Table 4.1 | Clinical strain CEACAM1-binding profiles. 
The CEACAM1-binding characteristics of all the clinical isolates used in the whole-genome 
sequencing study was determined across several studies with confirmation of some of the strains in 
this study by Western blot. 1 As determined in CHAPTER 3. 2 Consensus of results from data gathered 
in this study and unpublished work. 3 Variable binding observed. 4 Likely a mixed culture of F. vincentii 
and a Bacillus species.  
Strain Species1 CEACAM1 Binding2 
2B16 F. oralis  + 
2B17 F. vincentii + 
2B2 F. oralis + 
2B3 F. oralis + 
2B4 F. oralis + 
R15792 F. animalis +/- 3 
R16531 F. ovarium + 
R18528 F. nucleatum + 
R18932 F. animalis - 
R24394 F. nucleatum + 
R26872 F. vincentii + 
R28211 F. vincentii + 
R28385 F. nucleatum + 
R28400 F. nucleatum + 
R28427 F. oralis + 
R29976 F. vincentii + 
R30464 F. vincentii + 
R30604 F. vincentii + 
R30927 F. animalis - 
R31249 F. vincentii + 
R32310 F. vincentii + 
R32935 F. nucleatum + 
R33458 F. vincentii/Bacillus sp.4 + 
R33533 F. vincentii + 
R5001 F. animalis + 




Of the strains tested, all the strains identified as F. nucleatum or F. vincentii bound to 
CEACAM1, although some variation was observed. Variable binding could be due to a 
variety of factors such as uncharacterised phase or antigenic variation, protease action, or 
total protein differences caused by naturally low or high expression of CbpF. In FIGURE 4.2, 
there are clear bands that correspond to the predicted trimeric forms of CbpFa and CbpFb 
(144 and 154 kDa respectively), however, the bands are approximately 100 kDa larger than 
the predicted molecular weight. This is because these proteins cannot be dissociated and 
denatured using SDS-PAGE loading buffer alone (with 10 min at 95 °C), as the stability of 
the membrane anchor is very high and harsher treatments, such as heating in the presence 
of formic acid, are required to break apart this domain. Monomeric protein units would 
appear in the 50 kDa region. 
All the F. oralis strains, 2B2, 2B3, 2B4, 2B16 and R28427, were able to bind CEACAM1, 
which confirms CEACAM1-binding is not limited to Fn or Fv species within Fusobacterium. 
Moreover, there were also two F. animalis strains that could bind CEACAM1; these were 
R15792 (though variably) and R5001 (FIGURE 4.3). These two particular strains harboured a 
CbpF that resembled that of CbpFb but were distinctly different. This indicates that a third 
group of CEACAM1-binding proteins could exist. Interestingly, however, the sequence of 
R5001 is much closer to that of CbpFb than that of R15792 which contains regions that 
closer match CbpFa, indicating they may have obtained the gene at different points in their 
evolution. 
FIGURE 4.4 shows the phylogram representing the species of F. animalis and where the 
identified CEACAM1-binding strains fit into the underlying taxonomy. It is immediately 
evident that all the strains able to bind CEACAM1 are in a separate clade compared to the 
main group of the species, suggesting these strains have an inherent difference as well as 
being the only identified animalis strains able to bind CEACAM1. Interestingly, not all the 
other strains within this subgroup can bind CEACAM1 with R30927 not being able to 
physically bind CEACAM1 as well as lacking any discernible homologue within the 
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sequence. In addition to this, the previously unclassified strain, Fusobacterium CAG:649 
also falls into this subgroup of F. animalis and a CbpF-like gene can be identified within the 
sequence.  
 
Figure 4.3 | F. ovarium sp. nov., F. animalis and F. vincentii CEACAM1-binding profiles. 
Western blots of lysates from F. ovarium sp. nov. (Fov), F. animalis (Fa) and F. vincentii (Fv) strains 
against (A) CEACAM1-FC (CC1-FC) and the (B) CEACAM1 N-terminal IgV deletion mutant (CC1 ΔN-
FC). The Fv CEACAM1-binding protein is also from the CbpFa line of proteins, whereas the CbpF 
proteins in Fov R16531 and Fa R5001 differ in size with the protein from Fov appearing smaller and 
Fa larger than CbpFa. Blots were repeated three times; however, the displayed blot shows R15792 
being unable to bind, which conflicts with previous findings. 
  





Figure 4.4 | The F. animalis species distribution. 
The phylogenetic tree represents whole-genome comparisons using MUMi restricted to F. animalis 
strains. Highlighted in blue boxes are the two confirmed CEACAM1-binding strains. 
GCA_000433695 and GCA_001546435 (Fusobacterium sp. CAG:649 and Fusobacterium strain 
MJR7757B respectively) also have a CbpF homologue and can likely adhere to CEACAM1 too. The 
R30927 clinical strain does not contain a CbpF homologue in its genome as well as not being able 
to bind CEACAM1. The GenBank assembly accession numbers are given for the genomes used. 
The UPGMA method was used to infer evolutionary distance from the linearized MUMi 
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The final species confirmed to bind CEACAM1 in this study was F. ovarium sp. nov. (Fov). 
This strain is interesting as it exists as a singleton set apart from any other species though 
its closest relatives are Fn, Fv and Fa. In addition, there are more than one predicted CbpF-
like genes in this strain, each of which also has some unique properties not found in the 
other CbpFs. The first of these proteins is heavily truncated in the predicted stalk region 
and has only 387 amino acids, approximately 100 residues shorter than CbpFa. The second 
CbpF-like protein is more similar to CbpFa, but with two insertions with a resulting total 
length of 488 residues. These two proteins will be referred to as putative CbpFc1 and 
CbpFc2 respectively until CEACAM-binding profiles can be established for each individual 
protein.  
FIGURE 4.3 shows the results of a Western blot comparing the Fov and Fa CEACAM1-binding 
strains, as well as a comparison to F. vincentii. In this case, the Fa R15792 strain failed to 
demonstrate visible adhesion, while the Fa R5001 and Fov R16531 strains both showed 
CEACAM1-specific interactions. This experiment also shows that the size of the CEACAM1-
bining protein in Fov is markedly smaller than that of CbpFa and CbpFb, indicating that the 
CbpFc1 (with a trimer size of approximately 115 kDa) is the likely candidate for CEACAM1 
binding. 
The one common feature all the cbpF genes have (barring cbpFc2), is their proximity to 
certain surrounding genes. The cbpF gene is always found directly upstream of the nik-
operon (nikABCDE) followed by ribD and ribH. In addition to cbpF being restricted to 
CEACAM1-binding strains, these strains are also the only ones harbouring an intact nik-
operon. This is indicative of this whole region, at one point in time, being a mobile genetic 
element and evidence of a transposase further downstream of these genes can also be 
seen in some strains. The exception to this is the putative cbpFc2 gene in F. ovarium sp. 
nov. where this gene is inserted into a region downstream of a histidine kinase gene. 
  




FIGURE 4.5 shows the genetic map of the different CbpFs and how their genomic topology 
compares. As can be seen, not all elements upstream of the cbpF gene are present, though 
the downstream nik-operon is more or less the same in all strains.  
Contrary to the presence of the nik-operon, there is no evidence of the nikR gene present 
in the genomes of any Fusobacterium strain. The gene product NikR is responsible for 
regulation of the nik-operon (product NikABCDE) and is found within other strains that 
harbour this operon, which is responsible for nickel transport using an ABC-transporter. 
However, it is clear that this particular operon is not needed for successful growth or 
proliferation of Fusobacterium as it is not found in the vast majority of strains. It is unclear 
what the relationship between this operon and CbpF is, where it may be an incidental 
relationship that has no effect on one another or that the expression of one will lead to 
increased expression of the other for example. 
 
Figure 4.5 | The CbpF genomic island. 
The above map shows the position of the cbpF gene within A) F. nucleatum ATCC 25586, B) F. 
oralis sp. nov. 2B3, C) F. animalis R5001 and D) F. ovarium sp. nov. R16531 genomes. The cbpF 
region shown for F. ovarium sp. nov., is the area surrounding the cbpFc1 gene. The cbpF gene is 
found directly upstream of the nik-operon in each case with the ribD, H and E genes further 
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FIGURE 4.6 shows the evolutionary history of identified putative CbpF proteins within 
Fusobacterium. Here the two predominant branches of CbpF proteins can be seen as well 
as the internal variation within the CbpF types. From examining the sequence alignment 
(see APPENDIX D) of all the predicted CbpF proteins, it is clear one domain is completely 
conserved, that being the β-barrel coding region. The sequence then differs throughout the 
remaining domains in the protein with the primary difference being altering numbers of 
YadA-like domains in the head portion of the protein. The signal peptide is the other highly 
conserved region, with few changes in sequence, though this is to be expected for 
successful trafficking to occur. The stalk region also differs between strains, though it hard 
to make any predictions about how this would affect function, as this domain cannot be 
accurately characterised.   





Figure 4.6 | CbpF Evolutionary History. 
Putative CbpF proteins were identified within the above strains and aligned using MUSCLE (166). 
The evolutionary history was inferred using the BioNJ method in MEGA7 (167) and the optimal tree, 
with the sum of the branch lengths equal to 1.194, is shown. The percentage of replicate trees in 
which the associated taxa clustered together in the bootstrap test (193), with 1000 replicates, are 
shown next to the branches. The evolutionary distances (number of amino acid substitutions per site) 
were computed using the Poisson correction method as used in MEGA7 (167). Strains with partial 
CbpFs due to existing on contig ends, such as Fn CTI-2 and Fa CAG:649 were excluded.   
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4.2.2 Enzyme-linked Immunosorbent Assay with Purified Protein 
To examine the effects of CEACAM interactions more closely, assays were performed using 
purified protein. Both CbpFa and CbpFb from Fn ATCC 25586 and For 2B3 respectively 
were cloned in to pOPINE (pCRF1 and pCFR2 respectively) as described in the Methods 
and subsequently transformed into E. coli expression cells. Initially, BL21 (DE3) cells were 
used for expression and protein purified using the small-scale method. This, however, 
yielded very little protein, so the cell line was switched to BL21 (DE3) pLysS cells, which 
contained a plasmid responsible for preventing ‘leaky’ expression prior to induction. The 
induction time was also changed to O/N at RT. Protein was then purified using the same 
method as before and this greatly improved protein yield. Purified protein was subsequently 
exhaustively dialysed against PBS and kept at a concentration below 0.1 mg∙ml-1 and at RT 
to prevent aggregation and precipitation. CEACAM1 binding activity was confirmed using a 
Western blot using CEACAM1-FC (CC1-FC) in addition to using CbpF-specific polyclonal 
rabbit serum (PA5154). FIGURE 4.7 shows the activity and purity of purified recombinant 
CbpFa 22-330. 
ELISAs were then performed using the purified proteins against CEACAMs where the total 
amount of protein used to coat the wells was 3 pmol of each. The primary detection was 
done using soluble human CEACAM1, CEACAM3, CEA, CEACAM6, CEACAM8, 
CEACAM1-ΔN and mouse CEACAM1b hIgG1-FC conjugates at a concentration of 1 pmol 
per well as well as a blank 1 % (w/v) BSA negative control. Binding of these conjugates was 
detected using anti-human IgG alkaline phosphatase (āH-AP) antibody followed by 
development with SigmaFast® (see Materials and Methods). Absorbance at 405 nm was 
read after 45 minutes of development at 37 °C and the results standardised for each repeat 
(FIGURE 4.8). 
The experiment was repeated three times and ANOVA followed by a post-hoc Tukey HSD 
test was performed on the results to identify the significant differences. The graph of results 
in FIGURE 4.8 confirms binding of CbpFa and CbpFb to CEACAM1, but also shows that both 




are able to bind CEA, however no significant detection cold be observed using any of the 
other CEACAMs used in this experiment. Furthermore, it shows CbpFb binds to CEA 
significantly (𝑝𝑝 < 0.0001) more strongly than CbpFa with about twice the absorbance 
observed, and both CbpFs bind CEACAM1 significantly more than CEA (𝑝𝑝 < 0.0001), 
though to a lesser extent for CbpFb. 
 
Figure 4.7 | Conformation of purity and activity of recombinant of CbpFa. 
Recombinant CbpFa was heated (95 °C) with loading buffer (TABLE S 1) for 10 min and run on a 4-
20 % gradient SDS-PAGE gel for 30 min at 300 V before staining with Coomassie (left) or transferring 
to a nitrocellulose membrane and performing Western blots (see Methods) with recombinant 
CEACAM1-hIgG (CC1), CEACAM1-ΔN-hIgG (CC1-ΔN), polyclonal PA5154 day 70/72 (d70/72), and 
PA5154 day 0 (d0). * marks the band corresponding to CbpFa 22-330 at 32.0 kDa. ** marks residual 
dimeric CbpFa at 64 kDa. A faint laddering effect can be seen when examining the polyclonal serum 
blot indicating possible degradation, however a single distinct band is seen against CC1 indicating 
any signal from an ELISA will predominantly be from CbpFa. M – marker; A – purified CbpFa. 
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Figure 4.8 | ELISA examining interactions between CEACAMs and CbpFs. 
3 pmol of purified CbpFa (Fn ATCC 25586) or CbpFb (F. oralis sp. nov. 2B3) were overlaid on an 
ELISA plate O/N and blocked with BSA. 1 pmol of each CEACAM-hIgG1 FC variant were used 
followed by an anti-human secondary antibody to detect adhesion. Each CEACAM-FC conjugate 
contained all the extracellular IgC- and IgV-like domains except for the ΔN mutant that lacked the N-
terminal IgV-like domain. A BSA-only control (āH) was included as background negative control. 
Mouse CEACAM1b (mCEACAM1b) and CEACAM8 were also used as these have not been shown 
to bind any human pathogen adhesins. Three biological replicates consisting of three technical 
replicates were performed for each condition. A one-way ANOVA (𝐹𝐹(15) = 370.8; 𝑝𝑝 < 0.0001) 
followed by a post-hoc Tukey HSD test identified significant differences between CEA and 
CEACAM1 (*** 𝑝𝑝 < 0.0001) binding with CEA binding less for both CbpFa and b. CbpFa was also 
shown to bind to CEA with about half the affinity compared to CbpFb (* 𝑝𝑝 < 0.0001). A significant 
difference was also observed between CbpFa and CbpFb binding to CEACAM1 (** 𝑝𝑝 < 0.0001). 
   




4.2.3 Adhesion Assays with CbpF and CEACAMs 
In addition to purified proteins, we examined whole-cell binding as well to see if there was 
any difference when the protein was expressed in its native form on the surface of bacteria. 
In this study, interactions between CEACAM1, 3, 5 and 8 were examined. To observe these 
interactions, surface expressed forms of the proteins were used that were engineered to 
localise to the outer-membrane of E. coli using the pOAF expression vector. The full genes 
(excluding the N-terminal signal sequence) for CbpFa and CbpFb were cloned into this 
vector using ligation independent cloning as described in the Methods. E. coli BL21 (DE3) 
pLysS cells were transformed with the plasmids as well as empty vector, to assess the 
background levels of adhesion. These would best represent the in vivo forms of the proteins 
without using Fusobacterium as, currently, Fusobacterium have no straightforward direct 
genetic manipulation protocols. We performed an adhesion assay with 100 μl of bacteria 
per well at a concentration of approximately of 5 x 108 CFU∙ml-1, this represents a multiplicity 
of infection (MOI) of 500. In FIGURE 4.9, very good adherence of CbpFa- and CbpFb-
expressing bacteria to CEACAM1 was observed, as expected. In addition, we saw some 
cell-specific interactions of both CbpFa and CbpFb to CEACAM3, though this was not to 
the same extent as with CEACAM1. For CbpFa and CbpFb, there was also evident cell-
specific binding to CEA. These results contrast with the protein-only ELISA data; however, 
this experiment has more inherent variation due to the much higher number of parameters 
that could change. 
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Figure 4.9 | Whole-cell adhesion assay between CEACAMs and CbpFs. 
An adhesion assay using three E. coli BL21 (DE3) pLysS expression strains, harbouring the plasmids 
pOAF, pCFS1 and pCBS1 (TABLE 2.3), and HeLa cells expressing different CEACAMs was 
performed (see Methods for details). HeLa cell nuclei were stained with DAPI (blue) and bacteria 
were detected using a fluorescent antibody (green). E. coli containing the empty plasmid, pOAF, and 
non-CEACAM1-expressing HeLaNeo cells were used as negative controls.   
  




4.2.4 Inhibition Study 
To study the binding of CbpFa to CEACAM1, we performed an adhesion assay as 
previously explained, but prior to incubation with bacteria, different potential protein 
inhibitors were added (100 μl at 1 μg∙ml-1) to the cells and incubated for 30 min at 37°C, 
before being washed off with Medium-199. A purified peptide (rD-7) derived from UspA1 
from M. catarrhalis, which has been shown to bind to CEACAM1 was used as a potential 
inhibitor (118). If inhibition was seen with this peptide, then deductions may have been able 
to be made with respect to where the likely CbpF epitope is located on CEACAM1, as this 
has been determined for rD-7. In addition to this a media-only condition was setup as well 
as using another peptide fragment (MsfA) from the N. meningitidis protein Msf was used as 
a protein negative control, as this is a TAA that has not been shown to bind CEACAM1.  
FIGURE 4.10 shows the results of the adhesion assay. The media-only control behaves as 
expected with strong bacterial adhesion displayed and this is also the same for the condition 
containing MsfA. When looking at the effects of rD-7 on adhesion, there is a marked 
reduction on the level of adhesion down to basal levels. A one-way ANOVA followed by a 
post-hoc Tukey HSD test yielded significant differences between rD-7-inhibitded CEACAM1 
conditions compared to both Msf-containing and media-only conditions (𝑝𝑝 < 0.0001). 
Moreover, there was no significant difference between all conditions that remained largely 
negative or either of the two positive conditions. The experiment collected data from three 
biological repeats each having three technical repeats per condition. Image data was 
converted to numerical data using relative fluorescence as a metric for adhesion (see 
Methods). 
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Figure 4.10 | Inhibition of cellular adhesion between surface-expressed CbpFa and CEACAM1. 
A cell adhesion assay with the addition of inhibitor peptides with MsfA and rD-7, which were 
incubated with the eukaryotic cells for 30 min at 37 °C prior to addition of bacteria.  A) Sample image 
set from adhesion assay. B) Average relative fluorescence from wells. One-way ANOVA followed by 
a post-hoc Tukey HSD test yielded significant (𝑝𝑝 < 0.0001) differences for comparisons with any 
negative control to both uninhibited conditions between CbpFa and CEACAM1 (**); and with the 
inhibited rD-7 condition compared to the uninhibited ones (*). There was no significant difference 
between either positive condition. Key: E. coli pOAF – E. coli BL21 (DE3) pLysS pOAF (control 
bacteria); E. coli pCFS1 – E. coli BL21 (DE3) pLysS pCFS1 (CbpFa; TABLE 2.3).   




4.3 CbpF CEACAM1 Binding Epitope Elucidation 
4.3.1 Alternate TAAs in Adhesion Experiments 
To determine possible regions of CbpFa and CbpFb that are binding to CEACAM1, the 
binding profiles of other similar TAAs were determined. To do this the gene loci FN0471, 
FN0735 and FNP1391 from Fn ATCC 25586 and Fp ATCC 10953 were cloned into the 
plasmid vector pOAF using primers as described in TABLE 2.4. The successfully cloned 
plasmids were subsequently transformed into E. coli BL21 (DE3) pLysS cells. Adhesion 
assays were then carried out using CEACAM1-expressing HeLa cells and the TAA-
expressing bacteria. As the peptide fragment rD-7 was shown to inhibit CEACAM1 binding 
by CbpFa, this was included in the assays to detect any CEACAM1-binding inhibition. 
FIGURE 4.11 shows the result of the adhesion assay. CbpFa (FN1499) was included as a 
positive control and behaved as expected, binding to CEACAM1-expressing cells. Both 
FN0735 and FNP1391 showed little binding to the HeLa cells and no observable 
CEACAM1-specific binding. Interestingly, FN0471 bound very well to HeLa cells; however, 
CEACAM1-specific interactions could not be seen due to the high background. This 
suggests FN0471 is binding to a different receptor on HeLa cells. At this point, there is no 
evidence for what this receptor could be. To confirm that there were no CEACAM1-specific 
interactions with FN0471, western blots were performed on raw bacterial lysates expressing 
whole protein (not shown). These blots were overlaid with CEACAM1-Fc as used before. 
The blots came up positive for CbpFa (FN1499) and negative for FN0471, FN0735 and 
FNP1391, cementing the evidence for it not being able to bind to CEACAM1. 
 Chapter 4: Fusobacterium TAAs and Adhesion to CEACAMs 




Figure 4.11 | Alternate trimeric autotransporter adhesins adhesion to CEACAM1. 
The above figure shows an adhesion assay conducted using E. coli cells expressing different TAAs 
on their surface and if any of these can facilitate adhesion to CEACAM1-expressing HeLa cells. Five 
bacterial strains were used harbouring plasmids as described in TABLE 2.3. The peptide rD-7 was 
included to help distinguish specific and non-specific interactions as well as HeLa cells not 
expressing CEACAM1 (HeLaNeo). Two TAAs from Fn ATCC 25586 (FN0471 and FN0735) and one 
from F. polymorphum ATCC 10953 (FNP1391) were tested. In all three cases there were no specific 
CEACAM1 interactions observed, however, the FN0471-expressing strain bound indiscriminately to 
all HeLa cells used, indicating that this protein does bind to a human surface receptor. Additionally, 
FN0735- and FNP1391-expressing bacteria also bound to all HeLa cells, though not to as great an 
extent as FN0471. This image set is an example from one of three biological repeats. 
 




4.3.2 Rational Design of CbpF mutants 
Assuming CbpFa and CbpFb utilise a similar binding epitope on CEACAM1, the region 
responsible for adhesion on CbpF could be theorised using additive and subtractive 
alignment methods. The two sequences, in addition to other direct CbpFa homologues, 
were aligned and the matching regions scored. These hits were subsequently aligned 
against other TAAs from Fn that do not bind CEACAMs (FN0471 and FN0735) in a 
subtractive manner to remove background sequence hits. The scores for each of the 
regions of CbpFa are shown in FIGURE 4.12. This yields several possible regions in CbpFa 
that could be responsible for binding to CEACAM1. The residues from CbpFa (FN1499) 
148-179, 254-274 and 305-332 are the top three regions that emerge post completing the 
subtractive alignments. Using this information, deletion mutants and fragments containing 
these regions were created to experimentally determine the more important sections. 
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Figure 4.12 | CbpF sequence propensity. 
A) Sequential 10-residue regions of CbpFa (from Fn ATCC 25586) were aligned against and scored 
against two CbpFb proteins (from F. oralis sp. nov. 2B3 and F. animalis R5001) and CbpFc (from F. 
ovarium sp. nov.). These regions were also aligned against three other TAAs: FN0471, FN0735 (both 
from Fn ATCC 25586), and FNP1391 (from Fpoly ATCC 10953). The two alignment groups were 
averaged and the non-CbpF group score subtracted from the CbpF score. The net and weighted 
scores were plotted, where regions greater than 0 are more similar to other CbpFs than any other 
Fusobacterium TAA. The Needleman-Wunsch alignment algorithm (194) was used and alignments 
were scored using BLOSUM62 (195). Weighted scores produce a lower score for increased variation 
in the positive alignments. Indicated are the positions of three fragments (F1, F2 and F3) described 
in SECTION 4.3.3. B) The domains of CbpFa were annotated using the daTAA (Domain Annotation 
of Trimeric Autotransporter Adhesins) software package (97). 
4.3.3 Fragment production 
Initially, CbpFa was split into four distinct domains, each containing different regions 
spanning the entire extracellular domain. Primers were designed to generate the protein 
regions 22-128 (pCFR2), 128-180 (pCFR3), 180-235 (pCFR4) and 214-330 (pCFR5) from 
the FN1499 gene (see TABLE 2.4 for primers used), and following PCR, were cloned into 




pOPINE (TABLE 2.3). The resulting vectors were sequenced and checked for any mutations. 
Full details of the cloning procedure used can be found in the Material and Methods section. 
All four constructs were made successfully and BL21 (DE3) pLysS cells were transformed 
with the plasmids for expression. 
Multiple conditions were trialled initially using a range of temperatures and incubation 
periods on a small scale (< 100 ml cultures). A sample of cell suspension was taken post 
expression and SDS-PAGE loading buffer (TABLE S 1) was added and heated for 10 min at 
95 °C. The sample was then run down a 4-20 % SDS-PAGE gel and the was either stained 
with Coomassie or the proteins transferred to a nitrocellulose membrane before performing 
a Western blot using the polyclonal anti-CbpF sera (PA5154 day 72 or day 56). 
Unfortunately, very little to no expression was seen for all four constructs. When scaled up 
to 1 l cultures with protein being purified using the small-scale native purification method, 
no protein could be observed when trying to detect CbpF polyclonal antibody binding. 
Equally for the CEACAM1-FC conjugate, no binding could be detected. This is indicative of 
misfolding, at least for the domain involved in binding. From this, the constructs were 
redesigned and engineered for the pMAL expression system (NEB) that fuses Maltose-
binding protein (MBP) to the N-terminal domain. They were also increased in size with a 
greater overlap between the three resulting constructs: CbpFa residues 40-190 (F1; 
pCFM2), 120-240 (F2; pCFM3) and 180-331 (F2; pCFM4). The position of these constructs 
displayed in FIGURE 4.12. Immunodot blots were also used this time to increase sensitivity 
as the proteins would not be denatured and detected in their native form. Protein could be 
easily detected with the anti-MBP antibody that was supplied with the pMAL expression kit 
(NEB). FIGURE 4.13 shows expression of protein with the anti-MBP antibody detecting all 
three fragments. On this occasion, binding was observed between the proteins and anti-
CbpF polyclonal serum, though very weak in the case the CbpFa 120-240 fragment. Yet 
still, no binding was seen when blotting against CEACAM1-FC, suggesting the protein 
fragments may not be completely folded correctly. 
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Figure 4.13 | Dot blot of MBP-tagged CbpFa fragments. 
Rows A-F represent differing protein fragments with a corresponding 10X dilution beneath, detailed 
in the key. Each column uses a different antibody with a relevant negative control adjacent to it. 
Proteins were adjusted to 1 and 0.1 μg∙ml-1 in PBS before loading 100 μl to each position. A buffer 
only control was also carried out in row G. All proteins were detected successfully using āMBP, 
though it is evident that F2 is not at the same concentration as the other two fragments, but it was 
still detectable. āMBP – anti-MBP primary antibody; āM – anti-mouse IgG-AP; āR – anti-rabbit IgG-
AP; āH – anti-human IgG-AP; F1 – fragment 1 CbpFa 40-190; F2 – fragment 2 CbpFa 120-240; F3 
– fragment 3 CbpFa 180-331. 
 
Because the detection of CbpFa 120-240 fragment was very weak with the polyclonal 
antibody, it could be due to it lacking the immunodominant epitopes that could bias other 
domains more greatly. It could also be due to the biological unit not correctly assembling 
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from steric hindrance from the MBP linked on the N-terminus – though there is a 10-residue 
long asparagine linker which should prevent this occurring.  
4.3.4 Deletion mutants 
In addition to creating fragments of protein, some truncation mutants were designed that 
lacked particular regions of the protein. The two regions designed were CbpFa Δ148-179 
and CbpFa 22-283. To create CbpFa Δ148-179, two PCRs were conducted to generate the 
exterior regions (from residues 22 and up to 330) with XhoI sites added to the deletion ends 
and pOPINE addons on the exterior DNA ends. The two PCRs were then cut with XhoI and 
ligated using T4 DNA ligase before inserting into pOPINE using In-Fusion® to create pCFR6 
(TABLE 2.3). Primers used to create vectors pCFR6 (CbpFa Δ148-179) and pCRF7 (CbpFa 
22-283) are described in TABLE 2.4. 
Unfortunately, the CbpFa 22-283 failed to express, however the Δ148-179 mutant did show 
some expression and so some initial preliminary tests were carried out on purified protein. 
The first of which uses the polyclonal antibody against CbpFa to indicate the 
immunodominant epitopes are exposed, though further tests will need to be carried out to 
confirm protein folding. The protein was then directly compared to pure extracellular CbpFa 
in a Western blot using the recombinant fusion protein CEACAM1-4C1-hIgG1 FC as the 
primary detector and anti-human IgG-AP conjugated antibody as the secondary detection 
agent from which the blot was developed (see Methods). 
FIGURE 4.14 shows the polyclonal antibody against CbpFa (PA5154) successfully bound to 
CbpFa Δ148-179, whereas CEACAM1-FC failed to demonstrate any observable binding, 
whereas native protein bound both as expected. The results of this experiment are 
preliminary as more tests are required on purified CbpFa Δ148-179 to confirm the correct 
folding of all the regions. 
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Figure 4.14 | CbpFa Δ148-179 mutant preliminary CEACAM1 binding results. 
Western blots of purified CbpFa 22-330 and CbpFa Δ148-179 against anti-CbpFa polyclonal 
antibody (PA5154) and CEACAM1-4C-hIgG1 FC (CC1-FC). Lane 4 shows that the polyclonal 
antibody can bind the deletion mutant and it does run smaller than native protein which is to be 
expected. There is no observable binding to CEACAM1 with the Δ148-179 mutant though (lane 6) 
where native protein is behaving as expected (lane 5). A negative control was carried out using anti-
human and anti-rabbit secondary antibodies only. Additional bands at higher molecular weights in 
lanes 3 and 4 can also be seen, which correspond to dimeric and trimeric forms of the protein that 
have not been fully dissociated. āH – anti-human IgG; āR – anti-rabbit IgG. 
4.3.5 Truncation Mutants 
Further to the use of fragment and gapped mutants of CbpFa, we created some mutants 
that would be suitable for surface expression in pOAF. These were sequential truncations 
originating from the head domain through to the start of the β-barrel. These mutants have 
the advantage that they will be constrained at the C-terminus by the β-barrel, which should 
help with correct formation of the biological unit, which may not always be possible in 
solution. The mutants designed encoded the following CbpFa residues: 111-479, 180-479, 
214-479, 293-479 and 329-479 (see TABLE 2.4 for the primers used). 
The successfully cloned regions were transformed into E. coli BL21 (DE3) pLysS cells. The 
cells were grown to mid-log phase and were induced with 1 mM IPTG and grown O/N at 37 
°C as previously explained. Adhesion assays were then carried out as before with CbpFa 
1. CbpFa + āH + āR 
2. CbpFa Δ148-179 + āH + āR 
3. CbpFa + PA5154 + āR 
4. CbpFa Δ148-179 + PA5154 + āR 
5. CbpFa + CC1-FC + āH 
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and the bacteria stained and assessed for CEACAM1-specific binding. The results of these 
adhesion assays failed to show any specific interactions between any of the truncated 
protein constructs and CEACAM1-expressing HeLa cells. However these results were 
preliminary and the experiment had not been optimised, so further tests should still be 
performed. 
4.4 CEACAM1 Mutant Screen 
4.4.1 Premade Mutants 
To investigate which residues on CEACAM1 are important for binding, several point 
mutations were made on the N-terminus of CEACAM1. A previous study designed and 
produced a set of mutants which are as follows: Y34A, Y34F, Y34S, G47L, I91A, I91L, I91T, 
Q89N and V96A (133). These mutants were designed rationally and were shown to interfere 
with UspA1 and Opa interactions with CEACAM1 (133, 135). The mutants and the native 
protein used in this case were from a shorter construct of CEACAM1 containing the N, A1 
and B domains, lacking the A2 domain, that CEACAM1-4C1 contains, and were fused to 
hIgG1-FC. The CEACAM NA1B product is a natural splice variant known as CEACAM1-3. 
This shorter variant should not interfere with binding as the A2 domain is not needed for 
pathogen receptor interactions, but the native CEACAM1-3-FC form was used as a positive 
control in these experiments.  
Each mutation confers a change on the predicted receptor-binding surface of CEACAM1 
and FIGURE 4.15 shows the alignment of the CEA-family N-terminal domains highlighting 
where the mutations occur. As previously mentioned, each mutant influenced UspA1 
binding with some mutants binding more strongly to UspA1 and some completely knocking 
out binding and these will be compared later with the effects the equivalent mutants had on 
CbpFs.  
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4.4.2 Novel CEACAM1 Mutants 
Since CbpFa and b both bind to CEACAM1 and CEA, common residues that overlapped 
on the binding domain were identified which were unique to CEACAM1 and CEA and not in 
other non-binders, such as CEACAM3, 6 and 8. Two key residues were identified using a 
sequence alignment of the N-terminal IgV domains of all CEA family members (FIGURE 4.15). 
The residues identified were a phenylalanine at position 29 (F29) and a glutamine at 
position 44 (Q44). The combination of these two amino acids is only found in CEACAM1 
and CEA, although F29 is also found in CEACAM3 whereas Q44 is not found in any other 
CEACAM. 
To test the importance of these residues, mutants were constructed that altered one of 
these single amino acids to one found in other CEACAM variants. These mutants and their 
alternate CEACAM variant-like are as follows: F29I (CEACAM6), F29Y (CEACAM7), F29R 
(CEACAM8), F29G (mouse CEACAM1b), Q44L (CEACAM3 and CEACAM6), Q44R 
(CEACAM6 and CEACAM8), and Q44E (mouse CEACAM1b). The mutants were 
engineered into a CEACAM1-3-hIgG FC construct, similarly to the previous mutants. The 
detailed construction of these mutants is described in the Methods section.  
4.4.3 CEACAM1 Mutant Binding Results 
An ELISA was performed using purified CbpFa and b and all the CEACAM1 mutants stated. 
Protein was added at 1 pmol per well and incubated O/N at 4 °C in carbonate buffer before 
blocking with BSA (see Methods). 15 fmol of each CEACAM1-3-FC point mutant, native 
CEACAM1-3-FC, CEACAM1-4C1-FC and CEACAM1-A1BA2-FC (CC1 ΔN-FC) were added 
to each well and incubated for 3 hrs. A BSA-only well was also kept for each condition as a 
secondary negative control. All wells were then overlaid with an anti-human IgG-AP 
secondary antibody at a total 10 μg per well and incubated for 1 hr. All incubations were 
carried out at RT and washed between each step (as described in the Materials and 
Methods). The ELISA was developed for 5 hours at 37 °C and the absorbance was 
measured at 405 nm. The results for which are detailed in FIGURE 4.16.  





Figure 4.15 | Sequence alignment for the IgV-like domains of all human CEA-family members. 
The sequences of all human CEA-family members IgV-like domains were aligned using Clustal 
Omega (172). The partial IgV-like domain of CEACAM20 and the C-terminal IgV-like domain of 
CEACAM16 were excluded. The N-terminal of murine CEACAM1b (mCEACAM1b) was also 
included for comparison. Sites at which mutations were made in the recombinant CEACAM1-FC 
conjugate are also highlighted. See APPENDIX B for CEACAM numbering conventions. 
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Figure 4.16 | CbpF-CEACAM1 mutant binding assay. 
This graph shows the results of an ELISA examining the effects that different CEACAM1 N-terminal 
mutations have on adhesion to CbpFa and CbpFb. Equimolar amounts of each protein (3 pmol) were 
overlaid overnight followed by blocking with BSA and incubation for 3 hours with 15 fmol of mutant 
CEACAM1-3-hIgG1 FC (CC1-3-FC). In addition, CEACAM1-4C-FC (CC1-4C) and CEACAM1-A1BA2-
FC (ΔN) were used as positive and negative controls respectively as well as a BSA only control. Anti-
human IgG-AP (āH) was used to detect binding. The ELISA was developed for 5 hrs at 37 °C using 
the SigmaFast® kit. A two-way ANOVA followed by a post-hoc TukeyHSD test was used identify 
significant differences conditions (N-terminal mutant: 𝐹𝐹(19) = 42.86, 𝑝𝑝 < 0.0001; CbpF protein 
𝐹𝐹(1) = 7.87, 𝑝𝑝 < 0.01). Individual T-tests were carried out for the marked paired conditions and were 
found to be significantly different (* 𝑝𝑝 < 0.05). 𝑁𝑁 = 3. 
  




Examining FIGURE 4.16 and post statistical analyses with ANOVA, no significant difference 
between both positive control conditions, CEACAM1-3 and CEACAM1-4C1, was observed, 
as expected. The V96A mutant also had a negligible effect on CbpF adherence and was 
not significantly different.  
Changing Y34 in all cases had a negative impact on protein binding, where Y34A showed 
little though not significant, binding to CbpFb but Y34F and Y34S knocked detection down 
to basal levels for both CbpFs. Similarly, altering I91 had a detrimental effect on protein 
interactions, where I91L showed some adhesion to CbpFa only.  
Interestingly, Q89N bound reasonably strongly to CbpFb when compared to the other 
mutants, however, showed no observable interactions with CbpFa indicating a specificity 
not present in CbpFb. 
The F29G, I and R mutants all had a substantial impact on the binding potential for both 
proteins reducing it to basal levels. Interestingly, the F29Y mutant still shows some 
interaction with CbpFb but reduces it completely for CbpFa. Other than this, both CbpFa 
and b do not appear to bind any of the other mutants with Q44 appearing critical for 
CEACAM1 or CEA adhesion as this residue is unique to both these CEACAMs throughout 
the CEA family of proteins. In a separate preliminary experiment (FIGURE 4.17), rD-7 was 
shown to bind all Q44 mutants, in fact potentially having a higher affinity toward Q44E than 
native, though Q44L and Q44R both reduce it. 
The results from this study are largely preliminary with a mutant concentration limitation not 
allowing to study saturating conditions, where only very small quantities of mutant were 
added per well. 
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Figure 4.17 | rD-7 interactions with CEACAM1-3 IgV mutants. 
The above figure is a preliminary study (n=1) examining rD-7 interactions with the novel CEACAM1-
3 N-terminal IgV mutants. The experiment was carried out with identical parameters to the one 
detailed in FIGURE 4.16 with CbpFa included as a control. As can be seen, rD-7 was able to bind all 
Q44 mutants to some degree and even bound the Q44E mutant with a higher affinity than with native 
protein. Changing F29 however knocked out binding, though the F29Y mutant still showed some 
adhesion. CC1-ΔN – CEACAM1-A1BA2-FC. āH – anti-human IgG.  





















rD-7 CEACAM1 Mutant ELISA 
rD-7 CbpFa




4.4.4 CEACAM1 N-terminal Mutant Molecular Dynamics 
To assess the validity of the CEACAM1 N-terminal domain mutants, spatiotemporal 
molecular dynamics (MD) was employed. In addition to validating structural stability, we 
wanted to compare any feature differences displayed by the mutants compared to the native 
form in an attempt to explain observed differences in CbpF-binding. For example, the 
mutants could show less flexibility than the native, with this potentially reducing the 
availability of CbpF-binding site. 
MD was performed using the GROMACS (version 5.0) package (154, 155). The crystal 
structure of the IgV-like domain of CEACAM1 (PDB ID: 4WHD) was used as a template 
from which the relevant side chains were mutated and separate models were created. The 
system setup, energy minimisation, equilibration and production MD steps are described in 
detail in the Methods section. In brief, a truncated octahedral unit with periodic boundary 
conditions (PBC) containing the protein was solvated with water and NaCl (0.1 M) where 
the salt ions were adjusted to yield neutral conditions. Following energy minimisation, 
temperature and pressure equilibration, 20 ns of production MD was run (See APPENDIX F 
for longer runs of wild type protein.). The PBC were removed and the system centred on 
the protein backbone. Following this, the RMSD (root-mean-square deviation) of the protein 
backbone was calculated for the 20 ns of MD. Both the original crystal and energy minimised 
structures were used to calculate RMSD, where the original structure was used as a 
reference to confirm there were no major structural artefacts introduced following 
minimisation. The graph of these values is shown in FIGURE 4.18-A. Five rounds of MD were 
performed for each structure to confirm the validity of the results, where all cognate 
simulations displayed highly similar features. 
A large deviation can be seen early in the MD for the native CEACAM1 where there is a 
considerable jump at 6 ns. This jump is not observed in most of the other simulations, 
though the Q44R mutant does make this jump and sooner, just after 3 ns. FIGURE 4.18-B 
shows this deviation where three structures are shown from three points throughout the MD 
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simulation (0, 10 and 20 ns). One loop on the binding face (around the residue T52 between 
the C’ and C’’ sheets) folds outward, were it remains for the remainder of the simulation. 
Conversely, the F29Y mutant, for example, does not display this outward folding and neither 
do the other mutants (FIGURE 4.18-C). 
 
Figure 4.18 | Molecular dynamics of CEACAM1 mutants. 
A) The backbone RMSD (against the post-minimised state) values are from 20 ns of molecular 
dynamics simulation. The base protein was the N-terminal crystal structure of CEACAM1 (4WHD; 
CC1 N), which was mutated to produce the mutant models listed above. For clarity, the graph was 
smoothed by taking averages at 20 ps intervals. A continued RMSD below 0.3 nm is generally 
considered stable, and every protein examined here remained well below that value. B) Three frames 
from native CEACAM1 and C) from the F29Y mutant simulations. Blue – 0 ns; orange – 10 ns; green 
– 20 ns. All frames were superposed against a common reference. 





4.5.1 CEACAM binding is Species Dependant 
Unlike other TAAs from Fusobacterium, CEACAM-binding capable TAAs have only been 
identified in four species: nucleatum, vincentii, animalis and oralis sp. nov. Cellular binding 
has hitherto only been observed in these species, though an oralis-like CEACAM1-binding 
homologue has been identified in a previously unclassified animalis strain, Fa strain, 
CAG:649; it is unknown whether this strain can bind CEACAM1. However, three of the 
clinical strains (R5001, R15792 and R30927) fall into the same clade, but only two (R5001 
and R15792) exhibit the same homologue and were shown to bind CEACAM1, with R15792 
not consistently displaying adhesion. No other homologues have been identified elsewhere 
in Fp, Fw, Fh or Fperio. The various clinical strains that bound CEACAM all derived from 
Fn, Fv, F oralis sp. nov., F. ovarium sp. nov. or one of the two Fa strains.  
The CEACAM-binding TAA candidates identified are all found upstream of the nik-operon, 
which is responsible for nickel transport across the membrane. Downstream of this in Fn 
ATCC 25586 is a transposase gene, suggesting this region was at one point a mobile 
genetic element, though divergence of the TAAs into two very distinct classes suggests it 
is no longer mobile. Moreover, the presence of a homologue in only a few Fa strains 
suggests an ancestor of this clade obtained the gene and this group diverged separately 
from the main clade in F. animalis, though some of the strains in this subgroup have lost 
this gene as it may not have imposed an evolutionary disadvantage for these species. 
Conversely, it is found ubiquitously within Fn, Fv and For species, which suggests it is 
required for these particular species. 
Interestingly the newly classified F. ovarium sp. nov. species could also bind CEACAM1, 
though using a much smaller protein. As the putative cbpFc2 gene product is far removed 
from the main two clusters of CbpFs (FIGURE 4.6), in addition to not existing adjacent to the 
nik-operon, it will be disregarded as the CEACAM-binding candidate. Further evidence for 
this can be seen in FIGURE 4.3, where the size of the CEACAM1-binidng protein is 
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substantially smaller than the other proteins, whereas the CbpFc2 protein would be 
expected to be the same size as CbpFa. The CEACAM1-binding protein band more 
appropriately matches the CbpFc1 protein (approximately 100 amino acid residues shorter 
than CbpFa). Therefore, CbpFc will henceforth be used to refer specifically to the CbpFc1 
protein from Fov. 
With regards to the potential impact on disease for F. animalis, R5001 was isolated from 
the placenta; R30927 was isolated from a maternal blood culture following a preterm birth; 
MJR7757B was isolated from the vagina; CAG:649 isolated from GI tract – human gut 
metagenome (female with Crohn’s Disease); and R15792 isolated from knee pus (male with 
infected knee). From this limited data, it is hard to draw meaningful conclusions about this 
subgroup of Fa, though it is worth noting that these species may be more linked to preterm 
birth and pregnancy complications from two of the cases listed; however, the presence of 
the CbpF protein does not correlate with these disease phenotypes as the R30927 has no 
discernible cbpF gene. So, as previously stated it is possible the CbpFb protein is not 
required for these Fa strains, though further evidence will be required to assess the 
importance of CbpF in Fa. 
4.5.2 CbpFs Bind CEACAM1 and CEA Through Interactions with Specific 
Residues 
Experiments examining CbpFa and b binding, both on cells and solution, show that the only 
receptors, for which they can bind, is CEACAM1 and CEA (CEACAM5), with no definitive 
evidence seen for CEACAM3, 6 or 8 or mouse CEACAM1b. This, however, does not mean 
they cannot bind to other CEACAMs or other CEA-related receptors such as PSGs. 
Nonetheless, binding CEACAM1 specifically has the advantage of being able to potentiate 
local immunosuppression via the ITIM domain contained within the intracellular region of 
CEACAM1 (127, 196), while avoiding the immune-activating CEACAM3 receptor found on 
granulocytes, which could lead to bacterial phagocytosis (134).  




Other studies have examined ITIM signalling through the TIGIT receptor and how this may 
prevent natural killer (NK) cells from targeting tumour cells that Fusobacterium is bound to 
(45). This particular study focusses on the role of the Fap2 protein, but does not look into 
CEACAM1 effects, although mentioning it momentarily. If a similar effect could be induced 
by CEACAM1-CbpF interactions, this would provide more evidence for an active role of 
Fusobacterium in CRC progression for instance. 
As shown in the ELISA for comparing different point mutants on the predicted N-terminal 
binding interface, certain residues are important for maintaining interactions to CbpF. For 
example, Q44 appears to be a key residue involved in these interactions. This residue is 
shared only between CEACAM1 and CEA not appearing in any other CEA family member 
(FIGURE 4.15). As mutating this residue destroys binding to either CbpFa or CbpFb, it can be 
hypothesised that there is a direct interaction between CbpF and Q44 that is responsible 
for specificity. 
The F29 residue is another critical residue for CbpF interactions, again only appearing in 
CEACAM1, CEA, and CEACAM3. As neither CbpF can adhere to CEACAM3 (as 
determined by protein-only assay), this is not the only residue that is conferring adhesion. 
Moreover, mutating this amino acid to a tyrosine still allows CbpFb to bind, though slight, 
but not CbpFa. Interestingly, this F29Y change is found naturally in CEACAM7, which, 
unfortunately, was unable to be tested in any of the experiments carried out so it would be 
an informative experiment to perform in the future. However, as CEACAM7 lacks the Q44 
residue, where it has an arginine in its place, it will likely be unable to bind either CbpF as 
all Q44 mutants knocked out adhesion 
Additionally, mutating Y34 had a large impact on the ability for CbpFs to bind. This is likely 
a larger structural change that would alter this domain making it more flexible. Y34 is highly 
conserved among all the CEA-family members also appearing in the IgV-like domains of 
PSGs (FIGURE 4.15); this suggests it is a vital residue to confer normal function and structure 
of these proteins. 
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The mutation with the least impact on CbpF adhesion was the V96A mutant where the 
difference was not significant between either native CEACAM1 variant. This strongly implies 
that this residue is not involved in adhesion and does not form part of the binding interface. 
The only other mutant that is predicted to be on the binding surface of CEACAM1 that did 
not completely reduce adhesion, at least for CbpFb, was Q89N. As previously explained, 
there is a difference in affinity between the interactions of CbpFa and CbpFb with CEA 
where CbpFb binds more strongly to it than CbpFa, whereas, both bind to CEACAM1 
equally. One of the main differences between CEACAM1 and CEA is the amino acid residue 
Q89 where CEA has a histidine at this position. As changing this normally polar amino acid 
to a slightly positively charged amino acid (histidine in CEA) or normally negative residue 
(glutamic acid in CEACAM1 mutant) does not impact CbpFb as much as CbpFa, this 
residue can be theorised to not play as much of a role in binding to CbpFb. Conversely, it 
seems more important for maintaining CbpFa affinity and when changed to glutamic acid, 
completely removes the ability to adhere. FIGURE 4.19 shows the difference between the N-
terminal domains of CEACAM1, 5 and 6. Highlighted are the locations of some of the key 
amino acid mutations that affect CbpF-CEACAM1 interactions.  
In the I91L mutant, binding was retained slightly for CbpFa, however when changing this 
residue to alanine or threonine, the affinity was reduced completely. This mutant was the 
only example of CbpFa being able to bind more strongly than CbpFb, where there was no 
observed adhesion to any of the I91 mutants. Like Y34, I91 is highly conserved in the CEA 
family, appearing in all the native CEACAMs examined here, but it is an interesting feature 
that only CbpFa can bind, albeit slight, to a mutant of this residue.  





Figure 4.19 | Structural superposition of the N-terminal domains of CEACAMs. 
The structures of CEACAM1, CEA (CEACAM5) (139) and CEACAM6 (137) N-terminal domains 
(PDB IDs: 4WHD, 2QSQ and 4Y8A respectively) have been structurally aligned using superposed. 
Residues on the predicted binding interface have been labelled according to the residue on 
CEACAM1. Residues of interest have been highlighted with their sidechains represented as lines. 
The residues of the binding interface are highly similar between CEACAM1 and CEA, with two 
notable differences at residues 89 and 49 changing from glutamine to histidine and alanine to valine 
from CEACAM1 to CEA respectively. CEACAM1 and CEA also share certain residues not present 
in the CEACAM6 N-terminal domain such as F29 and Q44 which are replaced by isoleucine and 
leucine respectively. This residue is not present in the structures of other CEACAMs where in 
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Given the time and resources, this study would have examined other CEACAM1 mutants 
as well as mutants from CEA and CEACAM3. For example, it would be informative to see 
if mutating the CEACAM3 residue L44 to glutamine could allow binding of CbpFs. Q44 is 
the only unique sidechain to CEACAM1 and CEA, as CEACAM3 also contains the F29 
residue, unlike all other members of the CEA family. Likewise, it would be interesting to see 
if mutating the H89 on CEA to glutamine would increase binding affinity for CbpFa, as this 
is the primary difference on the CFG face between CEACAM1 and CEA. Notably, Q89H is 
also a naturally occurring single nucleotide polymorphism (SNP) for CEACAM1 found within 
the human genome. Nonetheless, the information gathered in this study provides an insight 
to the possible molecular interactions between CEACAM1 and CbpFs. 
  




Chapter 5: Structural Analysis and Modelling of CbpFs 
5.1 Introduction 
To help build an understanding of the molecular interactions between CbpFs and 
CEACAMs, structural information was needed to strengthen hypotheses generated from 
functional data. Structures of TAAs such as UspA1, BpaA, YadA and SadA have 
significantly aided the modelling of important molecular interactions with their respective 
receptor-targets (102, 103, 107, 108, 135). The HopQ virulence factor from H. pylori was 
even co-crystallised with the IgV-like domain of CEACAM1 providing a detailed model for 
protein-protein interactions and what epitopes would be important in vaccine design (140). 
Prior to this study, there was no structural information pertaining to CbpFs. As these proteins 
belong to the trimeric autotransporter adhesin family of proteins, some assumptions can be 
made regarding the overall topology. The most straightforward of which is the β-barrel, 
which is highly conserved among all TAAs and is extremely similar in CbpFs. In addition to 
this, there should be at least two other regions in the extracellular domain, consisting of a 
coiled-coil stalk extruding from the membrane anchor followed by a series of constraining 
head domains. However, other substructures could exist, for example it could have multiple 
CC regions or altering head-neck topologies, with examples detailed in TABLE 1.1, such as 
the case for SadA which has a complex domain organisation over the complete fibril (108). 
However, it could be a much simpler situation, such as YadA, only having one of each of 
the core components of stalk, neck and head domains (103).  
As these proteins originate from a species not closely related to other species with known 
TAA structures, there will likely be some structural nuances specific to Fusobacterium, 
especially considering the restricted codon bias imposed by the inherently low GC % 
content. 
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5.2 Computational prediction 
5.2.1 Sequence Analysis 
In addition to attempting to experimentally solve the structures of CbpFa and b, 
computational predictions of the secondary and tertiary structures were made using a 
variety of software. By performing these structure and domain predictions, we hoped this 
could aid in solving crystal structures through molecular replacement or provide the overall 
model, should experimental determination have failed. In addition to providing structural 
information, the analyses could help quickly identify similarities and differences between the 
different classes of CbpFs between species, such as domain possession or deletion to 
identify the key domains for function. 
Initially the overall topology of the proteins was determined using daTAA (Domain 
Annotation of Trimeric Autotransporter Adhesins) (97), which finds regions of homology with 
a dictionary of known TAA domain sequences. FIGURE 5.1 shows the annotation of the 
proteins according to daTAA. From examining the annotations provided by daTAA, there 
appear to be gapped regions where unknown and potential novel folds exist, with a common 
region in both CbpFa and CbpFb between the two YadA-like head clusters. The second 
smaller YadA-like cluster also has a different motif from that of the N-terminal cluster. The 
N-terminal YadA-like head cluster consists of conserved 14-residue repeat sequences and 
the motif has a well-defined fingerprint as shown in FIGURE 5.2. Each one of these repeats 
constitutes one turn of an O-shaped β-roll, as described in detail in SECTION 1.2.2. The 
second cluster of YadA-like domains that were annotated cannot be resolved to a common 
consensus sequence, though the glycine at the twelfth position, also in the first cluster, 
remains conserved in all four sequences. 
The closest neighbour to the N-terminal group of head domains, with a solved structure, is 
UspA1 from M. catarrhalis, however it contains one extra residue per turn of the O-shaped 
β-roll. The neck region that follows is most like that of Hia from H. influenzae (75 % identity) 
and BpaA from B. pseudomallei (73 % identity). By aligning the tetradecamer repeat 




sequence from CbpF to UspA1, we can predict the internal facing residues of the domain. 
The highly conserved SSAFG from positions 8-12 likely form the inner core of the trimeric 
biomolecule with the bulky phenylalanine residue forming hydrophobic interactions within 
the central core.  
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Figure 5.1 | Domain Annotation of CbpFa and b using daTAA. 
The software package daTAA (Domain Annotation of Trimeric Autotransporter Adhesins) was used 
to highlight conserved regions on both CbpFa and CbpFb using a domain dictionary containing all 
the known folds found within TAAs. Three known domains were detected, which were YadA-like 
head groups (Ylhead), a neck domain and the membrane anchor. The domain-dictionary alignment 
lookup also finds potential coiled-coil domains which are shown adjacent to the domain annotations. 
Additionally, it appears daTAA missed an extra YadA-like group off the end of the first cluster, which 
was identified by looking at the sequence manually.   
CbpFa 
[F. nucleatum ATCC 25586] 
CbpFb 
[F. oralis 2B3] 





Figure 5.2 | CbpFa and b YadA-like head repeat sequence logo. 
This shows the propensities for each amino acid residue of the tetradecamer repeat sequences 
within the initial cluster of YadA-like head domains in A) CbpFa (7 domains) and b (12 domains) and 
B) all identified CbpF proteins within Fusobacterium spp (314 domains combined from 44 proteins). 
The most conserved residue is at position 12, which was glycine and is present in all repeats from 
every species, including CbpFc. Positions 1, 3, 8, 9, 10 and 11 were all highly conserved and 
replaced by a similar amino acid if different. The exception to this is in the final group within the 
cluster where there is a tyrosine at position 1 in all CbpF proteins. Positions 4 and 5 are also weakly 
conserved, whereas residues 2, 6, 7, 13 and 14 show no clear preference. Sequence logos were 
generated using WebLogo (197). A detailed breakdown of the domains is shown in FIGURE S 6. 
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The region of the protein that has the largest (for CbpFa) unknown motif is the domain 
directly downstream from the neck that should comprise the stalk section of the protein. For 
CbpFa, this region does not have any indication that it would form a coiled-coil, when using 
the programs MARCOIL and PCOILS. Likewise, CbpFb is not predicted to have a coiled-
coil region here either, however, daTAA does predict a CC region between the neck and 
the membrane anchor (FIGURE 5.1). FIGURE 5.3 shows the CC prediction for four CbpF 
proteins including CbpFa, b and c. The stalk region should start at residue 236 for CbpFa 
directly after then neck, however, no CC inclination can be observed until much further 
downstream directly before the start of the membrane anchor. Moreover, the region that 
has some CC prediction is largely not included in the constructs used in this study as it is 
likely buried within the β-barrel of the membrane anchor and it is known not to be necessary 
for CEACAM1 interactions. The main reason for MARCOIL and PCOILS not predicting a 
CC, is likely due to the presence of a helix-breaking proline residue in the centre of this 
region, although a caveat to this is the  fourth protein examined in FIGURE 5.3, where CbpFc 
does not have this poly-glycine-proline motif.  
FIGURE 5.4 shows the sequence alignment from the end of the first YadA-like head cluster to 
the start of the membrane anchor. The beginning of the stalk region starts at residue 236 
on CbpFa and 306 on CbpFb. There is one insightful gap that CbpFb has when compared 
to CbpFa where it is missing 23 amino acids and then there is also a short 2-residue gap 
which then follows on CbpFa. As the average residues per turn on an CC alpha helix is 
approximately 3.5 with 7 possible registers total, it would be expected that the helix-breaking 
proline would follow the same register in both proteins, therefore only gaps of a multiple of 
7 would be allowed. When combining the two gapped regions on the alignment, the net 
difference in length is 21, equivalent to 3 full register cycles, or approximately 6 helix turns. 
This then poses another question regarding what follows, which is currently unknown where 
running a protein BLAST against the Protein Data Bank (PDB) database yielded no 
homologous regions. When examining the full alignment of all identified putative CbpF 




proteins (APPENDIX D), there is one exception to this CC register re-complementation. The 
presumed CbpFa from Fn R28400, a strain known to bind CEACAM1 (FIGURE 4.2), only has 
a net gap length of 20, where there is an extra glycine present at residue 262. All other 
CbpFa and CbpFb proteins have a net gap of 21. CbpFc has a large deletion in this whole 
domain, lacking the glycine-rich region followed by a proline, so is more likely to be all CC. 
 
Figure 5.3 | CbpF MARCOIL coiled-coil prediction 
MARCOIL was used to predict the coiled-coil likelihood for each region of four of the CbpF proteins 
including A) CbpFa [Fn ATCC 25586], B) CbpFb [For 2B3], C) CbpFb [Fa R5001] and D) CbpFc 
[Fov R16531]. All four show some propensity for a CC directly prior to the membrane anchor (first 
peak in all four panels) followed by a strong signal after the membrane anchor region. The stalk 
region starts after the neck domain at residues 236, 306, 292 and 221 for each protein respectively. 
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Figure 5.4 | CbpFa and b uncharacterised region sequence alignment. 
This alignment covers the least well-defined region of both CbpFa [Fn ATCC 25586] and CbpFb [For 
2B3] from the end of the first YadA-like head group cluster to the start of the membrane anchor. The 
stalk region beings at residues 236 and 306 for CbpFa and b respectively. 
5.2.2 Model Building 
For model building, several different online servers were used, with some using quantum 
mechanics for creating ab initio models and others relying on existing molecular homology. 
The combination of all these generated models was expected to give an indication whether 
the structures generated had any validity. The applications used were: SWISS-Model (198), 
M4T (199), I-TASSER (200), QUARK (201) and RaptorX (202). For QUARK, the input 
sequence was limited to 200 residues due to the complex nature of its algorithm. All four 
applications were able to generate models of the head domain, as expected, due to its 
highly conserved nature. 
FIGURE 5.5 shows an example of the models that were produced. It is evident that the models 
do not represent a complete structure of each protein. Interestingly, the RaptorX program 
managed to model further down the sequence of CbpFb compared to CbpFa, modelling 
approximately 100 more amino acid residues. Nonetheless, none of the tested modelling 
software gave high confidence for any of the modelled regions. In addition, none of the 
modelling software could produce a structure for the stalk domain. Out of the software used, 
only QUARK has the ability to build completely ab initio models with no prior information 
(201), however, no reliable structure could be made. As previously mentioned, the stalk 
CbpFa   GMGEFN-GQYQ YKNEGNNSY MIGNKNKIAS GSDDNFILGN NVHIGGGINN  187 
CbpFb   GVGFWNSGSHL YKNEGNNSY MIGNKNKIAS GSDDNFILGN NVEIGAGVQK  257 
 
CbpFa   SVALGNNSTVS ASNTVSVGS STLKRKIVNV GDGAISANSS DAVTGRQLYS  237 
CbpFb   SVVLGDGSASG GSNTVSVGS STLQRKIVNV ADGTISATST DAVTGRQLYS  307 
 
CbpFa   GNGIDTAAWQN KLNVTRKND YKDANDIDVN KWKAKLGVGS GGG--GGAPV  285 
CbpFb   GDGID------ --------- --------VN KWRTKLGVSS GGGASGGAPG  334 
 
CbpFa   DAYTKSEADNK FANKTDLND YTKKDDYKDA NGIDVDKWKA KLGTG       330 
CbpFb   DAYTKSEADNK FTSK----- ----DDYKDA NGIDVDKWKA KLGTG       370 




region has no homologues within the Protein Data Bank (PDB) (203), therefore programs 
that rely on pre-existing templates to produce models will fail to predict this region 
accurately. 
 
Figure 5.5 | De novo models of CbpFa and CbpFb. 
The models presented were generated by RaptorX and were cropped such that disordered low 
confidence regions were excluded for clarity. Residues from the signal-sequence to the C-terminus 
were input constituting approximately 480 amino acid residues. The model lost confidence in both 
cases following the first sequence of YadA-like head domains, however it managed to model further 
using CbpFb (up to residue 312; blue) than CbpFa (up to residue 207; orange). 
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The application CCBuilder (204) was used to artificially build de novo coiled-coils from an 
input sequence. As it is expected there should be a coiled-coil in the stalk domain, in 
conjunction with other TAAs and because prediction software refuted any existence of one, 
they had to be guessed. The top scoring models for stability were used to educate the 
register, as it could exist within 7 different conformations (FIGURE 1.8). Other information 
such as pitch and interface angle were drawn from the CCs belonging to most similar 
structural homologues to the stalk CbpF such as SadA. This should at least have 
comparable properties at the N-terminal end of the stalk where the CC joins the neck region; 
the neck region of CbpF shares high homology to equivalent regions of the SadA and BpaA 
structures. This was done in an attempt to solve a crystal structure as detailed in the 
following section. 
5.3 Experimental Data 
5.3.1 X-ray Crystallography 
Recombinant protein was prepared for CbpFa and CbpFb using the pCFR1 and pCBR2 
vectors respectively (TABLE 2.3). To achieve sufficiently high protein yields for use in protein 
crystallography, expression conditions were optimised using a variety of E. coli expression 
strains, expression media, induction time, expression time and temperatures. The most 
optimal expression conditions used are described in detail in SECTION 2.4.2. In short, 
Rosetta2® (DE3) pLacI E. coli were grown overnight in LB broth before diluting 1:100 in 8 l 
autoinduction terrific broth and were subsequently grown at 37 °C for 24 hrs with shaking 
at 200 RPM. Cells were pelleted by centrifugation and stored at -80 °C prior to protein 
purification.  
The proteins were initially purified using affinity chromatography with Ni-NTA agarose as 
described in SECTION 2.4.2. Elution fractions collected were analysed for protein using SDS-
PAGE and Coomassie straining, where fractions containing protein were pooled and 
concentrated to approximately 5 ml. Any contaminants were then removed using size 
exclusion chromatography (SEC). See FIGURE 5.6 for example purification. 





Figure 5.6 | Example affinity and size-exclusion chromatography for CbpFb. 
Cell lysate was loaded onto an Ni-NTA resin affinity chromatography column where the column was 
washed with 20 column volumes of loading buffer, followed by a gradient increase in imidazole 
concentration to elute bound proteins. Fractions from each stage were loaded onto and SDS-PAGE 
gel and run at 300 V for 30 min and stained with Coomassie quick stain (A). M – Marker; OT – Pre-
column sample; FT – flow-through pre elution. Fractions containing CbpFb protein (* expected 36.1 
kDa for monomer) were pooled and dialysed and run down a size-exclusion column where it was 
separated from degraded or contaminating proteins (**; B – shows the UV280 nm absorbance of the 
fractions over the cumulative volume of buffer passed down the column). 
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Following SEC and concentration, purified protein was laid on a multitude of 96-well high 
throughput crystallography screens (sitting drop vapour diffusion; SECTION 2.9), with varying 
drop volume, protein to precipitant ratio and protein concentration. The initial screens used 
were: JCSG-plus™, MIDAS-plus™, Morpheus®, Morpheus® II, PACT premier™, 
ProPlex™, HELIX™ and Structure Screen 1+2 (Molecular Dimensions). Any promising 
crystal hits were then optimised about by varying the well solution component 
concentrations, pH and protein concentrations.  
Unfortunately, CbpFa could not ever be optimised to give crystals suitable for data 
collection, though further screening and optimisation may be able to yield a crystal worth 
examining on the beamline. However, CbpFb had a few conditions where it crystallised 
readily without the requirement to optimise conditions. The most reliable condition contained 
0.1 M MES pH 6.5, 0.05 CsCl, 30 % (v/v) Jeffamine® which yielded protein crystals in the 
two screens that share this condition (JCSGplus™ and Structure Screen I+II). The optimal 
condition had a one-to-one ratio of protein (at 3.2 mg∙ml-1) to precipitant solution at 200 nl 
each in the drop and 50 μl precipitant solution in the reservoir. Crystals were visible after 
incubation at 20 °C for two weeks. Images were captured periodically to monitor growth and 
samples of positive conditions are shown in FIGURE 5.7. Images were captured using visible, 
cross-polarising and UV light and crystals absorbing strongly in the UV were examined 
further as these were more likely to be protein crystals. 
Crystals were looped and incubated in a buffer-matched cryoprotectant containing up to 30 
% (v/v) glycerol (see Methods). Unfortunately, several crystals dissolved or were severely 
damaged when cryopreserving. However, some did not undergo dissolution – these were 
crystals from the JCSGplus™ F1 (JF1) and MIDAS™ E11 (ME11) wells (see product sheets 
on Molecular Dimensions for screen details). These crystals were frozen in liquid nitrogen 
before collecting data on a high-energy X-ray beamline (I04-1 Diamond Light Source). 
Examination of the crystal at the beamline indicated there were some ice crystals, so the 




crystals were washed three times by inserting and removing the loop from the liquid nitrogen 
stack. Data frames were collected with 360° of rotation and 5 frames per degree. 
 
Figure 5.7 | CbpFb optimal crystallisation conditions. 
Shown are images captured with a cross-polarising light filter of conditions that yielded protein 
crystals of CbpFb. In addition to the conditions shown, the condition from Structure Screen I+II F12, 
which shares the conditions of JCSGplus™ F1 also produced crystals. The pCBR1 plasmid, 
encoding CbpFb 25-374 [F. oralis 2B3] and expressed in E. coli Rosetta2 pLacI cells, was used. The 
stock protein concentration that yielded crystals was 3.2 mg∙ml-1 (in SEC Buffer A).  
The data collected from the JF1 crystal showed strong diffraction with the resolution 
reaching 2.0 Å from initial analysis. The resulting data were subsequently processed using 
iMOSFLM (151). The data were integrated, merged and scaled using iMOSFLM and 
JCSGplus™ F1 
200:200 nl protein to precipitant drop 
50 μl reservoir volume 
Well solution: 
0.1 M MES pH 6.5, 0.05 M CsCl, 30 % (v/v) Jeffamine® 
M-600 
ProPlex™ G12 
200:200 nl protein to precipitant drop 
50 μl reservoir volume 
Well solution: 
0.1 M HEPES pH 7.0, 1 M tri-sodium citrate 
500 μm 
ProPlex™ E6 
200:200 nl protein to precipitant drop 
50 μl reservoir volume 
Well solution: 
0.1 M sodium cacodylate pH 5.5, 0.1 M calcium acetate, 
12 % (w/v) PEG 8000 
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AIMLESS (205) within the CCP4 software suite (152). A summary of the data and statistics 
is listed in TABLE 5.1. The dimensions of the resulting unit cell, as calculated by POINTLESS 
(206, 207), were as follows: 𝑎𝑎 = 𝑏𝑏 = 59.83,𝑐𝑐 = 497.28,𝛼𝛼 = 𝛽𝛽 = 90.00,𝛾𝛾 = 120.00 (where 
𝑎𝑎,𝑏𝑏, 𝑐𝑐 correspond to length in Å and 𝛼𝛼,𝛽𝛽,𝛾𝛾 correspond to angle in degrees). The space 
group R 3 2’’ (H 3 2; corresponding to a H-centred trigonal unit cell) was determined to be 
the most probable solution (Laue group probability = 0.998). The wavelength (λ) from the 
data collection was 0.916 Å. Following cell content analysis, the percent solvent was 
calculated to be 48.1 % with a Matthews Coefficient of 2.37 and 1 monomer in the 
asymmetric unit (probability = 1.0000). 





 Overall (51.36-2.74 Å) Highest Resolution (2.87-2.74 Å) 
𝑅𝑅𝑛𝑛𝑟𝑟𝑟𝑟𝑚𝑚𝑟𝑟1 0.041 0.317 
𝑁𝑁𝑜𝑜𝑎𝑎𝑎𝑎𝑟𝑟𝑟𝑟𝑜𝑜𝑎𝑎𝑜𝑜𝑖𝑖𝑜𝑜𝑛𝑛𝑎𝑎 34717 4633 
𝑁𝑁𝑢𝑢𝑛𝑛𝑖𝑖𝑢𝑢𝑢𝑢𝑟𝑟 9438 1214 
𝐼𝐼/𝜎𝜎(𝐼𝐼) 12.3 3.4 
Completeness 99.3 97.5 
Multiplicity 3.7 3.8 
 
Following a BLAST search against the PDB database, several partial homologues to CbpFb 
were identified with the closest match having a coverage of 84.4 %, with a percent identity 
of 33.4 %. This protein was a crystal structure of head and neck domain of the UspA1 
protein (PDB ID: 3PR7). Details of all the trialled structures are listed in TABLE 5.2. Each of 
these structures was remodelled using Sculptor (208) in the Phenix application suite (153) 
with varying parameters corresponding to sequence conservation. The models were then 
sequentially parsed to Phaser (209) for molecular replacement, with one monomer in the 
unit cell. In addition, cropped and whole models produced by RaptorX, SWISS-Model and 
M4T were also trialled in molecular replacement. None of the de novo coiled-coils built using 




CCBuilder, with varying registers, pitch and interface angles, produced a solution with 
molecular replacement in Phaser. 
The model that yielded the highest scoring data post molecular replacement was a sculpted 
model of the head domain of 3PR7. Electron density was modified prior to statistical chain 
tracing with BUCCANEER (210) and SHELX (211). The model was then iteratively manually 
built and refined. Model building was performed in Coot (212) and refinement with 
REFMAC5 (213). A model including residues 18-175 of the expressed protein could be built 
before the electron density map could no longer be built into. After multiple phase-build-
refine iterations, no accurate structure could be produced, with final Free-R of approximately 
0.5. 
Table 5.2 | Molecular replacement template list. 
A BLAST search of the expressed region of CbpFb [For 2B3] against the PDB database was 
performed and the resulting top hits are listed. Each template was subsequently trimmed and edited 
using Sculptor and each was trialled in molecular replacement. 
PDB ID Length Coverage (%) Identity (%) Similarity (%) 
3PR7 302 84.4 33.4 45.0 
3NTN 209 58.4 34.0 46.9 
3S6L 120 33.5 36.7 55.8 
3WP8 169 47.2 33.7 46.2 
2YO3 53 14.8 52.8 62.3 
3LA9 71 19.8 43.7 52.1 
2YO0 72 20.1 45.8 59.7 
4USX 35 9.8 57.1 71.4 
2XQH 110 30.7 35.5 52.7 
3EMO 24 6.7 70.8 83.3 
1P9H 48 13.4 39.6 60.4 
2YNZ 24 6.7 66.7 75.0 
3ZMF 23 6.4 60.9 78.3 
2YO2 23 6.4 60.9 78.3 
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To rule out contaminating proteins or degraded protein, the JF1 crystal was retained, 
washed and resolubilised in water. The solution was then analysed using liquid-
chromatography-mass spectrometry (LC-MS; a service provided by the University of Bristol 
proteomics facility). The results found no evidence of contaminating proteins and the 
presence of the majority of the expected protein (69.6 % coverage). The LC-MS results are 
detailed in APPENDIX H (FIGURE S 7). 
 
Figure 5.8 | Best model for CbpFb from X-ray data. 
The above model shows the regions 18-175 of CbpFb that could be modelled post molecular 
replacement, model building and refinement. Highlighted is the central core consisting mainly of 
phenylalanine residues, as well as isoleucine and leucine, forming the ‘phenylalanine zipper’. One 
turn of the tetradecameric head domain is shown on the right (residues G73-F86) and the best 
corresponding map overlaid (2Fo-Fc map with a 1.2 sigma contour). 




5.3.2 Circular Dichroism 
As CbpFa did not readily crystallise, indirect experimental methods were employed to infer 
its structural features. Initially, circular dichroism (CD) was used to estimate secondary 
structure proportions and whether this aligned with computational prediction from the 
sequence. Three concentrations of CbpFa 22-330, from the E. coli Rosetta™ 2 (DE3) 
pLacI::pCFR1 construct (TABLE 2.3), were prepared in SEC Buffer A (TABLE S 1) at 1, 2 and 
5 μM before collecting CD data with 190 to 250 nm wavelength, with a 0.5 nm interval. 
Relative ellipticity was recorded and is displayed in FIGURE 5.9-A.  
Several CD deconvolution and spectra matching programs were used to get an 
approximation of the relative composition of the protein. A newer algorithm devolved by 
Micsonai et al. (214, 215) was used and the proposed composition is detailed in FIGURE 5.9-
B. Due to the presence of chloride ions in the preparation buffer, the beta-sheet estimations 
will not be as accurate compared to the alpha helices. However, the overall estimation aligns 
well to what would be expected from examining the daTAA result, where the YadA-like head 
domains contribute toward 40 % of the beta-domains alone. The uncharacterised stalk 
region would only account for 30 % of the structure, which should be predominantly alpha-
helical, which compares to the 23 % estimation. 
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Figure 5.9 | CD spectra and secondary structure estimations from CbpFa. 
A) Data was collected with wavelengths from 190 to 250 nm (0.5 nm interval) over three 
concentrations of 1, 2 and 5 μM of recombinant CbpFa 22-330 in SEC Buffer A (TABLE S 1). B) The 
CD data was put through a deconvolution program to estimate the relative secondary structure 
composition (214, 215). The beta-sheet internal compositions will not be as accurate, due to higher 
background at the shorter wavelengths from with absorbance from chloride ions, however, the ratio 
of helical to beta-sheet regions is as expected. 
  




5.3.3 Small Angle X-ray Scattering of CbpFa 
To assess the overall topology of CbpFa, small-angle X-ray scattering (SAXS) data were 
collected from protein in solution. Protein from the E. coli Rosetta™ 2 (DE3) pLacI::pCFR1 
construct (TABLE 2.3) was purified using the native large-scale preparation technique (see 
SECTION 2.4.2) and concentrated to 10 mg∙ml-1 in SEC Buffer B (TABLE S 1). 45 μl of protein 
sample was loaded onto a Superdex 200 Increase (GE Healthcare) column with the eluate 
connected in-line with the X-ray beam and detector (B21 DLS). Prior to protein loading, the 
column was equilibrated with 10 column volumes of SEC Buffer B and a 10 mg∙ml-1 BSA 
control sample was then run through column and analysed to confirm validity of data 
collection. X-ray scattering data frames were collected at a rate of 3 frames∙sec-1 with a 
sample flow rate of 0.075 ml∙min-1. FIGURE 5.10 shows the HPLC trace for CbpFa at 10 
mg∙ml-1 as well as estimates for the radius of gyration (Rg) for each frame collected. Frames 
with a consistent Rg following any aggregated protein were then combined and averaged 
prior to analysis. 
Following frame collation and averaging, Guinier fitting was performed using ScÅtter 
(version 3.1) and a pair-distance, 𝑃𝑃(𝑟𝑟), distribution function was calculated. The averaged 
data are summarised in FIGURE 5.11. One feature that was immediately evident was that the 
primary scattering peak on the dimensionless Kratky plot greatly deviates from the ideal 
globular Guinier-Kratky point, which is indicative of a non-globular protein, such as TAA, 
which are rod-shaped. There are also signs of some disordered regions indicated by the 
high tail on the plot (FIGURE 5.11-C). The comparison of reciprocal-space values, derived 
from Guinier analysis, and real-space values, derived from the 𝑃𝑃(𝑟𝑟) distribution, is shown 
in FIGURE 5.12. The maximum dimension, 𝑑𝑑𝑛𝑛𝑎𝑎𝑥𝑥, was set to 229 Å with a resolution limit, 𝑞𝑞𝑛𝑛𝑎𝑎𝑥𝑥, 
equal to 0.185 Å-1. A summary of the processed data is detailed in TABLE 5.3. 
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Figure 5.10 | HPLC Trace for CbpFa with Rg estimates. 
This plot shows the A280 nm HPLC trace (orange) of the purified protein while it was traversing the X-
ray beam. Each point represents one frame of data. Also plotted are the radius of gyration (Rg) 
estimates (blue). The region prior to the consistent Rg frames had very large Rg values (not shown) 
and were aggregated protein, hence the earlier elution point. The consistent Rg frames were 
combined and averaged. 
  
  





Figure 5.11 | Summary of SAXS data for CbpFa. 
A) Log10 SAXS intensity, 𝐼𝐼(𝑞𝑞), plotted against the scattering vector, 𝑞𝑞. B) Total scattered intensity 
plot. C) Dimensionless Kratky plot with the Guinier-Kratky point displayed (1.1,√3), which indicates 
the primary peak position for globular proteins. As can be seen the main peak for CbpFa is far from 
this point due to it not being globular and instead, rod-shaped. D) Pair-distance, 𝑃𝑃(𝑟𝑟), distribution 
function for CbpFa with a maximum dimension, 𝑑𝑑𝑛𝑛𝑎𝑎𝑥𝑥, set to 229 Å. The fit to the data of the 𝑃𝑃(𝑟𝑟) 
function is displayed in FIGURE 5.12. 
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Figure 5.12 | Observed compared to calculated SAXS data. 
This plot compares the scattering vector, 𝑞𝑞, against 𝑞𝑞 ∙ 𝐼𝐼𝑜𝑜𝑎𝑎𝑎𝑎(𝑞𝑞) (orange points) and 𝑞𝑞 ∙ 𝐼𝐼𝑐𝑐𝑎𝑎𝑟𝑟𝑐𝑐(𝑞𝑞) (red 
line) obtained from the fitted 𝑃𝑃(𝑟𝑟) function. The limit of resolution, 𝑞𝑞𝑛𝑛𝑎𝑎𝑥𝑥, is 0.185 Å-1 with a maximum 
dimension set at 229 Å. 
Table 5.3 | CbpFa SAXS data analysis summary. 
This table lists all the metrics obtained from Guinier analysis and the 𝑃𝑃(𝑟𝑟) distribution and 
comparisons between the two where applicable. 1 Real space refers to values derived from the 𝑃𝑃(𝑟𝑟) 
distribution. 2 Reciprocal space refers to values derived from Guinier Analysis. 




Difference (%) RError (+/-) GError (+/-) 
𝐼𝐼(0) 8.59 x 10-2 9.55 x 10-2 10.6 6.11 x 10-4 2.29 x 10-4 
𝑅𝑅𝑚𝑚 (Å) 56.8 56.7 1.3 0.79 1.29 
Volume  1.47 x 105 1.50 x 105 2.0   
Mr (kDa) 88.09 97.96 10.1   
Porod 
Exponent  3.94    
𝑟𝑟 (Å) 66.7     
𝑑𝑑𝑛𝑛𝑎𝑎𝑥𝑥 (Å) 229     
  




Following analysis of SAXS data, dummy atom modelling was then performed to 
approximate the topology of CbpFa. This was achieved by running multiple instances of 
DAMMIF followed by DAMAVER (216, 217) on the output file from the 𝑃𝑃(𝑟𝑟) distribution. The 
envelope resolution calculated by SASRES (218) was 37 ± 3 Å. The resulting envelope is 
shown in FIGURE 5.13 together with a comparison to the structure of the closest homologue 
with a known structure, UspA1. The major axis has a maximum length of 230 Å with a 
maximum diameter of 43 Å on the minor axis. The latter is very similar to that of UspA1 
which has a maximum diameter of 45 Å across its minor axis. 
 
Figure 5.13 | CbpFa SAXS envelope. 
Shown is the envelope produced following dummy atom modelling with DAMMIN and DAMAVER for 
CbpFa (orange). A) The length of the model was calculated to be 230 Å and shown next the envelope 
is UspA1 (blue; PDB ID: 3NTN) (102) for comparison. B) The cross-section of the envelope had a 
maximum diameter of 43 Å which is very comparable to UspA1, which has maximum diameter of 45 
Å. The UspA1 model used has length of 210 amino residues and CbpFa has 317. The resolution for 
the envelope was calculated to 37 ± 3 Å using SASRES (218). 
  
230 Å 43 Å 
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From examining the sequences of CbpFs and performing structural predictions, several 
novel features could be identified. Firstly, it appears that the YadA-like head domains within 
CbpFs represent a highly conserved domain with an easily identifiable sequence motif 
(FIGURE 5.2). This is in contrast to the head domains of other TAAs that share this similar 
fold, where there is far less internal conservation of the sequence. The much higher protein 
sequence conservation found in CbpFs could have nothing to do with protein structure or 
function but rather as a consequence of Fusobacterium having a very low GC % content, 
therefore having a more restricted codon pool. The GC % content for the YadA-like heads 
of CbpFa is 34.7 %, about 8 % higher than the global content of Fn (27 %). When examining 
the codon usage for the head domains of CbpFa, AT skewed codons are used preferentially 
when possible, such as with the case for the central phenylalanine in register position 11 
using the TTT codon exclusively. The reason for the elevated content compared to the 
background primarily comes from the codons encoding the alanine and glycine residues at 
registers 10 and 12 respectively, as both of these amino acids require codons containing at 
least two thirds G or C. This points to these two residues being particularly important in 
maintaining the structure of this domain, otherwise they would have been switched out for 
lower GC-codon residues such as valine or serine. 
Another interesting feature about the YadA-like head domains of CbpFs is their extremely 
high propensity toward having strongly hydrophobic core consisting of only phenylalanine 
in CbpFa with the infrequent appearance of leucine, isoleucine or valine across the whole 
spectrum of CbpFs. This is in opposition to proteins like UspA1, which have a much less 
conserved motif and more variation at the core register position. For CbpFs, this creates a 
characteristic ‘phenylalanine zipper’ motif that likely is responsible for the incredible stability 
of these proteins. 
Solving the structure of the stalk domain of these proteins would prove very insightful, as 
seen in FIGURE 5.1 and FIGURE 5.3, the classical coiled-coil domain cannot be identified from 




sequence analysis alone, therefore if one can be found by solving the structure, that could 
vastly improve prediction software by uncovering a potential novel CC-encoding sequence. 
For the CbpF a and b proteins, at least, there is likely an insert within the CC-containing 
domain where there is a glycine-rich sequence followed by a proline (FIGURE 5.4) that would 
break any alpha-helical domain. This is not the case for CbpFc, however, where this domain 
has been lost. 
In addition, to sequence analysis and structure prediction, experimental methods confirm 
the expected overall predicted topology. Using CD and the latest deconvolution methods 
(214, 215), the helical to beta-sheet proportions are almost exactly what is expected for 
CbpFa (FIGURE 5.9), though CD deconvolution should always be treated sceptically. 
Moreover, SAXS analysis on CbpFa, yields an envelope (FIGURE 5.13) akin to the expected 
dimensions. The final piece in the puzzle remains solving the atomic structure. As, single 
domain expression proved very difficult (CHAPTER 4), other methods could be explored such 
as using GCN4 adaptors to restrict the ends of the expressed domains. This method was 
used to solve the structure of the TAA SadA from S. enterica by solving sequential partial 
domains fused to GCN4 adaptors (108). Alternatively, as CbpFb crystallised and diffracted 
well, experimental phasing could yield a solvable solution where molecular replacement 
could not, such as using iodide phasing as there are too few methionine residues for 
practicable Se-Met replacement. The structure of the TAA BpaA was solved using iodide 
phasing (107). Nevertheless, the structures or at least partial structures of the extracellular 
domains CbpFa and b will hopefully be solved within the next few years, which will expand 
the current domain dictionary for TAAs (98). 
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Chapter 6: Discussion 
Fusobacterium is a genus of bacteria that has become of recent interest in the scientific 
community due to its links to colorectal cancer (33-40). These links have yet to be fully 
established and clarified as there is still no definitive evidence for direct causation and 
remains a topic of discussion (219, 220). However, there are well-established associations 
between Fusobacterium spp. and pregnancy complications as well as many other human 
diseases such as IBD and Lemierre’s disease for example (49). Moreover, footrot caused 
by Fnec is very well-documented and causes a potentially larger problem from an economic 
perspective and therefore is where current vaccine development is focussed (68, 69). 
Nevertheless, the more information that can be unveiled with respect to Fusobacterium spp. 
pathogenesis, would benefit the community. 
Historically, the Fusobacterium genus consisted of two principal species, F. necrophorum 
and F. nucleatum, which were each subdivided into several distinct subspecies. The 
subspecies for Fn were as follows: Fn subsp. nucleatum, animalis, polymorphum and 
vincentii. When examining the genomes of the genus, it was found that the subspecies of 
Fn were in fact more distant than originally thought. Other studies also confirmed this 
discrepancy (22, 23), whereby each of these subspecies should be classified as a unique 
species. The two subspecies of Fnec (necrophorum and funduliforme), however, are 
sufficiently related to be considered the same species. Using this new set of criteria based 
on genomic distance, in this study, two novel species were uncovered when examining 
previously uncharacterised Fusobacterium clinical isolates (CHAPTER 3). These species were 
named F. oralis sp. nov. (For) and F. ovarium sp. nov. (Fov). Interestingly, Fov was the first 
documented species of its kind of, which from a collection of only 25 isolates, begs the 
question of how many more new species of Fusobacterium may exist. Furthermore, five For 
strains were within these isolates, therefore, approximately one fifth of all strains examined 
in this study were unique uncharacterised species. However, an For species genome did 
already exist in the GenBank database (182), but had not been characterised or labelled as 




a specific species until this point. In conjunction with the recent identification of the F. 
hwasookii species (25), this suggests that there may still be yet uncharacterised species to 
be discovered and classified. 
From examining the genome sequences of For, it was shown they are most closely related 
to F. periodonticum and therefore likely share similar biological characteristics. Moreover, 
all the For isolates examined were from an oral origin which correlates to the normal 
isolation site for Fperio strains. However, there are some notable differences between the 
two species, most notably the ability to adhere to human CEACAM1 and CEA via a trimeric 
autotransporter adhesin (CbpF). This could give these strains increased pathogenic 
strategies when compared to Fperio. 
Part of the reason that many Fusobacterium species have been misclassified is because 
the current genus is extremely polarised where the clades of Fn (and historical subspecies) 
and Fnec are far apart with another small cluster of species branching off approximately 
halfway in between the two. When examining genomic similarity within the Fusobacterium 
genus, as a control, other non-genus bacteria, such as Cetobacterium and Psychrilyobacter 
from the Fusobacteriaceae family, were included. When examining species clustering and 
inter-species difference (FIGURE 3.7), it was found that Fnec and F. gonidiaformans clustered 
on the level of other genera such as Ilyobacter, thus should not exist within the same genus 
of F. nucleatum, and associated species. This assertion is echoed by the very recent 
bacterial taxonomic reclassification study that normalised taxonomic boundaries based on 
whole-genome similarity (23). Additionally, the group of species that exist between the two 
major groups, containing F. varium, F. ulcerans and F.  mortiferum, should be split off into 
their own genus as well. The full list of reclassifications and the respective genus group they 
belong to are listed in TABLE S 2. Combined with the new sequencing data obtained in this 
research, a total of 188 classifications were made (this equates to 17766 pairwise 
comparisons per method used). 
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As discussed earlier in CHAPTER 3, there were a number of fringe cases, where certain 
pairwise genome comparisons did not yield a clear solution. For example, two species of F. 
periodonticum were within the boundary to other species of most Fperio strains, however, 
when compared against each other were below the threshold. This is a notable feature of 
this particular species, where there is a large amount of heterogeneity making species 
definitions difficult to draw. The lowest intraspecies Average Nucleotide Identity score was 
94.22 %, almost a percent below the acknowledged minimum species boundary of 95 % 
(180). This represents an interesting anomaly that shows the beginning of evolutionary 
divergence prior to speciation. 
The primary goal of the research conducted in this study was to characterise 
Fusobacterium-CEACAM interactions. These interactions were previously only thought to 
exist within the Fn and Fv species (as identified by unpublished work). Therefore, when 
handling the For 2B3 strain, prior to WGS, it was under the assumption that it was an Fn or 
at least Fn-like species, such as Fv. As this was revealed to be to be an incorrect 
classification, this eluded to the CbpF gene being on a possible mobile genetic element as 
other more closely related species, such as Fpoly, Fh and Fperio, did not harbour an 
analogous gene. This information also provided an improved insight into the evolutionary 
history of the CbpF proteins, as similar proteins also appeared in Fa (though not universally) 
and Fov. The encoding gene was found to exist juxtaposed to the nik-operon in all cases 
where it could be identified. Evidence for this whole region being a mobile element was 
increased when the genes for the nik-operon could not be identified in any strain that did 
not also harbour the cbpF gene indicating they moved together. Moreover, examining the 
surrounding sequence more closely, a transposase gene could be found further 
downstream of the nik-operon suggesting it was once self-mobilising, however, it is unclear 
whether it is still mobile. 
While all known and putative cbpF genes exist within an equivalent genomic surrounding, 
the resulting CbpF protein sequence varies between species. It appears that the majority of 




CbpFs fall into one of two groups: CbpFa (Fn and Fv) and CbpFb (For and some Fa), with 
an isolated case for a third group, CbpFc (Fov). This can be seen in FIGURE 4.6. The main 
differences between the two groups is within the variation in the N-terminal head group 
domain, however, CbpFc also has a deletion in the stalk region that is common to all other 
CbpFs. 
From examining the sequences from all identified CbpF proteins, we were able to identify a 
highly conserved 14-residue β-roll motif that encodes a YadA-like head fold. CbpF proteins 
contain a minimum of six repeats of this domain in the N-terminal head group. This cluster 
of YadA-like head domains underwent expansion at one point in time leading to a 
discontinuity in the number of repeats of the head group within CbpFs, where CbpFb-like 
proteins contain around 12 repeats and CbpFa-like have approximately half as many. 
Interestingly, the final YadA-like head domain (of the initial group) always share the trait of 
having a tyrosine in the first register position (always an asparagine in other cases; FIGURE 
5.2; FIGURE S 6), indicating the expansion went toward the N-terminus. This whole YadA-like 
head-containing region likely serves as the N-terminal trimer-stabilising region mediated 
through a hydrophobic core consisting of primarily of phenylalanine, and to a lesser extent 
leucine and isoleucine, residues in register position 11 (FIGURE 5.2). This region was the 
most promising for molecular replacement as it shares relatively high homology with the 
UspA1 protein, though an accurate model could not be obtained. 
The most insightful region, if ever solved will be the stalk region, as this perplexes all 
sequence-analysis and protein modelling software. This region is usually occupied by a 
trimeric coiled-coil in TAAs, however for the majority of this region, barring the extreme C-
terminus directly before the membrane anchor, is obstinately predicted to not contain any 
CC propensity (using MARCOIL and PCOILS; FIGURE 5.3). This region, or at least part of 
this region, is thought to be responsible for mediating CEACAM1 and CEA adhesion using 
an analogous mechanism to UspA1 (135). The structure of this region on CbpF proteins 
should enhance the overall understanding of protein folding and improve prediction 
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software, as through exhaustive trialling and educated modelling, no definitive complete 
structure could be solved using molecular replacement on an otherwise promising X-ray 
diffraction dataset. Short of solving the structure, this study was able to build several 
promising partial models of the head domain (FIGURE 5.8) that could be used later to aid 
solving the whole structure. Heavy atom phasing will most likely be required to determine 
the structure of the stalk domain. If a successful structure can be solved for this region, 
following studies would then likely be able to model the CbpF-CEACAM interactions through 
computational docking and MD, or even experimentally through X-ray crystallography or 
SAXS as done for HopQ (138) and UspA1 (135) respectively.  
As, identified in CHAPTER 4, the interactions between CbpFs and CEACAMs is highly specific 
with evidence only shown for CEACAM1 and CEA interactions. Additionally, single point 
mutations made within the probable binding surface on the IgV-like domain of CEACAM1 
(CFG face) almost always exhibited diminished adhesion (FIGURE 4.16). As well as not 
showing any specific interactions with other CEACAMs, this shows that the CbpF proteins 
are highly evolved and therefore probably use a conserved domain facilitate adhesion. By 
examining confirmed and putative CbpF proteins as well as other TAAs that do not bind 
CEACAMs, the possible locations for this domain can be greatly reduced to a small region 
in the stalk domain, though this would need to be confirmed experimentally. As expressing 
the domain by itself did not yield fruitful results, perhaps using a similar method that 
constrained regions of the SadA protein using GNC4 adapters (108, 110) may prove to be 
a more promising route to answering this question. Further studies will also need to 
characterise any differences in the CEACAM binding profile of CbpFc as currently, no 
recombinant protein has been produced, so it is unknown whether it can bind other 
CEACAMs as well as CEACAM1. Additionally, other variants of CbpFa- and CbpFb-like 
proteins should be examined, such as the CbpFb-like proteins found in a small subset of 
Fa strains. 




As well as further studying CbpF-CEACAM interactions, other potential ligands should be 
considered, such as extracellular matrix components, for example fibronectin or vitronectin. 
It is known that other TAAs can bind these components, for example both UspA1 and BadA 
have been shown to bind fibronectin (113, 115). 
The identification of the CbpF proteins also sheds light on the difference between certain 
species and why they may have tendencies to cause different diseases. Many studies have 
shown pathology delineation between the historical Fn subspecies (now distinct species) 
and highlighted the importance for identifying the specific subspecies (18, 56, 221, 222). 
For example, Fa is the predominant species isolated from intrauterine infections (56). 
Though other complications arise from the previous incorrect classification of some strains 
within these species, for example, one labelled Fpoly strain in the database, turned out to 
be an Fa species, thus previous studies not including whole-genome sequencing data 
should be treated with caution. Nonetheless, the apparent divide between the previous Fn 
subspecies could be due to the ability to adhere to CEACAM1 or CEA as these receptors 
are not universally expressed throughout the body. Elevated expression of both these 
proteins is seen in the colon for example (119).  
Currently, no CbpF-like protein has been identified in any Fpoly species or in the majority 
of Fa, however, some strains in this study, as well as at least two other strains in the 
database, harbour a CbpFb-like gene. This could indicate a reason why some species are 
more strongly associated with certain pathologies. To confirm the absolute importance of 
this protein, a study will need to be undertaken to detect the presence of this gene, as well 
as other species-defining genes, in diseased patients, to examine correlation between 
disease type, severity and outcome, for example, with the presence of CbpF. This would be 
particularly insightful for Fusobacterium-associated IBD, as CEACAM1 is known to play a 
role in this disease (223). This would give a clearer indication of the purpose for this protein 
in disease pathogenesis, as unfortunately, current patient data associated with the strains 
with whole genomes is sparse, in addition to the small total number of species sequenced. 
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As previously mentioned, the CbpF proteins only represent one of at least three groups of 
TAAs possessed by Fusobacterium, with two others briefly examined in this study. From 
data presented in FIGURE 4.11, it can be seen that one of these other TAAs (FN0471) 
indiscriminately binds to HeLa cells and very strongly too. The other TAAs tested, also 
bound above background levels, indicating that these proteins may facilitate interactions 
with other receptors present on human cells. More work will be needed to determine the 
human receptors responsible, but nevertheless, it provides more questions regarding 
mechanisms of pathogenesis and which interactions are important in mediating disease. 
To study all of these proteins further, Fusobacterium knockout mutants will need to be 
created to confirm receptor-binding specificity and possible redundancy. Currently, there is 
no straightforward way to create Fusobacterium knockouts, though some techniques have 
been described previously using sonoporation and a Fusobacterium-specific shuttle 
plasmid vector (6, 224). The greatly reduced transformation efficiencies associated with 
Fusobacterium spp. is likely due to the presence of a restriction modification system (224). 
These methods should be explored in the future in an effort to knock the adhesin genes out, 
with re-complementation with the shuttle vector. In addition to further examining CbpFs, the 
next TAA candidate adhesin to be studied should be the FN0735 gene product, because 
homologues to this protein can be found almost universally within Fn, Fv, Fa, Fpoly, Fperio, 
Fh, For and Fov, with partial hits in other Fusobacterium species. Conversely, the FN0471 
gene is found much less commonly. As of yet, almost no information is known regarding 
these two other TAAs found in Fusobacterium other than they show an ability to bind HeLa 
cells. The universal prevalence of TAAs among the entire genus suggests an intrinsic 
importance of these proteins for survival and environment adaptation, such as host 
restriction or expansion, such as the case for Fnec species that cause disease in both 
animals and humans. 
As mentioned previously, TAAs have been used successfully as vaccine antigens to elicit 
immune protection, such as the case for NadA for serogroup B N. meningitidis (147, 225). 




By adopting a similar rational, proteins such as CbpF and other TAAs within Fusobacterium 
spp. could be viable options in the development of novel vaccines. Their ubiquitous spread 
and low intraspecies variation would allow specific vaccines that could benefit both humans 
as well as livestock. As this work focussed primarily on F. nucleatum and similar species, 
further work should be conducted on the other clinically important species of F. 
necrophorum. This study identified TAAs in all Fnec strains as part of searching for CbpF 
homologues; though no direct CbpF homologues were identified, other TAAs were, which 
showed little variation thus presenting a potential antigenic target. Future work should 
characterise the properties of these other TAAs and determine whether any epitopes of 
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Appendix A: Buffer Compositions 
Table S 1 | Buffer compositions used throughout project. 
Any deviations or additions to these buffers are mentioned within the main text. Unless otherwise 
stated: pH was adjusted using HCl or NaOH; buffer concentrations are given at final working 
concentrations; reagents are from Merck Sigma-Aldrich. 1 Thermo Fisher Scientific. 2 For use on the 
Diamond Light Source B21 SAXS HPLC. 3 Severn Biotech Ltd. 4 Stock solutions of all components 
were made prior to formulation using a variety of solvents such as methanol, ethanol, DMSO and 
water. 
Buffer Name Composition pH 
Native Buffer A 50 mM Trizma®-HCl, 200 mM NaCl1, 20 mM imidazole 7.8 
Native Buffer B 50 mM Trizma®-HCl, 200 mM NaCl, 500 mM imidazole 7.8 
SEC Buffer A 50 mM Trizma®-HCl, 100 mM NaCl 7.5 
SEC Buffer B2 100 mM Trizma®-HCl, 100 mM NaCl 7.2 
Denaturing Buffer A 50 mM Trizma®-HCl, 200 mM NaCl, 20 mM imidazole, 8 M urea1 7.8 
Denaturing Buffer B 50 mM Trizma®-HCl, 200 mM NaCl, 500 mM imidazole, 8 M urea 7.8 
PAGE-Sample 
Buffer (4 X) 
200 mM Trizma®-HCl, 40 % (v/v) glycerol1, 8 % (w/v) 




Running Buffer 25 mM Trizma®-Base, 200 mM glycine
3, 0.1 % (w/v) SDS 8.5 
Transfer Buffer 25 mM Trizma®-Base, 200 mM glycine, 0.1 % (w/v) SDS, 20 % (v/v) methanol 8.5 
AP Buffer 1 M Trizma®-HCl, 5 M NaCl, 1 M MgCl2, 0.05% (v/v) TWEEN®-20 9.5 
PBS 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4 
7.4 
Carbonate Buffer 50 mM Na2CO3, 50 mM NaHCO3 9.6 
ELISA Wash Buffer 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, 0.05 % (v/v) TWEEN®-20 
7.4 
Protein A Loading 
Buffer 20 mM NaH2PO4, 250 mM NaCl 8.0 




Protein A Elution 




1 M Trizma®-HCl, 1 M NaCl 7.5 
Protease Inhibitor 
Cocktail (100 X)4 
100 mM PMSF, 100 μM E-64, 100 μM Pepstatin A, 6 μM 
Bestatin, 10 mM EDTA NA 
TBE 90 mM Trizma®-Base, 90 mM boric acid, 2 mM EDTA 8.0 
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Appendix B: CEACAM Numbering Conventions 
Previous studies have labelled residues by mature protein sequence only so, for historical 
reasons, some proteins are not numbered from the start methionine, but are instead 
enumerated from downstream sequence. As such, confusion can arise with the non-
standard numbering. The CEACAM1 proteins containing the N-terminal IgV-domain has its 
initial residue 34 amino acids from the start methionine. 
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Figure S 1 | pOPINE plasmid map. 
 
Appendix C: Plasmid Maps  




Figure S 2 | pOAF plasmid map. 





Figure S 3 | pMAL-c5X plasmid map.  
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Figure S 4 | pINFUSE-IgG1-Fc2 plasmid map. 
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All CbpFs Alignment: 
                     1         11        21        31        41         
CbpFa 
>GCA_000007325.1     MKKFVSLKLIVFSFILVAGSVSYSAAPVIKAG-TATDSTEAGVDNVANGV   49 
>GCA_000163915.2     MKKFVSLKLIVFSFILVAGSVSFS-ADAEFKKENGTDSIIAGISNEASGN   49 
>R18528              MKKFVSLKLIVFSFILVAGSVSYSAAPVIKAG-TATDSTEAGVDNVANGV   49 
>R28211              MKKFVSLKLIVFSFILVVGSVSFS-ADAEFKKENGTDSIIAGISNEASGN   49 
>R32935              MKKFVSLKLIVFSFILVAGSVSYSAAPVIKAG-TATDSTEAGVDNVANGV   49 
>GCA_000455945.1     MKKFVSLKLIVFSFILVAGSVSFS-VPVFQAG-TGTDSTVAGVNNEANGE   48 
>GCA_000178895.1     MKKFVSLKLIVFSFILVAGSVSFS-APVFQAG-TGTDSTVAGVNNEANGE   48 
>GCA_001510735.1     MKKFVSLKLIVFSFILVAGSVSFS-APVFQAG-TGTDSTVAGVNNEANGE   48 
>GCA_001296165.1     MKKFVSLKLIVFSFILVAGSVSFS-VPVFQAG-TGTDSTVAGVNNEANGE   48 
>GCA_001296185.1     MKKFVSLKLIVFSFILVAGSVSFS-APVFQAG-TGTDSTVAGVNNEANGE   48 
>GCA_002211605.1     MKKFVSLKLIVFSFILVAGSVSFS-VPVFQAG-TGTDSTVAGVNNEANGE   48 
>R24394              MKKFVSLKLIVFSFILVAGSVSFS-APVFQAG-TGTDSTVAGVNNEANGE   48 
>GCA_000158255.2     MKKFVSLKLIVFSFILVASSVSFS-VPAIQGG-TGSDSTVAGIGNDAS--   46 
>GCA_000162235.2     MKKFVSLKLIVFSFILVAGSVSFS-APGIHAG-TVTDSIIAGIDNIAS--   46 
>GCA_000182945.1     MKKFVSLKLIVFSFILVASSVSFS-VPVIQGG-TGSDSTVAGIGNDAS--   46 
>GCA_000347315.1     MKKFVSLKLIVFSFILVAGSVSFS-APGIHAG-TVTDSIIAGIDNIAS--   46 
>GCA_000479205.1     MKKFVSLKLIVFSFILVTGSVSFS-VPAIQGG-TGTDSIIAGIDNIAS--   46 
>GCA_000517705.1     MKKFVSLKLIVFSFILVTGSVSFS-VPAIQGG-TGTDSIIAGIDNIAS--   46 
>GCA_001296125.1     MKKFVSLKLIVFSFILVTGSVSFS-VPAIQGG-TGTDSIIAGIDNIAS--   46 
>GCA_001810995.1     MKKFVSLKLIVFSFILVASSVSFS-VPAIQGG-TGSDSTVAGIGNDAS--   46 
>GCA_001854465.1     MKKFVSLKLIVFSFILVTGSVSFS-VPAIQGG-TGTDSIIAGIDNIAS--   46 
>GCA_002749995.1     MKKFVSLKLIVFSFILVTGSVSFS-VPAIQGG-TGTDSIIAGIDNIAS--   46 
>GCA_002764055.1     MKKFVSLKLIVFSFILVASSVSFS-VPAIQGG-TGSDSTVAGIGNDAS--   46 
>GCA_000455965.1     MKKFVSLKLIVFSFILVTGSVSFS-VPAIQGG-TGTDSIIAGIDNIAS--   46 
>R26872              MKKFVSLKLIVFSFILVAGSVSFS-APGIHAG-TGTDSIIAGIDNIAS--   46 
>R28385              MKKFVSLKLIVFSFILVASSVSFS-VPAIQGG-TGSDSTIAGVDNIAS--   46 
>R28400              MKKFVSLKLIVFSFILVASSVSFS-VPAIQGG-TGSDSTIAGIENDAS--   46 
>2B17                MKKFVSLKLIVFSFILVASSVSFS-VPAIQGG-TGSDSTVAGIGNDAS--   46 
>R29976              MKKFVSLKLIVFSFILVTGSVSFS-VPAIQGG-TGSDSTVAGIGNDAS--   46 
>R30464              MKKFVSLKLIVFSFILVTGSVSFS-VPAIQGG-TGTDSIIAGIDNIAS--   46 
>R30604              MKKFVSLKLIVFSFILVAGSVSFS-APGIHAG-TVTDSIIAGIDNIAS--   46 
>R31249              MKKFVSLKLIVFSFILVASSVSFS-VPAIQGG-TGSDSTVAGIGNDAS--   46 
>R32310              MKKFVSLKLIVFSFILVASSVSFS-VPAIQGG-TGSDSTVAGIGNDAS--   46 
>R33458              MKKFVSLKLIVFSFILVASSVSFS-VPAIQGG-TGSDSTVAGIGNDAS--   46 
>R33533              MKKFVSLKLIVFSFILVTGSVSFS-APGIQGG-TGSDSTVAGIGNDAS--   46 
>GCA_002243405.1     MKKFVSLKLIVFSFILVVGSVSFS-APVFQGG-TGTDSTVAGVDNIAS--   46 
CbpFb 
>2B16                MKKFVSLKLIVFSLLLVTGGLSYSA-PAIGSG-TGANSIVAGETNEAT--   46 
>2B2                 MKKFVSLKLIVFSLLLVTGGLSYSA-PAIGSG-TGANSIVAGLNNTAD--   46 
>2B3                 MKKFVSLKLIVFSLLLVTGGLSYSA-PAFGTG-TGANSIVAGEANEAT--   46 
>2B4                 MKKFVSLKLIVFSLLLVTGGLSYSA-PAIGSG-TGANSIVAGLNNTAD--   46 
>R5001               MKKFVSLKLIVFSFILVAGSVSYSATPEIKQG-DIADSIVAGVNNKAS--   47 
>GCA_001546435.1     MKKFISLKLIVFSFILVTSAVSYSN-PKIEEG-TVADSIKAGLKNAAD--   46 
>R15792              MKKFISLKLIVFSFILVTSAVSYSN-PKIEAG-TGANSIKAGLDNEAD--   46 
CbpFc 
>R16531_1            MKKIVSLKLIIFSLLLVTVGISYS-APAINPG-TGTNSIIAGEDNKAT--   46 
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                     51        61        71        81        91         
CbpFa 
>GCA_000007325.1     KSSAFGYDNKAIEKES------------------------SAFGTG----   71 
>GCA_000163915.2     ESSAFGYKNKATEEKS------------------------SAFGHS----   71 
>R18528              KSSAFGYDNKAIEKES------------------------SAFGTG----   71 
>R28211              ESSAFGYKNKATEEKS------------------------SAFGHS----   71 
>R32935              KSSAFGYDNKAIEKES------------------------SAFGTG----   71 
>GCA_000455945.1     KSSAFGYENKAKEKLSSAFGYKNIANGIEG----------SAFGIS----   84 
>GCA_000178895.1     KSSAFGYENKAKEKLSSAFGYKNIANGIEG----------SAFGIS----   84 
>GCA_001510735.1     KSSAFGYENKAKEKLSSAFGYKNIANGIEG----------SAFGIS----   84 
>GCA_001296165.1     KSSAFGYENKAKEKLSSAFGYKNIANGIEG----------SAFGIS----   84 
>GCA_001296185.1     KSSAFGYENKAKEKLSSAFGYKNIANGIEG----------SAFGIS----   84 
>GCA_002211605.1     KSSAFGYENKAKEKLSSAFGYKNIANGIEG----------SAFGIS----   84 
>R24394              KSSAFGYENKAKEKLSSAFGYKNIANGIEG----------SAFGIS----   84 
>GCA_000158255.2     ------------GENS------------------------SAFGFH----   56 
>GCA_000162235.2     ------------EEKS------------------------SAFGFK----   56 
>GCA_000182945.1     ------------GENS------------------------SAFGFH----   56 
>GCA_000347315.1     ------------EEKS------------------------SAFGFK----   56 
>GCA_000479205.1     ------------EEKS------------------------SAFGFK----   56 
>GCA_000517705.1     ------------EEKS------------------------SAFGFK----   56 
>GCA_001296125.1     ------------EEKS------------------------SAFGFK----   56 
>GCA_001810995.1     ------------GENS------------------------SAFGFH----   56 
>GCA_001854465.1     ------------EEKS------------------------SAFGFK----   56 
>GCA_002749995.1     ------------EEKS------------------------SAFGFK----   56 
>GCA_002764055.1     ------------GENS------------------------SAFGFH----   56 
>GCA_000455965.1     ------------EEKS------------------------SAFGFK----   56 
>R26872              ------------EEKS------------------------SAFGFK----   56 
>R28385              ------------EEKS------------------------SAFGFK----   56 
>R28400              ------------GENS------------------------SAFGFH----   56 
>2B17                ------------GENS------------------------SAFGFH----   56 
>R29976              ------------GENS------------------------SAFGFH----   56 
>R30464              ------------EEKS------------------------SAFGFK----   56 
>R30604              ------------EEKS------------------------SAFGFK----   56 
>R31249              ------------GENS------------------------SAFGFH----   56 
>R32310              ------------GENS------------------------SAFGFH----   56 
>R33458              ------------GENS------------------------SAFGFH----   56 
>R33533              ------------GENS------------------------SAFGFH----   56 
>GCA_002243405.1     ------------EEKS------------------------SAFGTG----   56 
CbpFb 
>2B16                ------------QEKSSAIG----------YGNKAKGKFSSAIGYDNIAS   74 
>2B2                 ------------KEKSSAFG----------YGNKANGKYSSSFGYDNTAS   74 
>2B3                 ------------QEKSSAIG----------YGNKANGKFSSAFGNDNKAS   74 
>2B4                 ------------KEKSSAFG----------YGNKANGKYSSSFGYDNTAS   74 
>R5001               ------------ELASSAFG----------HSNTAEGARSSAFGYNNKAK   75 
>GCA_001546435.1     ------------KEQSLAFG----------YFNRALGKKSSAFGNA----   70 
>R15792              ------------GEESSAFG----------FHNITDKSGSSAFGNG----   70 
CbpFc 
>R16531_1            ------------KDKS------------------------SAFGHS----   56 
 
  




                     101       111       121       131       141        
CbpFa 
>GCA_000007325.1     --------------------------------------------------   71 
>GCA_000163915.2     --------------------------------------------------   71 
>R18528              --------------------------------------------------   71 
>R28211              --------------------------------------------------   71 
>R32935              --------------------------------------------------   71 
>GCA_000455945.1     --------------------------------------------------   84 
>GCA_000178895.1     --------------------------------------------------   84 
>GCA_001510735.1     --------------------------------------------------   84 
>GCA_001296165.1     --------------------------------------------------   84 
>GCA_001296185.1     --------------------------------------------------   84 
>GCA_002211605.1     --------------------------------------------------   84 
>R24394              --------------------------------------------------   84 
>GCA_000158255.2     --------------------------------------------------   56 
>GCA_000162235.2     --------------------------------------------------   56 
>GCA_000182945.1     --------------------------------------------------   56 
>GCA_000347315.1     --------------------------------------------------   56 
>GCA_000479205.1     --------------------------------------------------   56 
>GCA_000517705.1     --------------------------------------------------   56 
>GCA_001296125.1     --------------------------------------------------   56 
>GCA_001810995.1     --------------------------------------------------   56 
>GCA_001854465.1     --------------------------------------------------   56 
>GCA_002749995.1     --------------------------------------------------   56 
>GCA_002764055.1     --------------------------------------------------   56 
>GCA_000455965.1     --------------------------------------------------   56 
>R26872              --------------------------------------------------   56 
>R28385              --------------------------------------------------   56 
>R28400              --------------------------------------------------   56 
>2B17                --------------------------------------------------   56 
>R29976              --------------------------------------------------   56 
>R30464              --------------------------------------------------   56 
>R30604              --------------------------------------------------   56 
>R31249              --------------------------------------------------   56 
>R32310              --------------------------------------------------   56 
>R33458              --------------------------------------------------   56 
>R33533              --------------------------------------------------   56 
>GCA_002243405.1     --------------------------------------------------   56 
CbpFb 
>2B16                GLDSSAFGRSNIADKEGSSAIGYYNTASGKNSSSFGYKNTASGENSSAFG   124 
>2B2                 GLDSSAFGRSNIADKEASSAIGYYNTASGKNSSSFGYKNTASGENSSAFG   124 
>2B3                 GENSSAFGRSNIASNGTSSAFGYYNTASGLRSSAFGHNNTASGENSSAFG   124 
>2B4                 GLDSSAFGRSNIADKEASSAIGYYNTASGKNSSSFGYKNTASGENSSAFG   124 
>R5001               GKDSLGFGHS--------------NTAEGEKSLGFGHSNTAKGAESLAIG   111 
>GCA_001546435.1     --------------------------------------------------   70 
>R15792              --------------------------------------------------   70 
CbpFc 
>R16531_1            --------------------------------------------------   56 
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                     151       161       171       181       191        
CbpFa 
>GCA_000007325.1     ----------------NRATGEFSSAFGFHNIASKIHSSAFGSNNAADGV   105 
>GCA_000163915.2     ----------------NEASGKFSSAFGYMNEANGKYSSAFGTKNIASEE   105 
>R18528              ----------------NRATGEFSSAFGFHNIASKIHSSAFGSNNAADGV   105 
>R28211              ----------------NEASGKFSSAFGYKNIASSLRSSAFGVGNKASGN   105 
>R32935              ----------------NRATGEFSSAFGFHNIASKIHSSAFGSNNAADGV   105 
>GCA_000455945.1     ----------------NLAKGQYSSAFGFRNVANKRHSSAFGSGNEANGE   118 
>GCA_000178895.1     ----------------NLAKGQYSSAFGFRNVANKRHSSAFGSGNEANGE   118 
>GCA_001510735.1     ----------------NLAKGQYSSAFGFRNVANKRHSSAFGSGNEANGE   118 
>GCA_001296165.1     ----------------NLAKGQYSSAFGFRNVANKRHSSAFGSGNEANGE   118 
>GCA_001296185.1     ----------------NLAKGQYSSAFGFRNVANKRHSSAFGSGNEANGE   118 
>GCA_002211605.1     ----------------NLAKGQYSSAFGFRNVANKRHSSAFGSGNEANGE   118 
>R24394              ----------------NLAKGQYSSAFGFRNVANKRHSSAFGSGNEANGE   118 
>GCA_000158255.2     ----------------NTASGKFSSAFGFRNIASKLRSSAFGTGNKADGE   90 
>GCA_000162235.2     ----------------NKASGKFSSAFGYMNEANGKYSSAFGTKNIASEE   90 
>GCA_000182945.1     ----------------NTASGKFSSAFGFRNIASKLRSSAFGTGNKADGE   90 
>GCA_000347315.1     ----------------NKASGKFSSAFGYMNEANGKYSSAFGTKNIASEE   90 
>GCA_000479205.1     ----------------NKASGKFSSAFGYMNEANGQYSSAFGAGNKASGE   90 
>GCA_000517705.1     ----------------NKASGKFSSAFGYMNEANGQYSSAFGAGNKASGE   90 
>GCA_001296125.1     ----------------NKASGKFSSAFGFRNIASKLRSSAFGTGNKADGE   90 
>GCA_001810995.1     ----------------NTASGKFSSAFGFRNIASKLRSSAFGTGNKADGE   90 
>GCA_001854465.1     ----------------NKASGKFSSAFGYMNEANGQYSSAFGAGNKASGE   90 
>GCA_002749995.1     ----------------NKASGKFSSAFGFRNIASKLRSSAFGTGNKADGE   90 
>GCA_002764055.1     ----------------NTASGKFSSAFGFRNIASKLRSSAFGTGNKADGE   90 
>GCA_000455965.1     ----------------NKASGKFSSAFGFRNIASKLRSSAFGTGNKADGE   90 
>R26872              ----------------NKASGKFSSAFGYMNEANGKYSSAFGTKNIASEE   90 
>R28385              ----------------NKASGKFSSAFGYMNEANGKYSSAFGTKNIASEE   90 
>R28400              ----------------NKASGKFSSAFGFRNIASKLRSSAFGTGNKADGE   90 
>2B17                ----------------NTASGKFSSAFGFRNIASKLRSSAFGTGNKADGE   90 
>R29976              ----------------NTASGKFSSAFGFRNIASKLRSSAFGTGNKADGE   90 
>R30464              ----------------NKASGKFSSAFGYMNEANGQYSSAFGAGNKASGE   90 
>R30604              ----------------NKASGKFSSAFGYMNEANGKYSSAFGTKNIASEE   90 
>R31249              ----------------NTASGKFSSAFGFRNIASKLRSSAFGTGNKADGE   90 
>R32310              ----------------NTASGKFSSAFGFRNIASKLRSSAFGTGNKADGE   90 
>R33458              ----------------NTASGKFSSAFGFRNIASKLRSSAFGTGNKADGE   90 
>R33533              ----------------NTASGKFSSAFGFRNIASKLRSSAFGTGNKADGE   90 
>GCA_002243405.1     ----------------NNASGKFSSAFGYKNIASRLRSSAFGTGNKAIGE   90 
CbpFb 
>2B16                YFNTASEENTSAIGFKNEASGKQSSAFGYLNKASALRSSAFGINNTADGE   174 
>2B2                 YFNTASEENTSAIGFKNEASGKQSSAIGYLNTASALRSSAFGINNTADGE   174 
>2B3                 YFNTASEENTSAIGFKNEASGKQSSAIGYLNTASALRSSAFGINNTASGE   174 
>2B4                 YFNTASEENTSAIGFKNEASGKQSSAIGYLNTASALRSSAFGINNTADGE   174 
>R5001               HSNLAFKEKASAIGYKNEASGEVSSAIGYVNKATGARSSAFGINNTADGE   161 
>GCA_001546435.1     ----------------NIAVGENSSAFGYHNIANNNQSSAFGFGNKSIGE   104 
>R15792              ----------------NVAIGENSSAFGFHNIASKIHSSAFGSSNEVDGD   104 
CbpFc 
>R16531_1            ----------------NEANGNVSSAFGYKNKANGERSSAFGTANTADGE   90 
 
  




                     201       211       221       231       241        
CbpFa 
>GCA_000007325.1     NSSAFGFKNTVS------------GFNSSAFGSQYQVTGNFSGAFGMGEF   143 
>GCA_000163915.2     QSSAFGFLNKAS------------GGKSSVFGSQYEVTGNSSGAFGVGEY   143 
>R18528              NSSAFGFKNTVS------------GFNSSAFGSQYQVTGNFSGAFGMGEF   143 
>R28211              ESSAFGFLNKAS------------GGKSSVFGSQYEVTGNSSGAFGVGEY   143 
>R32935              NSSAFGFKNTVS------------GFNSSAFGSQYQVTGNFSGAFGMGEF   143 
>GCA_000455945.1     QSSAFGFKNTVS------------GFNSSAFGSQYQVTGNFSGAFGMGEF   156 
>GCA_000178895.1     QSSAFGFKNTVS------------GFNSSAFGSQYEVTGNFSGAFGMGEF   156 
>GCA_001510735.1     QSSAFGFKNTVS------------GFNSSAFGSQYEVTGNFSGAFGMGEF   156 
>GCA_001296165.1     QSSAFGFKNTVS------------GFNSSAFGSQYQVTGNFSGAFGMGEF   156 
>GCA_001296185.1     QSSAFGFKNTVS------------GFNSSAFGSQYEVTGNFSGAFGMGEF   156 
>GCA_002211605.1     QSSAFGFKNTVS------------GFNSSAFGSQYQVTGNFSGAFGMGEF   156 
>R24394              QSSAFGFKNTVS------------GFNSSAFGSQYEVTGNFSGAFGMGEF   156 
>GCA_000158255.2     DSSAFGSLNIAS------------GKFSSAFGSQYEVTGNSSGAFGVGEF   128 
>GCA_000162235.2     QSSAFGFLNKAS------------GGKSSVFGSQYEVTGNSSGAFGVGEY   128 
>GCA_000182945.1     DSSAFGSLNIAS------------GKFSSAFGSQYEVTGNSSGAFGVGEF   128 
>GCA_000347315.1     QSSAFGFLNKAS------------GGKSSVFGSQYEVTGNSSGAFGVGEY   128 
>GCA_000479205.1     QSSAFGFLNKAS------------GRKSSVFGSQYEVTGNSSGAFGVGEF   128 
>GCA_000517705.1     QSSAFGFLNKAS------------GRKSSVFGSQYEVTGNSSGAFGVGEF   128 
>GCA_001296125.1     DSSAFGSLNIAS------------GKFSSAFGSQYEVTGNSSGAFGVGEF   128 
>GCA_001810995.1     DSSAFGSLNIAS------------GKFSSAFGSQYEVTGNSSGAFGVGEF   128 
>GCA_001854465.1     QSSAFGFLNKAS------------GRKSSVFGSQYEVTGNSSGAFGVGEF   128 
>GCA_002749995.1     DSSAFGSLNIAS------------GKFSSAFGSQYEVTGNSSGAFGVGEF   128 
>GCA_002764055.1     DSSAFGSLNIAS------------GKFSSAFGSQYEVTGNSSGAFGVGEF   128 
>GCA_000455965.1     DSSAFGSLNIAS------------GKFSSAFGSQYEVTGNSSGAFGVGEF   128 
>R26872              QSSAFGFLNKAS------------GGKSSVFGSQYEVTGNSSGAFGVGEY   128 
>R28385              QSSAFGFLNKAS------------GGKSSVFGSQYEVTGNSSGAFGVGEY   128 
>R28400              DSSAFGSLNIAS------------GKFSSAFGSQYEVTGNSSGAFGVGEY   128 
>2B17                DSSAFGSLNIAS------------GKFSSAFGSQYEVTGNSSGAFGVGEF   128 
>R29976              DSSAFGSLNIAS------------GKFSSAFGSQYEVTGNSSGAFGVGEF   128 
>R30464              QSSAFGFLNKAS------------GRKSSVFGSQYEVTGNSSGAFGVGEF   128 
>R30604              QSSAFGFLNKAS------------GGKSSVFGSQYEVTGNSSGAFGVGEY   128 
>R31249              DSSAFGSLNIAS------------GKFSSAFGSQYEVTGNSSGAFGVGEF   128 
>R32310              DSSAFGSLNIAS------------GKFSSAFGSQYEVTGNSSGAFGVGEF   128 
>R33458              DSSAFGSLNIAS------------GKFSSAFGSQYEVTGNSSGAFGVGEF   128 
>R33533              DSSAFGSLNIAS------------GKFSSAFGSQYEVTGNSSGAFGVGEF   128 
>GCA_002243405.1     DSSAFGSLNIAS------------GKFSSAFGSQYEVTGNSSGAFGVGEF   128 
CbpFb 
>2B16                NSSAFGFKNIVS------------GFNSSAFGSQYEVTGNFSGAFGMGEF   212 
>2B2                 NSSAFGFKNKIS------------GKWSSAFGNQYEVTGEKSGTFGVGEY   212 
>2B3                 GSSAFGYINKVS------------GANSSVLGNQYEVTGNSSGAFGVGFW   212 
>2B4                 NSSAFGFKNKIS------------GKWSSAFGNQYEVTGEKSGTFGVGEY   212 
>R5001               NSSAFGFKNKIS------------GKWSSAFGNQYEVTGEKSGTFGVGEY   199 
>GCA_001546435.1     QSSAFGSLNVVGKLKSDGNPDENYGKKSLAFGSEYEVTGNSSGAFGVGHW   154 
>R15792              FSSAFGVKNKIS------------GKWSSAFGNQYEVTGEKSGTFGVGEY   142 
CbpFc 
>R16531_1            NSSAFGILNKTS------------GKNSSVFGSQYEVTGDSSGALGKGEY   128 
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                     251       261       271       281       291        
CbpFa 
>GCA_000007325.1     NG-QYQYKNEGNNSYMIGNKNKIASGSDDNFILGNNVHIGGGINNSVALG   192 
>GCA_000163915.2     NG-SYQYKNEGNNSYMIGNKNKIASGSDDNFILGNNVHIGGGINNSVALG   192 
>R18528              NG-QYQYKNEGNNSYMIGNKNKIASGSDDNFILGNNVHIGGGINNSVALG   192 
>R28211              NG-SYQYKNEGNNSYMIGNKNKIASGSDDNFILGNNVHIGGGINNSVALG   192 
>R32935              NG-QYQYKNEGNNSYMIGNKNKIASGSDDNFILGNNVHIGGGINNSVALG   192 
>GCA_000455945.1     NG-QYQYKNEGNNSYMIGNKNKIASGSDDNFILGNNVHIGGGINNSVALG   205 
>GCA_000178895.1     NG-QYQYKNEGNNSYMIGNKNKIASGSNDNFILGNNVHIGGGINNSVALG   205 
>GCA_001510735.1     NG-QYQYKNEGNNSYMIGNKNKIASGSNDNFILGNNVHIGGGINNSVALG   205 
>GCA_001296165.1     NG-QYQYKNEGNNSYMIGNKNKIASGSDDNFILGNNVHIGGGINNSVALG   205 
>GCA_001296185.1     NG-QYQYKNEGNNSYMIGNKNKIASGSNDNFILGNNVHIGGGINNSVALG   205 
>GCA_002211605.1     NG-QYQYKNEGNNSYMIGNKNKIASGSDDNFILGNNVHIGGGINNSVALG   205 
>R24394              NG-QYQYKNEGNNSYMIGNKNKIASGSNDNFILGNNVHIGGGINNSVALG   205 
>GCA_000158255.2     NG-SYQYKNEGNNSYMIGNKNKIASGSNDNFILGNNVHIGGGINNSVALG   177 
>GCA_000162235.2     NG-SYQYKNEGNNSYMIGNKNKIASGSDDNFILGNNVHIGGGINNSVALG   177 
>GCA_000182945.1     NG-SYQYKNEGNNSYMIGNKNKIASGSNDNFILGNNVHIGGGINNSVALG   177 
>GCA_000347315.1     NG-SYQYKNEGNNSYMIGNKNKIASGSDDNFILGNNVHIGGGINNSVALG   177 
>GCA_000479205.1     NG-QHLYKNEGNNSYMIGNKNKIASGSDDNFILGNNVHIGGGINNSVALG   177 
>GCA_000517705.1     NG-QHLYKNEGNNSYMIGNKNKIASGSDDNFILGNNVHIGGGINNSVALG   177 
>GCA_001296125.1     NG-SYQYKNEGNNSYMIGNKNKIASGSNDNFILGNNVHIGGGINNSVALG   177 
>GCA_001810995.1     NG-SYQYKNEGNNSYMIGNKNKIASGSNDNFILGNNVHIGGGINNSVALG   177 
>GCA_001854465.1     NG-QHLYKNEGNNSYMIGNKNKIASGSDDNFILGNNVHIGGGINNSVALG   177 
>GCA_002749995.1     NG-SYQYKNEGNNSYMIGNKNKIASGSNDNFILGNNVHIGGGINNSVALG   177 
>GCA_002764055.1     NG-SYQYKNEGNNSYMIGNKNKIASGSNDNFILGNNVHIGGGINNSVALG   177 
>GCA_000455965.1     NG-SYQYKNEGNNSYMIGNKNKIASGSNDNFILGNNVHIGGGINNSVALG   177 
>R26872              NG-SYQYKNEGNNSYMIGNKNKIASGSDDNFILGNNVHIGGGINNSVALG   177 
>R28385              NG-SYQYKNEGNNSYMIGNKNKIASGSNDNFILGNNVHIGGGINNSVALG   177 
>R28400              NG-SYQYKNEGNNSYMIGNKNKIASGSDDNFILGNNVHIGGGINNSVALG   177 
>2B17                NG-SYQYKNEGNNSYMIGNKNKIASGSNDNFILGNNVHIGGGINNSVALG   177 
>R29976              NG-SYQYKNEGNNSYMIGNKNKIASGSNDNFILGNNVHIGGGINNSVALG   177 
>R30464              NG-QHLYKNEGNNSYMIGNKNKIASGSDDNFILGNNVHIGGGINNSVALG   177 
>R30604              NG-SYQYKNEGNNSYMIGNKNKIASGSDDNFILGNNVHIGGGINNSVALG   177 
>R31249              NG-SYQYKNEGNNSYMIGNKNKIASGSNDNFILGNNVHIGGGINNSVALG   177 
>R32310              NG-SYQYKNEGNNSYMIGNKNKIASGSNDNFILGNNVHIGGGINNSVALG   177 
>R33458              NG-SYQYKNEGNNSYMIGNKNKIASGSNDNFILGNNVHIGGGINNSVALG   177 
>R33533              NG-SYQYKNEGNNSYMIGNKNKIASGSNDNFILGNNVHIGGGINNSVALG   177 
>GCA_002243405.1     NG-SYQYKNEGNNSYMIGNKNKIASGSDDNFILGNNVHIGGGINNSVALG   177 
CbpFb 
>2B16                N-GQYQYKNEGNNSYMIGNKNKIASGSDDNFILGNNVTIGAGVQKSVVLG   261 
>2B2                 N-GQYKYKNEGNNSYMIGNYNKIASGSDDNFILGNNVTIGAGVQKSVVLG   261 
>2B3                 NSGSHLYKNEGNNSYMIGNKNKIASGSDDNFILGNNVEIGAGVQKSVVLG   262 
>2B4                 N-GQYKYKNEGNNSYMIGNYNKIASGSDDNFILGNNVTIGAGVQKSVVLG   261 
>R5001               N-GQYKYKNEGNNSYMIGNYNKIAKDSNDNFILGNNVEIGAGVQKSVVLG   248 
>GCA_001546435.1     DTGKYIYKNEGNNSYMIGNKNKIASGSNDNFILGNNVEIGAGVQKSVVLG   204 
>R15792              N-GQYKNKNEGNNSYMIGNYNKIAKDSNDNFILGNNVEIGAGVQKSVVLG   191 
CbpFc 
>R16531_1            NG-QYQYKNEGHNSYMIGNKNKIAKGSNDNFILGNNVSIGKGIQNSVALG   177 
 
  




                     301       311       321       331       341        
CbpFa 
>GCA_000007325.1     NNSTVSASNTVSVGSSTLKRKIVNVGDGAISANSSDAVTGRQLYSGNGID   242 
>GCA_000163915.2     NNSTVSASNTVSVGSSTLKRKIVNVGDGEISASSTDAVTGRQLYSGNGID   242 
>R18528              NNSTVSASNTVSVGSSTLKRKIVNVGDGAISANSSDAVTGRQLYSGNGID   242 
>R28211              NNSTVSASNTVSVGSSTLKRKIVNVGDGEISASSTDAVTGRQLYSGNGID   242 
>R32935              NNSTVSASNTVSVGSSTLKRKIVNVGDGAISANSSDAVTGRQLYSGNGID   242 
>GCA_000455945.1     NNSTVSASNTVSVGSSTLKRKIVNVGDGAISANSSDAVTGRQLYSGNGID   255 
>GCA_000178895.1     NNSTVSASNTVSVGSSTLKRKIVNVGDGAISANSSDAVTGRQLYSGNGID   255 
>GCA_001510735.1     NNSTVSASNTVSVGSSTLKRKIVNVGDGAISANSSDAVTGRQLYSGNGID   255 
>GCA_001296165.1     NNSTVSASNTVSVGSSTLKRKIVNVGDGAISANSSDAVTGRQLYSGNGID   255 
>GCA_001296185.1     NNSTVSASNTVSVGSSTLKRKIVNVGDGAISANSSDAVTGRQLYSGNGID   255 
>GCA_002211605.1     NNSTVSASNTVSVGSSTLKRKIVNVGDGAISANSSDAVTGRQLYSGNGID   255 
>R24394              NNSTVSASNTVSVGSSTLKRKIVNVGDGAISANSSDAVTGRQLYSGNGID   255 
>GCA_000158255.2     NNSTVSASNTVSVGSSTLKRKIVNVGDGEISASSTDAVTGRQLYSGNGID   227 
>GCA_000162235.2     NNSTVSASNTVSVGSSTLKRKIVNVGDGEISASSTDAVTGRQLYSGNGID   227 
>GCA_000182945.1     NNSTVSASNTVSVGSSTLKRKIVNVGDGEISASSTDAVTGRQLYSGNGID   227 
>GCA_000347315.1     NNSTVSASNTVSVGSSTLKRKIVNVGDGEISASSTDAVTGRQLYSGNGID   227 
>GCA_000479205.1     NNSTVSASNTVSVGSSTLKRKIVNVGDGEISASSTDAVTGRQLYSGNGID   227 
>GCA_000517705.1     NNSTVSASNTVSVGSSTLKRKIVNVGDGEISASSTDAVTGRQLYSGNGID   227 
>GCA_001296125.1     NNSTVSASNTVSVGSSTLKRKIVNVGDGEISASSTDAVTGRQLYSGNGID   227 
>GCA_001810995.1     NNSTVSASNTVSVGSSTLKRKIVNVGDGEISASSTDAVTGRQLYSGNGID   227 
>GCA_001854465.1     NNSTVSASNTVSVGSSTLKRKIVNVGDGEISASSTDAVTGRQLYSGNGID   227 
>GCA_002749995.1     NNSTVSASNTVSVGSSTLKRKIVNVGDGEISASSTDAVTGRQLYSGNGID   227 
>GCA_002764055.1     NNSTVSASNTVSVGSSTLKRKIVNVGDGEISASSTDAVTGRQLYSGNGID   227 
>GCA_000455965.1     NNSTVSASNTVSVGSSTLKRKIVNVGDGEISASSTDAVTGRQLYSGNGID   227 
>R26872              NNSTVSASNTVSVGSSTLKRKIVNVGDGTISANSSDAVTGRQLYSGNGID   227 
>R28385              NNSTVSASNTVSVGSSTLKRKIVNVGDGEISASSTDAVTGRQLYSGNGID   227 
>R28400              NNSTVSASNTVSVGSSTLKRKIVNVGDGEISASSTDAVTGRQLYSGNGID   227 
>2B17                NNSTVSASNTVSVGSSTLKRKIVNVGDGEISASSTDAVTGRQLYSGNGID   227 
>R29976              NNSTVSASNTVSVGSSTLKRKIVNVGDGEISASSTDAVTGRQLYSGNGID   227 
>R30464              NNSTVSASNTVSVGSSTLKRKIVNVGDGEISASSTDAVTGRQLYSGNGID   227 
>R30604              NNSTVSASNTVSVGSSTLKRKIVNVGDGEISASSTDAVTGRQLYSGNGID   227 
>R31249              NNSTVSASNTVSVGSSTLKRKIVNVGDGEISASSTDAVTGRQLYSGNGID   227 
>R32310              NNSTVSASNTVSVGSSTLKRKIVNVGDGEISASSTDAVTGRQLYSGNGID   227 
>R33458              NNSTVSASNTVSVGSSTLKRKIVNVGDGEISASSTDAVTGRQLYSGNGID   227 
>R33533              NNSTVSASNTVSVGSSTLKRKIVNVGDGEISASSTDAVTGRQLYSGNGID   227 
>GCA_002243405.1     NNSTVSASNTVSVGSSTLKRKIVNVGDGEISASSTDAVTGRQLYSGNGID   227 
CbpFb 
>2B16                DGSASGGSNTVSVGSSTLQRKIVNVADGTISATSTDAVTGRQLYSGDGID   311 
>2B2                 DGSASGGSNTVSVGSSTLQRKIVNVADGTISATSTDAVTGRQLYSGDGID   311 
>2B3                 DGSASGGSNTVSVGSSTLQRKIVNVADGTISATSTDAVTGRQLYSGDGID   312 
>2B4                 DGSASGGSNTVSVGSSTLQRKIVNVADGTISATSTDAVTGRQLYSGDGID   311 
>R5001               DGSASGGSNTVSVGSSTLQRKIVNVADGTISATSTDAVTGRQLYSGDGID   298 
>GCA_001546435.1     DGSASGGSNTVSVGSSTLQRKIVNVADGTISATSTDAVTGRQLYSGDGID   254 
>R15792              DGSASGGSNTVSVGSSTLQRKIANVADGTISATSTDAVTGRQLYSGDGID   241 
CbpFc 
>R16531_1            NNSTVTASNTVSVGSATLKRKIVNVGDGEVSATSSDAVTGKQLYRGEGID   227 
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                     351       361       371       381       391        
CbpFa 
>GCA_000007325.1     TAAWQNKLNVTRKNDYKDANDIDVNKWKAKLGVG--SGGGGGAPVDAYTK   290 
>GCA_000163915.2     TAAWQNKLNVTKKNDYKDANDIDVNKWRTKLGVG--SGGSGGAPVDSYTK   290 
>R18528              TAAWQNKLNVTRKNDYKDANDIDVNKWKAKLGVG--SGGGGGAPVDAYTK   290 
>R28211              TAAWQNKLNVTKKNDYKDANDIDVNKWRTKLGVG--SGGVGGAPVDSYTK   290 
>R32935              TAAWQNKLNVTRKNDYKDANDIDVNKWKAKLGVG--SGGGGGAPVDAYTK   290 
>GCA_000455945.1     TAAWQNKLNVTRKNDYKDANDIDVNKWKAKLGVG--SGGGGGAPVDAYTK   303 
>GCA_000178895.1     TAAWQNKLNVTRKNDYKDANDIDVNKWKAKLGVG--SGGGGGAPVDAYTK   303 
>GCA_001510735.1     TAAWQNKLNVTRKNDYKDANDIDVNKWKAKLGVG--SGGGGGAPVDAYTK   303 
>GCA_001296165.1     TAAWQNKLNVTRKNDYKDANDIDVNKWKAKLGVG--SGGGGGAPVDAYTK   303 
>GCA_001296185.1     TAAWQNKLNVTRKNDYKDANDIDVNKWKAKLGVG--SGGGGGAPVDAYTK   303 
>GCA_002211605.1     TAAWQNKLNVTRKNDYKDANDIDVNKWKAKLGVG--SGGGGGAPVDAYTK   303 
>R24394              TAAWQNKLNVTRKNDYKDANDIDVNKWKAKLGVG--SGGGGGAPVDAYTK   303 
>GCA_000158255.2     TAAWQNKLNVTKKNDYKDANDIDVNKWRTKLGVG--SGGGGGAPVDSYTK   275 
>GCA_000162235.2     TAAWQNKLNVTRKNDYKDANDIDVNKWRTKLGVG--SGGGGGAPVDSYTK   275 
>GCA_000182945.1     TAAWQNKLNVTKKNDYKDANDIDVNKWRTKLGVG--SGGGGGAPVDSYTK   275 
>GCA_000347315.1     TAAWQNKLNVTRKNDYKDANDIDVNKWRTKLGVG--SGGGGGAPVDSYTK   275 
>GCA_000479205.1     TAAWQNKLNVTKKNDYKDANDIDVNKWRTKLGVG--SGGGGGAPVDSYTK   275 
>GCA_000517705.1     TAAWQNKLNVTKKNDYKDANDIDVNKWRTKLGVG--SGGGGGAPVDSYTK   275 
>GCA_001296125.1     TAAWQNKLNVTKKNDYKDANDIDVNKWRTKLGVG--SGGGGGAPVDSYTK   275 
>GCA_001810995.1     TAAWQNKLNVTKKNDYKDANDIDVNKWRTKLGVG--SGGGGGAPVDSYTK   275 
>GCA_001854465.1     TAAWQNKLNVTKKNDYKDANDIDVNKWRTKLGVG--SGGGGGAPVDSYTK   275 
>GCA_002749995.1     TAAWQNKLNVTKKNDYKDANDIDVNKWRTKLGVG--SGGGGGAPVDSYTK   275 
>GCA_002764055.1     TAAWQNKLNVTKKNDYKDANDIDVNKWRTKLGVG--SGGGGGAPVDSYTK   275 
>GCA_000455965.1     TAAWQNKLNVTKKNDYKDANDIDVNKWRTKLGVG--SGGGGGAPVDSYTK   275 
>R26872              TAAWQNKLNVTKKNDYKDANDIDVNKWRTKLGVG--SGGGGGAPVDSYTK   275 
>R28385              TAAWQNKLNVTKKNDYKDANDIDVNKWRTKLGVG--SGGGGGAPVDSYTK   275 
>R28400              TAAWQSKLNVTKKNDYKDANDIDVNKWRTKLGVGG-SGGGGGAPVDSYTK   276 
>2B17                TAAWQNKLNVTKKNDYKDANDIDVNKWRTKLGVG--SGGGGGAPVDSYTK   275 
>R29976              TAAWQNKLNVTKKNDYKDANDIDVNKWRTKLGVG--SGGGGGAPVDSYTK   275 
>R30464              TAAWQNKLNVTKKNDYKDANDIDVNKWRTKLGVG--SGGGGGAPVDSYTK   275 
>R30604              TAAWQNKLNVTRKNDYKDANDIDVNKWRTKLGVG--SGGGGGAPVDSYTK   275 
>R31249              TAAWQNKLNVTKKNDYKDANDIDVNKWRTKLGVG--SGGGGGAPVDSYTK   275 
>R32310              TAAWQNKLNVTKKNDYKDANDIDVNKWRTKLGVG--SGGGGGAPVDSYTK   275 
>R33458              TAAWQNKLNVTKKNDYKDANDIDVNKWRTKLGVG--SGGGGGAPVDSYTK   275 
>R33533              TAAWQNKLNVTKKNDYKDANDIDVNKWRTKLGVG--SGGGGGAPVDSYTK   275 
>GCA_002243405.1     TAAWQNKLNVTRKNDYKDANDIDVNKWRTKLGVG--SGGGGGAPVDAYTK   275 
CbpFb 
>2B16                -----------------------VNKWRTKLGVSSGGGASGGAPGDAYTK   338 
>2B2                 -----------------------VNKWRTKLGVSSGGGASGGAPGDAYTK   338 
>2B3                 -----------------------VNKWRTKLGVSSGGGASGGAPGDAYTK   339 
>2B4                 -----------------------VNKWRTKLGVSSGGGASGGAPGDAYTK   338 
>R5001               -----------------------VNKWRTRLGVGSGGGAGGGAPVDAYTK   325 
>GCA_001546435.1     -----------------------VNKWRTRLGVGSGGGAGGGAPVDAYTK   281 
>R15792              -----------------------VNKWRTRLGVGSGGGAGGGAPVDAYTK   268 
CbpFc 
>R16531_1            -----------------------VNAWRAKLGVG----------------   238 
 
  




                     401       411       421       431       441        
CbpFa 
>GCA_000007325.1     SEADNKFANKTDLNDYTKKDDYKDANGIDVDKWKAKLGTGAGTADIENLR   340 
>GCA_000163915.2     SEADNKFANKTDLDNYTKKDDYKDANGIDVDKWKAKLGTGAGTADIENLR   340 
>R18528              SEADNKFANKTDLNDYTKKDDYKDANGIDVDKWKAKLGTGAGTADIENLR   340 
>R28211              SEADNKFANKTDLDNYTKKDDYKDANGIDVDKWKAKLGTGAGTADIENLR   340 
>R32935              SEADNKFANKTDLNDYTKKDDYKDANGIDVDKWKAKLGTGAGTADIENLR   340 
>GCA_000455945.1     SEADNKFANKTDLNDYTKKDDYKDANGIDVDKWKAKLGTGAGTADIENLR   353 
>GCA_000178895.1     SEADNKFANKTDLNDYTKKDDYKDANGIDVDKWKAKLGTGAGTADIENLR   353 
>GCA_001510735.1     SEADNKFANKTDLNDYTKKDDYKDANGIDVDKWKAKLGTGAGTADIENLR   353 
>GCA_001296165.1     SEADNKFANKTDLNDYTKKDDYKDANGIDVDKWKAKLGTGAGTADIENLR   353 
>GCA_001296185.1     SEADNKFANKTDLNDYTKKDDYKDANGIDVDKWKAKLGTGAGTADIENLR   353 
>GCA_002211605.1     SEADNKFANKTDLNDYTKKDDYKDANGIDVDKWKAKLGTGAGTADIENLR   353 
>R24394              SEADNKFANKTDLNDYTKKDDYKDANGIDVDKWKAKLGTGAGTADIENLR   353 
>GCA_000158255.2     SEADNKFANKTDLDNYTKKDDYKDANGIDVDKWKAKLGTGAGTADIENLR   325 
>GCA_000162235.2     SEADNKFANKTDLDNYTKKDDYKDANGIDVDKWKAKLGTGAGTADIENLR   325 
>GCA_000182945.1     SEADNKFANKTDLDNYTKKDDYKDANGIDVDKWKAKLGTGAGTADIENLR   325 
>GCA_000347315.1     SEADNKFANKTDLDNYTKKDDYKDANGIDVDKWKAKLGTGAGTADIENLR   325 
>GCA_000479205.1     SEADNKFANKTDLDNYTKKDDYKDANGIDVDKWKAKLGTGAGTADIENLR   325 
>GCA_000517705.1     SEADNKFANKTDLDNYTKKDDYKDANGIDVDKWKAKLGTGAGTADIENLR   325 
>GCA_001296125.1     SEADNKFANKTDLDNYTKKDDYKDANGIDVDKWKAKLGTGAGTADIENLR   325 
>GCA_001810995.1     SEADNKFANKTDLDNYTKKDDYKDANGIDVDKWKAKLGTGAGTADIENLR   325 
>GCA_001854465.1     SEADNKFANKTDLDNYTKKDDYKDANGIDVDKWKAKLGTGAGTADIENLR   325 
>GCA_002749995.1     SEADNKFANKTDLDNYTKKDDYKDANGIDVDKWKAKLGTGAGTADIENLR   325 
>GCA_002764055.1     SEADNKFANKTDLDNYTKKDDYKDANGIDVDKWKAKLGTGAGTADIENLR   325 
>GCA_000455965.1     SEADNKFANKTDLDNYTKKDDYKDANGIDVDKWKAKLGTGAGTADIENLR   325 
>R26872              SEADNKFANKTDLDNYTKKDDYKDANGIDIDKWKAKLGTGAGTADIENLR   325 
>R28385              SEADNKFANKTDLDNYTKKDDYKDANGIDVDKWKAKLGTGAGTADIENLR   325 
>R28400              SEADNKFANKTDLDNYTKKDDYKDANGIDVDKWKAKLGTGAGTADIENLR   326 
>2B17                SEADNKFANKTDLDNYTKKDDYKDANGIDVDKWKAKLGTGAGTADIENLR   325 
>R29976              SEADNKFANKTDLDNYTKKDDYKDANGIDVDKWKAKLGTGAGTADIENLR   325 
>R30464              SEADNKFANKTDLDNYTKKDDYKDANGIDVDKWKAKLGTGAGTADIENLR   325 
>R30604              SEADNKFANKTDLDNYTKKDDYKDANGIDVDKWKAKLGTGAGTADIENLR   325 
>R31249              SEADNKFANKTDLDNYTKKDDYKDANGIDVDKWKAKLGTGAGTADIENLR   325 
>R32310              SEADNKFANKTDLDNYTKKDDYKDANGIDVDKWKAKLGTGAGTADIENLR   325 
>R33458              SEADNKFANKTDLDNYTKKDDYKDANGIDVDKWKAKLGTGAGTADIENLR   325 
>R33533              SEADNKFANKTDLDNYTKKDDYKDANGIDVDKWKAKLGTGAGTADIENLR   325 
>GCA_002243405.1     SEADNKFANKTDLDNYTKKDDYKDANGIDVDKWKAKLGT--GTANIENLR   323 
CbpFb 
>2B16                SEADNKFTSK---------DDYKDANGIDVDKWKAKLGTGGSSSDIQNLR   379 
>2B2                 SEADNKFTSK---------DDYRDANGIDVDKWKAKLGTGASSTDIQNLR   379 
>2B3                 SEADNKFTSK---------DDYKDANGIDVDKWKAKLGTGGGSADIQNLR   380 
>2B4                 SEADNKFTSK---------DDYRDANGIDVDKWKAKLGTGASSTDIQNLR   379 
>R5001               SEADNKFANKTDLDNYTKKDDYKDANGIDVDKWKAKLGTGADSADIQNLR   375 
>GCA_001546435.1     SEADNKFANKTDLDNYTKKDDYKDANGIDVDKWKAKLGTGAGSADIQNLR   331 
>R15792              SEADNKFANKTDLDNYTKKDDYKDANGIDVDKWKAKLGTGADSADIQNLR   318 
CbpFc 
>R16531_1            --------------------------------------TGS--ADIQNLR   248 
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                     451       461       471       481       491        
CbpFa 
>GCA_000007325.1     NEVNEKIDDVKDEVRTVGSLSAALAGLHPMQYDPKAPVQVMAALGHYRDK   390 
>GCA_000163915.2     NEVNEKIDDVKDEVRTVGSLSAALAGLHPMQYDPKAPVQVMAALGHYRDK   390 
>R18528              NEVNEKIDNVKDEVRTVGSLSAALAGLHPMQYDPKAPVQVMAALGHYKDK   390 
>R28211              NEVNEKIDDVKDEVRTVGSLSAALAGLHPMQYDPKAPVQVMAALGHYRDK   390 
>R32935              NEVNEKIDDVKDEVRTVGSLSAALAGLHPMQYDPKAPVQVMAALGHYRDK   390 
>GCA_000455945.1     NEVNEKIDNVKDEVRTVGSLSAALAGLHPMQYDPKAPVQVMAALGHYRDK   403 
>GCA_000178895.1     NEVNEKIDDVKDEVRTVGSLSAALAGLHPMQYDPKAPVQVMAALGHYRDK   403 
>GCA_001510735.1     NEVNEKIDNVKDEVRTVGSLSAALAGLHPMQYDPKAPVQVMAALGHYRDK   403 
>GCA_001296165.1     NEVNEKIDNVKDEVRTVGSLSAALAGLHPMQYDPKAPVQVMAALGHYRDK   403 
>GCA_001296185.1     NEVNEKIDNVKDEVRTVGSLSAALAGLHPMQYDPKAPVQVMAALGHYRDK   403 
>GCA_002211605.1     NEVNEKIDNVKDEVRTVGSLSAALAGLHPMQYDPKAPVQVMAALGHYRDK   403 
>R24394              NEVNEKIDDVKDEVRTVGSLSAALAGLHPMQYDPKAPVQVMAALGHYRDK   403 
>GCA_000158255.2     NEVNEKIDDVEDEVRTVGSLSAALAGLHPMQYDPKAPVQVMAALGHYRDK   375 
>GCA_000162235.2     NEVNEKIDDVKDEVRTVGSLSAALAGLHPMQYDPKAPVQVMAALGHYRDK   375 
>GCA_000182945.1     NEVNEKIDDVKDEVRTVGSLSAALAGLHPMQYDPKAPVQVMAALGHYRDK   375 
>GCA_000347315.1     NEVNEKIDDVKDEVRTVGSLSAALAGLHPMQYDPKAPVQVMAALGHYRDK   375 
>GCA_000479205.1     NEVNEKIDDVKDEVRTVGSLSAALAGLHPMQYDPKAPVQVMAALGHYRDK   375 
>GCA_000517705.1     NEVNEKIDDVKDEVRTVGSLSAALAGLHPMQYDPKAPVQVMAALGHYRDK   375 
>GCA_001296125.1     NEVNEKIDDVEDEVRTVGSLSAALAGLHPMQYDPKAPVQVMAALGHYRDK   375 
>GCA_001810995.1     NEVNEKIDDVKDEVRTVGSLSAALAGLHPMQYDPKAPVQVMAALGHYRDK   375 
>GCA_001854465.1     NEVNEKIDDVKDEVRTVGSLSAALAGLHPMQYDPKAPVQVMAALGHYRDK   375 
>GCA_002749995.1     NEVNEKIDDVEDEVRTVGSLSAALAGLHPMQYDPKAPVQVMAALGHYRDK   375 
>GCA_002764055.1     NEVNEKIDDVKDEVRTVGSLSAALAGLHPMQYDPKAPVQVMAALGHYRDK   375 
>GCA_000455965.1     NEVNEKIDDVEDEVRTVGSLSAALAGLHPMQYDPKAPVQVMAALGHYRDK   375 
>R26872              NEVNEKIDDVKDEVRTVGSLSAALAGLHPMQYDPKAPVQVMAALGHYRDK   375 
>R28385              NEVNEKIDDVKDEVRTVGSLSAALAGLHPMQYDPKAPIQVMAALGHYRDK   375 
>R28400              NEVNEKIDDVKDEVRTVGSLSAALAGLHPMQYDPKAPVQVMAALGHYRDK   376 
>2B17                NEVNEKIDDVKDEVRTVGSLSAALAGLHPMQYDPKAPVQVMAALGHYRDK   375 
>R29976              NEVNEKIDDVKDEVRTVGSLSAALAGLHPMQYDPKAPVQVMAALGHYRDK   375 
>R30464              NEVNEKIDDVKDEVRTVGSLSAALAGLHPMQYDPKAPVQVMAALGHYRDK   375 
>R30604              NEVNEKIDDVKDEVRTVGSLSAALAGLHPMQYDPKAPVQVMAALGHYRDK   375 
>R31249              NEVNEKIDDVKDEVRTVGSLSAALAGLHPMQYDPKAPVQVMAALGHYRDK   375 
>R32310              NEVNEKIDDVKDEVRTVGSLSAALAGLHPMQYDPKAPVQVMAALGHYRDK   375 
>R33458              NEVNEKIDDVEDEVRTVGSLSAALAGLHPMQYDPKAPVQVMAALGHYRDK   375 
>R33533              NEVNEKIDDVKDEVRTVGSLSAALAGLHPMQYDPKAPVQVMAALGHYRDK   375 
>GCA_002243405.1     NEVNEKIDNVKDEVRTVGSLSAALAGLHPMQYDPKAPVQVMAALGHYKDK   373 
CbpFb 
>2B16                NEVNEKIDNVKDEVRGVGSLSAALAGLHPMQYDPKAPAQVMAALGHYKNR   429 
>2B2                 NEVNEKIDNVKDEVRGVGSLSAALAGLHPMQYDPKAPAQVMAALGHYKDR   429 
>2B3                 NEVNEKIDNVKDEVRGVGSLSAALAGLHPMQYDPKAPAQVMAALGHYKDR   430 
>2B4                 NEVNEKIDNVKDEVRGVGSLSAALAGLHPMQYDPKAPAQVMAALGHYKDR   429 
>R5001               NEVYERIDNVKDEVRDVGSLSAALAGLHPMQYDPKAPAQVMAALGHYKDR   425 
>GCA_001546435.1     NEVYERIDNVKDEVRDVGSLSAALAGLHPMQYDPKAPAQVMAALGHYKDR   381 
>R15792              NEVYERIDNVKDEVRDVGSLSAALAGLHPMQYDPKAPAQVMAALGHYKDR   368 
CbpFc 
>R16531_1            NEVYERIDNVKDEVRDVGSLSAALAGLHPMQYDPKAPAQVMAALGHYKDR   298 
 
  




                     501       511       521       531       541        
CbpFa 
>GCA_000007325.1     QSVAVGASYYFNDRFMMSTGIALSGEKRTKTMANVGFTLKLGKGSGVTYD   440 
>GCA_000163915.2     QSVAVGASYYFNDRFMMSTGIALSGEKRTKTMANVGFTLKLGKGSGVAYN   440 
>R18528              QSVAVGASYYFNDRFMMSTGIALSGEKRTETMANVGFTLKLGKGSGVTYD   440 
>R28211              QSVAVGASYYFNDRFMMSTGIALSGEKRTKTMANVGFTLKLGKGSGVAYN   440 
>R32935              QSVAVGASYYFNDRFMMSTGIALSGEKRTKTMANVGFTLKLGKGSGVTYD   440 
>GCA_000455945.1     QSVAVGASYYFNDRFMMSTGIALSGEKRTKTMANVGFTLKLGKGSGVTYD   453 
>GCA_000178895.1     QSVAVGASYYFNDRFMMSTGIALSGEKKTKTMANVGFTLKLGKGSGVTYD   453 
>GCA_001510735.1     QSVAVGASYYFNDRFMMSTGIALSGEKRTKTMANVGFTLKLGKGSGVTYD   453 
>GCA_001296165.1     QSVAVGASYYFNDRFMMSTGIALSGEKRTKTMANVGFTLKLGKGSGVTYD   453 
>GCA_001296185.1     QSVAVGASYYFNDRFMMSTGIALSGEKRTKTMANVGFTLKLGKGSGVTYD   453 
>GCA_002211605.1     QSVAVGASYYFNDRFMMSTGIALSGEKRTKTMANVGFTLKLGKGSGVTYD   453 
>R24394              QSVAVGASYYFNDRFMMSTGIALSGEKKTKTMANVGFTLKLGKGSGVTYD   453 
>GCA_000158255.2     QSVAVGASYYFNDRFMMSTGIALSGEKRTKTMANVGFTLKLGKGSGVAYN   425 
>GCA_000162235.2     QSVAVGASYYFNDRFMMSTGIALSGEKRTKTMANVGFTLKLGKGSGVAYN   425 
>GCA_000182945.1     QSVAVGASYYFNDRFMMSTGIALSGEKRTKTMANVGFTLKLGKGSGVTYN   425 
>GCA_000347315.1     QSVAVGASYYFNDRFMMSTGIALSGEKRTKTMANVGFTLKLGKGSGVAYN   425 
>GCA_000479205.1     QSVAVGASYYFNDRFMMSTGIALSGEKRTKTMANVGFTLKLGKGSGVAYN   425 
>GCA_000517705.1     QSVAVGASYYFNDRFMMSTGIALSGEKRTKTMANVGFTLKLGKGSGVAYN   425 
>GCA_001296125.1     QSVAVGASYYFNDRFMMSTGIALSGEKRTKTMANVGFTLKLGKGSGVAYN   425 
>GCA_001810995.1     QSVAVGASYYFNDRFMMSTGIALSGEKRTKTMANVGFTLKLGKGSGVTYN   425 
>GCA_001854465.1     QSVAVGASYYFNDRFMMSTGIALSGEKRTKTMANVGFTLKLGKGSGVAYN   425 
>GCA_002749995.1     QSVAVGASYYFNDRFMMSTGIALSGEKRTKTMANVGFTLKLGKGSGVAYN   425 
>GCA_002764055.1     QSVAVGASYYFNDRFMMSTGIALSGEKRTKTMANVGFTLKLGKGSGVTYN   425 
>GCA_000455965.1     QSVAVGASYYFNDRFMMSTGIALSGEKRTKTMANVGFTLKLGKGSGVAYN   425 
>R26872              QSVAVGASYYFNDRFMMSTGIALSGEKRTKTMANVGFTLKLGKGSGVTYN   425 
>R28385              QSVAVGASYYFNDRFMMSTGIALSGEKRTKTMANVGFTLKLGKGSGVTYN   425 
>R28400              QAVAVGASYYFNDRFMMSTGIALSGEKRTKTMANVGFTLKLGKGSGVTYN   426 
>2B17                QSVAVGASYYFNDRFMMSTGIALSGEKRTKTMANVGFTLKLGKGSGVTYN   425 
>R29976              QSVAVGASYYFNDRFMMSTGIALSGEKRTKTMANVGFTLKLGKGSGVAYN   425 
>R30464              QSVAVGASYYFNDRFMMSTGIALSGEKRTKTMANVGFTLKLGKGSGVAYN   425 
>R30604              QSVAVGASYYFNDRFMMSTGIALSGEKRTKTMANVGFTLKLGKGSGVAYN   425 
>R31249              QSVAVGASYYFNDRFMMSTGIALSGEKRTKTMANVGFTLKLGKGSGVTYN   425 
>R32310              QSVAVGASYYFNDRFMMSTGIALSGEKRTKTMANVGFTLKLGKGSGVTYN   425 
>R33458              QSVAVGASYYFNDRFMMSTGIALSGEKRTKTMANVGFTLKLGKGSGVAYN   425 
>R33533              QSVAVGASYYFNDRFMMSTGIALSGEKRTKTMANVGFTLKLGKGSGVAYN   425 
>GCA_002243405.1     QSVAVGASYYFNDRFMMSTGIALSGEKRTETMANVGFTLKLGKGSGVTYN   423 
CbpFb 
>2B16                QAVAVGASYYFNDKFMMSTGVALSGEKRTEAMANVGFTLKIGKGSGTTYT   479 
>2B2                 QAVAVGASYYFNDKFMMSTGVALSGEKRTEAMANVGFTLKIGKGSGTTYT   479 
>2B3                 QAVAVGASYYFNDKFMMSTGVALSGEKRTEAMANVGFTLKIGKGSGTTYT   480 
>2B4                 QAVAVGASYYFNDKFMMSTGVALSGEKRTEAMANVGFTLKIGKGSGTTYT   479 
>R5001               QAVAVGASYYFNDRFMMSTGVALSGEKKTKTMANVGFTLKLGKGSGTTYS   475 
>GCA_001546435.1     QAVAVGASYYFNDRFMMSTGVALSGEKKTKTMANVGFTLKLGKGSGTTYS   431 
>R15792              QAVAVGASYYFNDRFMMSTGVALSGEKKTKTMANVGFTLKLGKGSGTTYS   418 
CbpFc 
>R16531_1            QAVAVGASYYFNDRFMMSTGVALSGEKKTKTMANVGFTLKLGKGSGTTYS   348 
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                     551       561       571       581       591        
CbpFa 
>GCA_000007325.1     ETPQYVVQNEVKRLTVEN-------QELKERVRNLEEKLNMLLKNK       483 
>GCA_000163915.2     ETPLYTIQDEVKRLTVENNKQAKENQELKERVRNLEEKLNMLLKNK       490 
>R18528              ETPQYVVQNEVKRLTVEN-------QELKERLRNLEEKLETLLKNK       483 
>R28211              ETPLYTIQDEVKRLTVENNKQAKENQELKERVRNLEEKLNMLLKNK       490 
>R32935              ETPQYVVQNEVKRLTVEN-------QELKERVRNLEEKLNMLLKNK       483 
>GCA_000455945.1     ETPQYVVQNEVKRLTVEN-------QELKERLRNLEEKLEMLLKNK       496 
>GCA_000178895.1     ETPQYVVQNEVKRLTVEN-------QELKERVRNLEEKLNMLLKNK       496 
>GCA_001510735.1     ETPQYVVQNEVKRLTVEN-------QELKERLRNLEEKLEMLLKNK       496 
>GCA_001296165.1     ETPQYVVQNEVKRLTVEN-------QELKERLRNLEEKLEMLLKNK       496 
>GCA_001296185.1     ETPQYVVQNEVKRLTVEN-------QELKERLRNLEEKLEMLLKNK       496 
>GCA_002211605.1     ETPQYVVQNEVKRLTVEN-------QELKERLRNLEEKLEMLLKNK       496 
>R24394              ETPQYVVQNEVKRLTVEN-------QELKERVRNLEEKLNMLLKNK       496 
>GCA_000158255.2     ETPLYTIQDEVKRLTVENNKQAKENQELKERVRNLEEKLNMLLKNK       475 
>GCA_000162235.2     ETPLYTIQDEVKRLTVENNKQAKENQELKERVRNLEEKLNMLLKNK       475 
>GCA_000182945.1     ETPLYTIQDEVKRLTVENNKQAKENQELKERVRNLEEKLNMLLKNK       475 
>GCA_000347315.1     ETPLYTIQDEVKRLTVENNKQAKENQELKERVRNLEEKLNMLLKNK       475 
>GCA_000479205.1     ETPLYTIQDEVKRLTVENNKQAKENQELKERVRNLEEKLNMLLKNK       475 
>GCA_000517705.1     ETPLYTIQDEVKRLTVENNKQAKENQELKERVRNLEEKLNMLLKNK       475 
>GCA_001296125.1     ETPLYTIQDEVKRLTVENNKQAKENQELKERVRNLEEKLNMLLKNK       475 
>GCA_001810995.1     ETPLYTIQDEVKRLTVENNKQAKENQELKERVRNLEEKLNMLLKNK       475 
>GCA_001854465.1     ETPLYTIQDEVKRLTVENNKQAKENQELKERVRNLEEKLNMLLKNK       475 
>GCA_002749995.1     ETPLYTIQDEVKRLTVENNKQAKENQELKERVRNLEEKLNMLLKNK       475 
>GCA_002764055.1     ETPLYTIQDEVKRLTVENNKQAKENQELKERVRNLEEKLNMLLKNK       475 
>GCA_000455965.1     ETPLYTIQDEVKRLTVENNKQAKENQELKERVRNLEEKLNMLLKNK       475 
>R26872              ETPLYTIQDEVKRLTVENNKQAKENQELKERVRNLEEKLNMLLKNK       475 
>R28385              ETPLYTIQDEVKRLTVENNKQAKENQELKERVRNLEEKLNMLLKNK       475 
>R28400              ETPLYTIQDEVKRLTVENNKQAKENQELKERVRNLEEKLNMLLKNK       476 
>2B17                ETPLYTIQDEVKRLTVENNKQAKENQELKERVRNLEEKLNMLLKNK       475 
>R29976              ETPLYTIQDEVKRLTIENNKQAKENQELKERVRNLEEKLNMLLKNK       475 
>R30464              ETPLYTIQDEVKRLTVENNKQAKENQELKERVRNLEEKLNMLLKNK       475 
>R30604              ETPLYTIQDEVKRLTVENNKQAKENQELKERVRNLEEKLNMLLKNK       475 
>R31249              ETPLYTIQDEVKRLTVENNKQAKENQELKERVRNLEEKLNMLLKNK       475 
>R32310              ETPLYTIQDEVKRLTVENNKQAKENQELKERVRNLEEKLNMLLKNK       475 
>R33458              ETPLYTIQDEVKRLTVENNKQAKENQELKERVRNLEEKLNMLLKNK       475 
>R33533              ETPLYTIQDEVKRLTVENNKQAKENQELKERVRNLEEKLNMLLKNK       475 
>GCA_002243405.1     ETPQYVVQNEVKRLTVEN-------QELKERLRNLEEKLEMLLKNK       466 
CbpFb 
>2B16                ETPQYVVQNEVKRLTVEN-------QELKERVRNLEEKLNMLLKNK       522 
>2B2                 ETPQYVVQNEVKRLTVEN-------QELKERVRNLEEKLNMLLKNK       522 
>2B3                 ETPQYVVQNEVKRLTVEN-------QELKERVRNLEEKLNMLLKNK       523 
>2B4                 ETPQYVVQNEVKRLTVEN-------QELKERVRNLEEKLNMLLKNK       522 
>R5001               ETPQYVVQNEVKRLTVEN-------QELKERLRNLEQKLEILLKNK       518 
>GCA_001546435.1     ETPQYVVQNEVKRLTVEN-------QELKERLRNLEQKLEILLKNK       474 
>R15792              ETPQYVVQNEVKRLTVEN-------QELKERLRNLEQKLEILLKNK       461 
CbpFc 
>R16531_1            ETPQYVVQNEVKRLTVEN-------QELKERVRNLEEKLNMLLKSK       391 
  




Appendix E: List of Fusobacterium Reclassifications 
Table S 2 | List of all Fusobacterium classifications and reclassifications from CHAPTER 3. 
All Fusobacterium genomes listed on NCBI, were classified according to the MUMi, ANI and PLSA 
scores such that a consensus could be reached where every strain was within the species threshold. 
The proposed genus reclassification groups (A, B and C) are also shown – blanks are species that 
do not exist within the Fusobacteriaceae family or where there was ambiguity in the genome, such 
as for R33458. 
Assembly 
Accession or 
WGS Strain ID 
Organism Name (NCBI) Strain ID New Species Classification 
Genus 
Group 
GCA_000158275.2 F. nucleatum subsp. animalis 7_1 animalis A 
GCA_000158535.2 F. nucleatum subsp. animalis D11 animalis A 
GCA_000162355.2 F. nucleatum subsp. animalis 3_1_33 animalis A 
GCA_000218645.2 F. nucleatum subsp. animalis 21_1A animalis A 
GCA_000218655.1 F. nucleatum subsp. animalis 11_3_2 animalis A 
GCA_000220825.1 F. nucleatum subsp. animalis 
ATCC 
51191 animalis A 
GCA_000234075.2 F. nucleatum subsp. polymorphum F0401 animalis A 
GCA_000242975.1 F. nucleatum subsp. animalis OT 420 animalis A 
GCA_000273605.1 F. nucleatum subsp. animalis F0419 animalis A 
GCA_000273625.1 F. nucleatum subsp. animalis 7_1 animalis A 
GCA_000400875.1 F. nucleatum subsp. animalis 4_8 animalis A 
GCA_000433695.1 F. sp. CAG:649 animalis A 
GCA_000455985.1 F. nucleatum subsp. animalis 
ChDC 
F324 animalis A 
GCA_000479225.1 F. nucleatum CTI-5 animalis A 
GCA_000479245.1 F. nucleatum CTI-3 animalis A 
GCA_000479285.1 F. nucleatum CTI-1 animalis A 
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GCA_000524215.1 F. sp. CM1 animalis A 
GCA_001296085.1 F. nucleatum subsp. animalis 
KCOM 
1279 animalis A 
GCA_001296145.1 F. nucleatum subsp. animalis 
KCOM 
1325 animalis A 
GCA_001546435.1 F. nucleatum MJR7757B animalis A 
GCA_001813745.1 F. sp. HMSC065F01 animalis A 
GCA_002211645.1 F. nucleatum subsp. animalis 
ChDC 
F332 animalis A 
GCA_002573475.1 F. nucleatum subsp. animalis 
ChDC 
F318 animalis A 
GCA_002762005.1 F. nucleatum subsp. animalis P2_CP animalis A 
GCA_002762015.1 F. nucleatum subsp. animalis P2_LM animalis A 
GCA_002884895.1 F. nucleatum UMB0249 animalis A 
R15792  R15792 animalis A 
R18932  R18932 animalis A 
R30927  R30927 animalis A 
R5001  R5001 animalis A 
GCA_900015295.1 F. sp.  closii sp. nov. B 
GCA_000158235.1 F. gonidiaformans 3_1_5R gonidiaformans C 
GCA_000158835.2 F. gonidiaformans  ATCC 25563 gonidiaformans C 
GCA_001546395.1 F. equinum CMW8396 gonidiaformans C 
GCA_003019695.1 F. gonidiaformans ATCC 25563 gonidiaformans C 
GCA_000292935.1 F. hwasookii ChDC F128 hwasookii A 
GCA_000455865.1 F. hwasookii ChDC F145 hwasookii A 
GCA_000455885.1 F. hwasookii ChDC F174 hwasookii A 
GCA_000455905.1 F. hwasookii ChDC F206 hwasookii A 
GCA_000455925.1 F. hwasookii ChDC F300 hwasookii A 




GCA_001455085.1 F. hwasookii ChDC F206 hwasookii A 
GCA_001455105.1 F. hwasookii ChDC F300 hwasookii A 
GCA_001455145.1 F. hwasookii ChDC F174 hwasookii A 
GCA_900095705.1 F. massiliense Marseille-P2749 massiliense A 
GCA_000158195.2 F. mortiferum ATCC 9817 mortiferum B 
GCA_003019315.1 F. mortiferum ATCC 9817 mortiferum B 
GCA_003438345.1 F. mortiferum OM06-15BH mortiferum B 
GCA_003014445.1 F. naviforme ATCC 25832 naviforme 
 
GCA_900450945.1 F. naviforme NCTC13121 naviforme 
 
GCA_900450765.1 F. necrogenes NCTC10723 necrogenes B 
GCA_000158295.2 F. necrophorum D12 necrophorum C 
GCA_000242215.1 F. necrophorum subsp. funduliforme 1_1_36S necrophorum C 
GCA_000262225.1 F. necrophorum subsp. funduliforme 
ATCC 
51357 necrophorum C 
GCA_000292975.1 F. necrophorum subsp. funduliforme Fnf 1007 necrophorum C 
GCA_000600355.1 F. necrophorum subsp. funduliforme B35 necrophorum C 
GCA_000622045.1 F. necrophorum HUN048 necrophorum C 
GCA_000691645.1 F. necrophorum BL necrophorum C 
GCA_000691665.1 F. necrophorum DJ-1 necrophorum C 
GCA_000691685.1 F. necrophorum BFTR-1 necrophorum C 
GCA_000691705.1 F. necrophorum DAB necrophorum C 
GCA_000691725.1 F. necrophorum BFTR-2 necrophorum C 
GCA_000691745.1 F. necrophorum DJ-2 necrophorum C 
GCA_000814775.1 F. necrophorum subsp. funduliforme B35 necrophorum C 
GCA_001596475.1 F. necrophorum subsp. funduliforme LS_1260 necrophorum C 
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GCA_001596485.1 F. necrophorum subsp. funduliforme LS_1264 necrophorum C 
GCA_001596495.1 F. necrophorum subsp. funduliforme LS_1197 necrophorum C 
GCA_001597305.1 F. necrophorum subsp. funduliforme LS_1195 necrophorum C 
GCA_001597315.1 F. necrophorum subsp. funduliforme LS_1266 necrophorum C 
GCA_001597325.1 F. necrophorum subsp. funduliforme LS_1280 necrophorum C 
GCA_001597335.1 F. necrophorum subsp. funduliforme LS_1272 necrophorum C 
GCA_001597385.1 F. necrophorum subsp. funduliforme LS_1291 necrophorum C 
GCA_001597395.1 F. necrophorum subsp. funduliforme F1248 necrophorum C 
GCA_001597405.1 F. necrophorum subsp. funduliforme F1285 necrophorum C 
GCA_001597445.1 F. necrophorum subsp. funduliforme F1250 necrophorum C 
GCA_001597465.1 F. necrophorum subsp. funduliforme F1267 necrophorum C 
GCA_001597475.1 F. necrophorum subsp. funduliforme F1309 necrophorum C 
GCA_001597485.1 F. necrophorum subsp. funduliforme F1314 necrophorum C 
GCA_001597525.1 F. necrophorum subsp. funduliforme F1353 necrophorum C 
GCA_001597545.1 F. necrophorum subsp. funduliforme F1330 necrophorum C 
GCA_001597565.1 F. necrophorum subsp. funduliforme F1365 necrophorum C 
GCA_001597575.1 F. necrophorum subsp. funduliforme F1351 necrophorum C 
GCA_002761995.1 F. necrophorum subsp. funduliforme P1_CP necrophorum C 
GCA_002762025.1 F. necrophorum subsp. funduliforme P1_LM necrophorum C 
GCA_003019715.1 F. necrophorum subsp. funduliforme 1_1_36S necrophorum C 
GCA_900104395.1 F. necrophorum ATCC 25286 necrophorum C 
GCA_900451075.1 F. necrophorum subsp. necrophorum 
NCTC13
726 necrophorum C 
GCA_000007325.1 F. nucleatum subsp. nucleatum 
ATCC 
25586 nucleatum A 
GCA_000178895.1 F. nucleatum subsp. nucleatum 
ATCC 
23726 nucleatum A 




GCA_000455945.1 F. nucleatum subsp. nucleatum 
ChDC 
F316 nucleatum A 
GCA_000479265.1 F. nucleatum CTI-2 nucleatum A 
GCA_001296165.1 F. nucleatum subsp. nucleatum 
KCOM 
1322 nucleatum A 
GCA_001296185.1 F. nucleatum subsp. nucleatum 
KCOM 
1250 nucleatum A 
GCA_001510735.1 F. nucleatum subsp. nucleatum 
ChDC 
F311 nucleatum A 
GCA_002211605.1 F. nucleatum subsp. nucleatum 
ChDC 
F317 nucleatum A 
GCA_002243405.1 F. sp. oral taxon 203 W7671 nucleatum A 
GCA_003019295.1 F. nucleatum subsp. nucleatum 25586 nucleatum A 
GCA_003019785.1 F. nucleatum subsp. nucleatum 
ATCC 
23726 nucleatum A 
R18528  R18528 nucleatum A 
R24394  R24394 nucleatum A 
R28385  R28385 nucleatum A 
R28400  R28400 nucleatum A 
R32935  R32935 nucleatum A 
2B16  2B16 oralis sp. nov. A 
2B2  2B2 oralis sp. nov. A 
2B3  2B3 oralis sp. nov. A 
2B4  2B4 oralis sp. nov. A 
GCA_000235465.1 F. sp. oral taxon 370 F0437 oralis sp. nov. A 
R28427  R28427 oralis sp. nov. A 
R16531  R16531 ovarium sp. nov. A 
GCA_000622245.1 F. perfoetens ATCC 29250 perfoetens B 
GCA_000158215.3 F. periodonticum 2_1_31 periodonticum A 
GCA_000163935.1 F. periodonticum 1_1_41FAA periodonticum A 
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GCA_000297655.1 F. periodonticum D10 periodonticum A 
GCA_002761935.1 F. periodonticum KCOM 1321 periodonticum A 
GCA_002761955.1 F. periodonticum KCOM 1259 periodonticum A 
GCA_002763595.1 F. periodonticum KCOM 1283 periodonticum A 
GCA_002763625.1 F. periodonticum KCOM 1261 periodonticum A 
GCA_002763695.1 F. periodonticum KCOM 1263 periodonticum A 
GCA_002763735.1 F. periodonticum KCOM 1277 periodonticum A 
GCA_002763775.1 F. periodonticum KCOM 1282 periodonticum A 
GCA_002763815.1 F. periodonticum KCOM 2305 periodonticum A 
GCA_002763875.1 F. periodonticum KCOM 2555 periodonticum A 
GCA_002763915.1 F. periodonticum KCOM 1262 periodonticum A 
GCA_002763925.1 F. periodonticum KCOM 2653 periodonticum A 
GCA_003019755.1 F. periodonticum 2_1_31 periodonticum A 
GCA_000153625.1 F. nucleatum subsp. polymorphum 
ATCC 
10953 polymorphum A 
GCA_000479185.1 F. nucleatum CTI-6 polymorphum A 
GCA_000523555.1 F. nucleatum 13_3C polymorphum A 
GCA_000524235.1 F. sp. OBRC1 polymorphum A 
GCA_000524395.1 F. sp. CM22 polymorphum A 
GCA_001433955.1 F. nucleatum subsp. polymorphum 
ChDC 
F306 polymorphum A 
GCA_001455125.1 F. nucleatum subsp. polymorphum 
ChDC 
F319 polymorphum A 
GCA_001457555.1 F. nucleatum subsp. polymorphum 
NCTC10
562 polymorphum A 
GCA_001815715.1 F. sp. HMSC064B11 polymorphum A 
GCA_002202115.1 F. nucleatum subsp. polymorphum 
ChDC 
F218 polymorphum A 
GCA_002204435.1 F. nucleatum subsp. polymorphum 
KCOM 
1001 polymorphum A 




GCA_002211625.1 F. nucleatum subsp. polymorphum 
KCOM 
1275 polymorphum A 





GCA_002573625.1 F. nucleatum subsp. polymorphum 
ChDC 
F37 polymorphum A 
GCA_002591465.1 F. nucleatum subsp. polymorphum 
ChDC 
F309 polymorphum A 
GCA_002591475.1 F. nucleatum subsp. polymorphum 
ChDC 
F290 polymorphum A 
GCA_002591505.1 F. nucleatum subsp. polymorphum 
ChDC 
F113 polymorphum A 
GCA_002591515.1 F. nucleatum subsp. polymorphum 
ChDC 
F305 polymorphum A 
GCA_002591545.1 F. nucleatum subsp. polymorphum 
ChDC 
F186 polymorphum A 
GCA_002591555.1 F. nucleatum subsp. polymorphum 
ChDC 
F175 polymorphum A 
GCA_002591585.1 F. nucleatum subsp. polymorphum 
ChDC 
F313 polymorphum A 
GCA_002591645.1 F. nucleatum subsp. polymorphum 
ChDC 
F330 polymorphum A 
GCA_002761915.1 F. periodonticum KCOM 1265 polymorphum A 
GCA_003226385.1 F. nucleatum 12230 polymorphum A 
GCA_000160475.1 F. periodonticum ATCC 33693 
pseudoperiodo
nticum sp. nov. A 
GCA_002356455.1 F. varium Fv113-g1 
pseudovarium 
sp. nov. B 





GCA_000158315.2 F. ulcerans ATCC 49185 ulcerans B 
GCA_000242995.2 F. ulcerans 12_1B ulcerans B 
GCA_003019675.1 F. ulcerans ATCC 49185 ulcerans B 
GCA_900478315.1 F. ulcerans NCTC12112 ulcerans B 
GCA_000159915.2 F. varium ATCC 27725 varium B 
GCA_001810475.1 F. sp. HMSC073F01 varium B 
GCA_003019655.1 F. varium ATCC 27725 varium B 
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GCA_003436335.1 F. varium TM07-10 varium B 
2B17  2B17 vincentii A 
GCA_000158255.2 F. nucleatum subsp. vincentii 4_1_13 vincentii A 
GCA_000162235.2 F. nucleatum subsp. vincentii 
3_1_36A
2 vincentii A 
GCA_000163915.2 F. nucleatum subsp. vincentii 3_1_27 vincentii A 
GCA_000182945.1 F. nucleatum subsp. vincentii 
ATCC 
49256 vincentii A 
GCA_000279975.1 F. nucleatum subsp. fusiforme 
ATCC 
51190 vincentii A 
GCA_000347315.1 F. nucleatum CC53 vincentii A 
GCA_000455965.1 F. nucleatum subsp. vincentii ChDC F8 vincentii A 
GCA_000479205.1 F. nucleatum CTI-7 vincentii A 
GCA_000517705.1 F. sp. CM21 vincentii A 
GCA_001296125.1 F. nucleatum subsp. vincentii 
KCOM 
1231 vincentii A 
GCA_001810995.1 F. sp. HMSC064B12 vincentii A 
GCA_001854465.1 F. nucleatum AB1 vincentii A 
GCA_002749995.1 F. nucleatum subsp. vincentii 
KCOM 
2880 vincentii A 
GCA_002764055.1 F. nucleatum subsp. vincentii 
KCOM 
2931 vincentii A 
GCA_900450795.1 F. nucleatum subsp. vincentii 
NCTC11
326 vincentii A 
R26872  R26872 vincentii A 
R28211  R28211 vincentii A 
R29976  R29976 vincentii A 
R30464  R30464 vincentii A 
R30604  R30604 vincentii A 
R31249  R31249 vincentii A 
R32310  R32310 vincentii A 




R33533  R33533 vincentii A 
GCA_000493815.1 F. nucleatum subsp. W1481 W1481 W1481 A 
GCA_000437775.1 F. sp. CAG:815   
GCA_000438175.1 F. sp. CAG:439   
R33458  R33458   
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Appendix F: CEACAM1 N-terminal Domain Molecular 
Dynamics 
 
Figure S 5 | CEACAM1 N-terminal domain molecular dynamics simulations. 
A) 100 ns production MD; plot of backbone RMSD vs energy-minimised structure. B) 100 ns 
production MD; plot of backbone RMSD vs original crystal structure. C) 250 ns production MD; plot 
of backbone RMSD vs energy-minimised structure. The maximum RMSD remained below 0.3 nm 
throughout all simulations indicating a stable inflexible structure.  




Appendix G: CbpF YadA-like head sequence conservation 
 
Figure S 6 | CbpF YadA-like head sequence logos. 
Sequence logos for the different YadA-like head domains from CbpFa (A and B), CbpFb (C and D) 
and CbpFc (E and F) were created as well as the global (G and H) representation. The N-terminal 
group of YadA-like heads were split into two groups: the final domain of the cluster (B, D, F and H) 
and all the ones prior (A, C, E and G). As only one CbpFc has been identified, only one example of 
the final YadA-like domain exists so conservation could not be calculated (F). Sequence logos were 
generated using WebLogo (197). 
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Appendix H: CbpFb Mass Spectroscopy Results 
 
Accession Description Score Coverage # Unique Peptides # PSMs Area 




PE=1 SV=1 - 
[TRYP_PIG] 
383.05 40.69 10 101 4.929E8 
 
Figure S 7 | CbpFb JF1 crystal mass spectroscopy results. 
Highlighted are the regions identified within the expected sequence of the crystallised protein. The 
table shows a summary of the data analysis, showing no evidence for contaminating proteins except 
for the trypsin used to digest the protein solution. Peptide-spectrum matches (PSMs) were filtered 
with a 1 % false discovery rate (FDR) to remove any proteins that were only matched by a single 
peptide.  
  












Appendix I: Digital Data 
Common scripts used can be found at GitHub: https://github.com/mb1511 
Large data sets from molecular dynamics, X-ray diffraction and whole-genome comparisons 
will be available by request to Prof RL Brady1 or Dr DJ Hill1. 
1 University of Bristol, Biomedical Sciences Building, University Walk, Bristol BS8 1TD 
